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High	  risk	  human	  papillomaviruses	  (HPVs)	  are	  the	  causative	  agents	  of	  cervical	  cancer.	  The	  
three	   approved	   prophylactic	   vaccines	   do	   not	   benefit	   already	   infected	   individuals;	  
therefore,	  there	  is	  still	  an	  urgent	  need	  for	  therapeutic	  vaccines.	  The	  HPV	  oncoproteins	  E6	  
and	   E7	   are	   ideal	   targets	   for	   the	  development	  of	   such	   vaccines,	   as	   they	   are	   expressed	  
throughout	  the	  viral	  life	  cycle	  and	  in	  tumours.	  They	  could	  be	  used	  to	  elicit	  strong	  cytotoxic	  
lymphocyte	  (CTL)	  responses	  which	  would	  aid	  in	  viral	  clearance,	  and	  could	  also	  be	  effective	  
against	   tumours.	   Granadillo	   et	   al.	   (2011)	   developed	   an	   Escherichia	   coli-­‐produced	  
therapeutic	  vaccine	  candidate,	  consisting	  of	  the	  HPV-­‐16	  E7	  protein	  and	  a	  cell	  membrane-­‐
penetrating	  and	  immunomodulatory	  peptide	  (LALF),	  whose	  fusion	  to	  HPV-­‐16	  E7	  aided	  in	  
the	   immunogenicity	   and	   antigen	   presentation	   of	   the	   oncoprotein.	   	   However,	   such	  
vaccines	   need	   not	   only	   to	   be	   effective,	   but	   also	   to	   have	   a	   low	   cost.	   Plant	   expression	  
systems	  represent	  an	  attractive	  alternative	  to	  conventional	  expression	  systems	  based	  on	  
bacterial,	  yeast,	  mammalian	  and	  other	  cell	  cultures,	  and	  are	  potentially	   far	  more	  cost-­‐
effective.	  	  
The	  aim	  of	  the	  present	  project	  was	  to	  produce	  LALF-­‐E7	  in	  Nicotiana	  benthamiana	  leaves	  
via	   Agrobacterium-­‐mediated	   transient	   expression,	   and	   to	   optimize	   its	   expression,	  
extraction	   and	   purification.	   This	   was	   done	   by	   expressing	   LALF-­‐E7	   using	   different	  
expression	   vectors,	   testing	   different	   subcellular	   localizations,	   and	   testing	   the	   effect	   of	  
gene	   silencing	   suppressors.	   By	   using	   our	   group’s	   replicating	   expression	   vector	   and	  
targeting	   LALF-­‐E7	   to	   the	   chloroplasts,	   the	   expression	   of	   the	   candidate	   vaccine	   in	   N.	  
benthamiana	   leaves	   was	   increased	   26.8	   fold	   compared	   to	   non-­‐replicating	   vectors	   or	  
cytoplasmic	  localization.	  Furthermore,	  silencing	  suppressors	  did	  not	  significantly	  increase	  
the	  expression	  of	  LALF-­‐E7	  when	  expressed	  by	  the	  replicating	  vector	  and	  targeted	  to	  the	  
chloroplasts.	  	  
I	   showed,	  by	   fluorescence	  microscopy,	   that	   LALE-­‐E7	  was	   indeed	  being	   targeted	   to	   the	  
plants’	   chloroplasts	   and	   that	   it	   possibly	   forms	   proteins	   bodies	   (PBs)	   that	   are	   closely	  
associated	  to	  the	  chloroplast	  envelope.	  I	  further	  hypothesized	  a	  mechanism	  by	  which	  the	  
PBs-­‐like	  structures	  form.	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Once	  the	  expression	  of	  LALF-­‐E7	  was	  optimized	  in	  plant	  leaves,	  a	  purification	  strategy	  was	  
developed	   by	   testing	   different	   extraction	   methods	   and	   using	   metal	   ion	   affinity	  
chromatography.	   The	  extraction	  protocol	   developed	  pre-­‐purified	   LALF-­‐E7	  by	   removing	  
the	  majority	  of	  soluble	  proteins	  from	  the	  final	  extract.	  However,	  LALF-­‐E7	  was	  not	  fully	  
purified	  by	  affinity	  chromatography,	  suggesting	  that	  other	  purification	  strategies	  should	  
be	  used.	  
Finally,	  I	  tested	  the	  partially	  purified	  plant-­‐produced	  LALF-­‐E7	  candidate,	  and	  compared	  it	  
to	   the	   E.	   coli-­‐produced	   counterpart,	   in	   tumour	   regression	   experiments	   using	  mice	   as	  
animal	  models.	  Due	  to	  low	  antigen	  doses	  and	  a	  large	  number	  tumourigenic	  cells	  used	  to	  
inoculate	   the	   mice	   animal	   models,	   the	   effect	   of	   the	   plant-­‐produced	   LALF-­‐E7	   as	   a	  
therapeutic	  vaccine	  was	  inconclusive.	  However,	  it	  was	  suggested	  that	  it	  could	  potentially	  
be	  comparable	  to	  the	  E.	  coli-­‐produced	  counterpart.	  	  	  
In	  summary,	  I	  report	  for	  the	  first	  time	  the	  entire	  chain	  of	  research	  involving	  the	  expression	  
of	  LALF-­‐E7	  in	  plants,	  its	  extraction,	  purification	  and	  the	  testing	  of	  its	  immunogenicity	  in	  a	  
mouse	  model.	  This	  research	  also	  suggests	  new	  avenues	  for	  the	  use	  of	  the	  LALF	  peptide	  as	  
a	  PB-­‐inducer	  which	   could	  be	  useful	   in	   increasing	   the	  expression	  of	  other	   recombinant	  
proteins.	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Chapter	  1:	  Literature	  review	  
“Therapeutic	  vaccines	  for	  high-­‐risk	  HPVs”	  
1.1.	  Introduction	  
It	  is	  now	  acknowledged	  that	  a	  number	  of	  infectious	  agents	  contribute	  to	  the	  development	  
of	  malignancies	  in	  humans:	  in	  2008	  approximately	  16.1%	  of	  all	  cancers	  were	  estimated	  to	  
be	  caused	  by	  infectious	  agents	  (De	  Martel	  et	  al.,	  2012).	  For	  example,	  hepatitis	  B	  and	  C	  
viruses,	  high-­‐risk	  human	  papillomaviruses	  (hr-­‐HPVs)	  and	  Helicobacter	  pylori	  cause	  liver,	  
cervical	  and	  gastric	  cancers,	  respectively.	  The	  fact	  that	  these	  cancers	  are	  caused	  by	  non-­‐
human	  agents	  allows	   for	  design	  of	  new	  therapeutic	  or	  preventative	  vaccines	   targeting	  
non-­‐human	  antigens,	  preventing	  auto-­‐immune	  reactions,	  and	  offering	  a	  vast	  number	  of	  
possible	   new	   strategies	   for	   the	   development	   of	   anti-­‐cancer	   therapeutics	   (Zur	  Hausen,	  
2009;	  De	  Martel	  et	  al.,	  2012;	  Morrow,	  Yan	  and	  Sardesai,	  2013).	  
Cancer	   is	   a	   global	   leading	   cause	   of	   death,	   and	   HPV-­‐related	   cancers	   represent	   30%	   of	  
infectious	  agent-­‐born	  cases	  (Schottenfeld	  and	  Beebe-­‐Dimmer,	  2015).	  Of	  these,	  the	  most	  
common	  cancer	  is	  that	  of	  the	  cervix,	  which	  is	  in	  turn	  the	  fourth	  most	  common	  cancer	  in	  
women	  worldwide	  (Centers	  for	  disease	  control	  and	  prevention,	  2012).	  There	  are	  at	  least	  
170	  HPV	  genotypes	  described,	  which	  are	  categorised	   into	   two	  groups:	   	   low-­‐risk	   types,	  
including	  HPV-­‐6,	  -­‐11,	  -­‐40,	  -­‐42,	  -­‐43,	  -­‐44,	  -­‐54,	  -­‐61,	  and	  -­‐72	  which	  cause	  genital	  warts,	  and	  
high-­‐risk	   types	   including	  HPV-­‐16,	   -­‐18,	   -­‐31,	   -­‐35,	   -­‐39,	   -­‐45,	   -­‐51,	   -­‐52,	   -­‐56,	   -­‐58,	   -­‐66	  and	  -­‐68,	  
which	  are	  responsible	  for	  99.7%	  of	  cervical	  cancer	  cases	  (Zur	  Hausen,	  2002;	  Parkin	  and	  
Bray,	   2006;	   de	   Villiers,	   2013).	   There	   are	   approximately	   530,000	   new	   cases	   of	   cervical	  
cancer	  and	  270,000	  deaths	  per	  year	  (World	  Health	  Organization	  2016).	  HPV-­‐16	  and	  -­‐18	  
are	  the	  most	  prevalent	  types	  worldwide,	  causing	  more	  than	  70%	  of	  cervical	  cancer	  cases.	  
Developing	  countries	  carry	  the	  greatest	  burden	  of	  HPV	  infections	  and	  malignancies	  due	  
to	  their	  lack	  of	  resources	  to	  implement	  efficient	  vaccination	  and	  screening	  programmes.	  
Besides	  cervical	  cancer,	  hr-­‐HPVs	  also	  cause	  vaginal,	  vulvar,	  penile,	  anal	  and	  oropharyngeal	  
cancers	  (Zur	  Hausen,	  2002;	  Parkin	  and	  Bray,	  2006).	  
Human	  papillomavirus	  particles	  are	  non-­‐enveloped	  and	  have	  an	  icosahedral	  morphology.	  
As	  shown	  in	  Figure	  1.1.,	  their	  8	  kb	  double-­‐stranded	  circular	  DNA	  genome	  encodes	  for	  six	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early	  regulatory	  proteins	  -­‐	  E1,	  E2,	  E4,	  E5,	  E6	  and	  E7	  -­‐	  and	  the	  two	  late	  structural	  proteins	  
L1	  and	  L2.	  The	  virus	  infects	  basal	  epithelial	  cells	  through	  anatomically	  accessible	  points	  
such	  as	  microlesions	  in	  the	  skin,	  genital	  organs	  and	  oropharyngeal	  areas.	  Capsid	  proteins	  
L1	   and	   L2	   attach	   to	   epithelial	   cell	   receptors	   and	   a	   long	   process	   of	   entry	   commences,	  
resulting	  in	  cytoplasmic	  uncoating	  of	  the	  virus	  and	  entry	  of	  its	  genome	  into	  the	  nucleus	  of	  
the	  infected	  cell,	  where	  it	  is	  transcribed	  and	  then	  replicated.	  Early	  proteins	  are	  expressed	  
first	  and	  regulate	  the	  host	  cell	  life	  cycle	  and	  genome	  replication.	  They	  also	  regulate	  the	  
expression	  of	  late	  proteins	  in	  a	  cell	  differentiation-­‐dependent	  manner:	  L1	  and	  L2	  are	  only	  
expressed	   in	   mature	   squamous	   cells.	   Maturation	   of	   virions	   occurs	   after	   terminal	  
differentiation	   of	   epithelial	   cells,	   and	   their	   release	   coincides	  with	   natural	   shedding	   of	  
senescent	  cells	  at	  the	  end	  of	  epithelial	  cell	  life	  cycle	  (Zur	  Hausen,	  2002).	  	  
	  
Figure	   1.1.	   Linear	   genome	   organization	   of	   a	   typical	   HPV.	  E1-­‐7,	   early	   regulatory	   proteins	   open	   reading	  
frames.	  L1-­‐2,	  late	  structural	  proteins	  open	  reading	  frames.	  LCR,	  long	  control	  region.	  Ruler,	  number	  of	  base-­‐
pairs	  (bp).	  Adapted	  from	  Stanley,	  (2006).	  
	  
Most	  HPV	  infections	  are	  cleared	  by	  the	  host’s	  immune	  system.	  A	  small	  portion	  of	  cases	  
progress	  into	  persistent	  infections	  that,	  in	  the	  case	  of	  hr-­‐HPVs,	  cause	  vaginal	  and	  cervical	  
intraepithelial	  neoplasia	   (VIN	  and	  CIN,	  respectively),	  also	  referred	  to	  as	  VIL	  and	  CIL	   for	  
lesions	  (Zur	  Hausen,	  2002).	  These	  are	  graded	  according	  to	  the	  severity	  of	  the	  lesion	  as	  1,	  
2	  or	  3,	  where	  CIN-­‐1	  is	  the	  least	  severe	  and	  CIN-­‐3	  is	  the	  most	  severe.	  Lesion	  progression	  
varies	  between	  individuals	  and	  they	  can	  regress	  either	  spontaneously	  or	  with	  treatment.	  
Women	  that	  have	  CIN-­‐3	  have	  a	  greater	  chance	  of	  developing	  cervical	  cancer.	  Similarly,	  
women	   infected	  by	  HPV-­‐16	  and	   -­‐18	  have	   the	  highest	   chance	  of	   developing	  CIN-­‐3	   and	  
eventually	  cancer	  (Wheeler,	  2008).	  	  
In	  a	  typical	  hr-­‐HPV	  carcinogenesis	  (Figure	  1.2.),	  the	  genome	  of	  the	  virus	  is	  integrated	  into	  
the	  host’s	  chromosomal	  DNA	  and	  the	  E2	  sequence	  is	  disrupted	  during	  the	  linearization	  of	  
the	   genome.	   The	   E2	   protein	   is	   the	   transcriptional	   repressor	   of	   E6	   and	   E7;	   therefore,	  
expression	  from	  these	  genes	  becomes	  constitutive	  once	  E2	  is	  disrupted.	  The	  E6	  protein	  
E6	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subsequently	  promotes	  the	  degradation	  of	  the	  host	  apoptosis	  regulator	  protein	  p53,	  and	  
activates	  telomerase	  which	  results	  in	  extended	  cell	  life.	  The	  E7	  protein	  targets	  the	  tumour	  
suppressor	  retinoblastoma	  protein	  (pRb)	  for	  degradation	  and	  leads	  to	  the	  transition	  of	  
the	  cell	  life	  cycle	  to	  the	  S-­‐phase	  and	  subsequent	  host	  cell	  genome	  replication.	  Overall	  E6	  
and	  E7	  disrupt	  the	  cell	  cycle	  regulation	  and	  promote	  prolonged	  host	  cell	  life,	  leading	  to	  
genomic	  instability	  and	  eventually	  cancer	  (Zur	  Hausen,	  2002).	  
	  	  
Figure	  1.2.	  The	  life-­‐cycle	  of	  a	  typical	  hr-­‐HPV.	  Infection	  occurs	  at	  basal	  epithelial	  cells	  through	  anatomically	  
accessible	  points	  such	  as	  microlesions.	  The	  genomes	  of	  HPVs	  stay	  as	  episomes	  in	  the	  host’s	  cell	  nuclei.	  Cells	  
proliferate	  and	  differentiate.	  The	  expression	  of	  structural	  proteins,	  L1	  and	  L2,	  viral	  assembly	  and	  release	  
only	  occur	  at	  late	  stages	  of	  the	  cell	  life	  cycle.	  Integration	  of	  the	  viral	  genome	  into	  the	  host’s	  genome	  leads	  
to	  overexpression	  of	  E6	  and	  E7	  which	  disrupt	  the	  cell	  life	  cycle	  regulation	  and	  promotes	  prolonged	  cell	  life	  
leading	  to	  genomic	  instability	  and	  cancer.	  At	  this	  stage	  no	  viral	  structural	  proteins	  are	  expressed.	  Adapted	  
from	  Moody	  and	  Laimins,	  (2010)	  
	  
Currently,	  there	  are	  three	  commercially	  available	  HPV	  vaccines.	  All	  exploit	  the	  fact	  that	  
HPV	  L1	  protein	  can	  form	  virus-­‐like	  particles	  (VLPs)	  when	  expressed	  alone	  in	  a	  variety	  of	  
cell	   types,	   that	   are	   morphologically	   and	   antigenically	   highly	   similar	   to	   native	   virions	  
(Kirnbauer	  et	  al.,	  1992).	  The	  first,	  Cervarix®	  (GlaxoSmithKline	  Inc.),	  is	  a	  bivalent	  vaccine	  
produced	  in	  insect	  cells	  using	  a	  baculovirus	  expression	  system,	  that	  targets	  HPV-­‐16	  and	  -­‐
18.	  The	  second,	  Gardasil®	  (Merck	  &	  Co.,	  Inc.),	  is	  a	  quadrivalent	  vaccine	  produced	  in	  yeast	  
cells	  that	  targets	  HPV-­‐16	  and	  -­‐18,	  and	  the	  genital	  wart-­‐associated	  HPV-­‐6	  and	  -­‐11.	  The	  third	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are	  the	  HPV-­‐31,	  -­‐33,	  -­‐45,	  -­‐52	  and	  -­‐58,	  with	  the	  potential	  to	  prevent	  up	  to	  90%	  of	  cervical	  
cancer,	   20%	   more	   than	   its	   quadrivalent	   counterpart.	   This	   vaccine	   has	   recently	   been	  
approved	  by	  the	  Food	  and	  Drug	  Administration	  Department	  (FDA)	  (Merck,	  2014).	  These	  
three	  vaccines	  effectively	  prevent	  HPV	  infections	  caused	  by	  the	  targeted	  types	  by	  eliciting	  
the	  production	  of	  neutralizing	  antibodies	  that	  bind	  to	  the	  viral	  particles	  and	  block	  their	  
entrance	  into	  host	  cells	  (Harper	  et	  al.,	  2004;	  Villa	  et	  al.,	  2005;	  Joura	  et	  al.,	  2015).	  However,	  
these	   vaccines	   are	  not	   effective	   at	   eliminating	  pre-­‐existing	   infections,	   since	   the	   target	  
antigens,	   L1	   capsid	   proteins,	   are	   not	   expressed	   in	   infected	   basal	   epithelial	   cells	  	  
(Hildesheim	   et	   al.,	   2007,	   2016;	   Hung	   et	   al.,	   2008).	   Therefore,	   the	   large	   number	   of	  
individuals	  already	  infected	  with	  HPV	  do	  not	  benefit	  from	  the	  current	  vaccines.	  	  
The	   lack	   of	   appropriate	   Pap-­‐smear	   screening	   leads	   to	   many	   women	   only	   detecting	  
infections	  when	   they	   have	   already	  progressed	  past	   CIN-­‐1	   or	  when	   cancer	   has	   already	  
developed.	  Additionally,	  many	  women,	  especially	   in	  developing	  countries,	  do	  not	  have	  
access	   to	   follow-­‐up	   treatment	   of	   detected	   malignancies.	   Even	   if	   efficient	   vaccination	  
programmes	  were	  implemented	  worldwide,	  their	  impact	  will	  only	  be	  seen	  in	  several	  years	  
since	  these	  vaccines	  were	  approved	  only	  recently.	  In	  addition,	  the	  current	  commercially	  
available	  vaccines	  are	  expensive	  and	  therefore,	  except	  when	  sponsored	  by	  the	  state	  or	  
other	  organisations,	  are	  not	  accessible	  to	  low-­‐income	  populations.	  New	  types	  of	  vaccines	  
are	   thus	   needed	   that	   can	   eliminate	   established	   infections	   and	   that	   are	   also	   more	  
accessible	  to	  poorer	  communities	  (Hildesheim	  et	  al.,	  2007;	  Giorgi,	  Franconi	  and	  Rybicki,	  
2010).	  
Cell-­‐mediated	  rather	  than	  humoral	  immune	  responses	  are	  important	  for	  the	  clearance	  of	  
established	   infections.	   It	   has	   been	   observed	   that	   spontaneous	   clearance	   and	   slow	  
progression	   of	   HPV	   infections	   are	   associated	   with	   a	   strong	   cell-­‐mediated	   immune	  
response	  involving	  mainly	  T-­‐helper	  type	  1	  cells	  and	  cytotoxic	  T-­‐cells	  derived	  from	  CD4+	  
and	  CD8+	  T-­‐cells	  respectively	  (van	  der	  Burg	  and	  Melief,	  2011).	  	  
The	   HPV	   E6	   and	   E7	   oncoproteins	   are	   essential	   for	   the	   onset	   and	   maintenance	   of	  
malignancy	  thus	  they	  are	  unlikely	  to	  escape	  immune	  responses	  by	  mutation.	  They	  are	  also	  
expressed	  constitutively	  and	  at	  high	  levels	  and	  therefore,	  represent	  ideal	  targets	  for	  the	  
development	  of	  therapeutic	  vaccines	  against	  established	  HPV	  infections	  and	  lesions	  (Zur	  
Hausen,	  2002;	  Lin,	  Doolan,	  et	  al.,	  2010;	  Morrow,	  Yan	  and	  Sardesai,	  2013).	  Other	  proteins	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useful	   for	   targeting	   of	   early	   viral	   infections	   are	   E1	   (viral	   helicase)	   and	   E2	   which	   are	  
expressed	   at	   higher	   levels	   than	   E6	   and	   E7	   at	   very	   early	   stages	   before	   viral	   genome	  
integration	  (Yang	  et	  al.,	  1993;	  Šmídková	  et	  al.,	  2012).	  	  Overall,	  an	  ideal	  therapeutic	  vaccine	  
would	  target	  these	  proteins	  to	  induce	  strong	  tumour-­‐specific	  T-­‐cell	  type	  1	  and	  cytotoxic	  
lymphocyte	  (CTL)	  responses	  able	  to	  kill	   infected	  and	  malignant	  cells	   (van	  der	  Burg	  and	  
Melief,	  2011).	  	  
There	   are	   currently	   no	   HPV	   therapeutic	   vaccines	   approved	   for	   use	   in	   humans.	  
Nevertheless,	   there	   have	   been	   numerous	   and	   extensive	   studies	   that	   have	   generated	  
promising	  candidates	  tested	  in	  animal	  models	  and	  in	  clinical	  trials.	  Diverse	  strategies	  have	  
been	  explored,	  including	  live	  vector,	  nucleic	  acid,	  protein,	  whole	  cell	  and	  combinatorial	  
vaccines.	   These	   strategies	   will	   be	   reviewed	   giving	   the	   advantages,	   disadvantages	   and	  
some	  important	  examples	  of	  each.	  	  	  
	  
1.2.	  Types	  of	  HPV	  therapeutic	  vaccine	  strategies	  
1.2.1.	  Live	  vector	  vaccines	  
Live	   vectors	   include	   bacteria	   such	   as	   Listeria	   monocytogenes,	   Lactoccocus	   lactis,	   and	  
Salmonella	  spp.	  and	  viruses	  such	  as	  adenovirus	  and	  vaccinia	  virus,	  and	  can	  be	  used	  to	  
present	  the	  antigen	  of	  interest	  on	  their	  surfaces.	  Live	  vectors	  can	  replicate	  inside	  the	  host	  
cells,	  facilitating	  the	  spread	  of	  antigens.	  They	  can	  drive	  antigen	  presentation	  through	  both	  
major	   histocompatibility	   complex	   (MHC)	   class	   I	   and	   class	   II	   pathways,	   therefore	  
stimulating	  CD8+	  cytotoxic	  T-­‐cells	  and	  CD4+	  helper	  T-­‐cells,	   respectively,	   thus	  providing	  
high	  immunogenicity	  (Lin,	  Doolan,	  et	  al.,	  2010).	  
Bermúdez-­‐humarán	  et	  al.	  (2005)	  were	  the	  first	  to	  demonstrate	  the	  therapeutic	  effect	  of	  
a	  live	  recombinant	  bacterial	  vector	  against	  cancer.	  The	  vaccine,	  LL-­‐E7,	  consisted	  of	  L.	  lactis	  
strains	  presenting	  the	  HPV-­‐16	  E7	  antigen	  on	  the	  cell	  wall	  surface	  and	  secreting	  a	  form	  of	  
interleukin	  (IL)-­‐12.	  Mice	  were	  immunized	  intranasally	  and	  showed	  full	  protection	  against	  
tumour	  development	  induced	  by	  high	  doses	  of	  the	  HPV-­‐16	  E6	  and	  E7-­‐expressing	  cell	  line	  
TC-­‐1.	  When	   tumour-­‐bearing	   mice	   were	   vaccinated	   with	   LL-­‐E7	   they	   developed	   an	   E7-­‐
specific	   cell-­‐mediated	   response	   capable	   of	   containing	   tumour	   growth.	   There	  was	   also	  
detection	  of	  some	  E7-­‐specific	  antibody	  production	  in	  vaccinated	  mice.	  The	  researchers	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showed	   that	   a	   live	   vector	   could	   be	   used	   for	   the	   development	   of	   a	   low-­‐cost	   and	   non-­‐
invasive	  HPV	  vaccine	  with	  therapeutic	  as	  well	  as	  prophylactic	  activity.	  	  
Listeria	  monocytogenes	  (Lm)	  is	  of	  particular	  interest	  for	  vaccine	  development	  since	  it	  is	  
able	   to	   act	   as	   a	   natural	   adjuvant.	   It	   infects	   macrophages	   without	   being	   captured	   by	  
phagocytosis	   and	   is	   able	   to	   direct	   antigen	   processing	   via	   MHCI	   and	   MHCII	   pathways	  
(Goossens	  et	  al.,	  1995;	  Gunn	  et	  al.,	  2001).	  	  The	  latter	  used	  two	  live-­‐attenuated	  Lm-­‐based	  
vaccines	   that	   secreted	   the	   HPV-­‐16	   E7	   only	   (Lm-­‐E7)	   or	   E7	   fused	   to	   a	   non-­‐haemolytic	  
portion	  of	   listeriolysin	  O	  (Lm-­‐LLO-­‐E7).	  Both	  vaccines	  elicited	  specific	  CTL	  responses	  but	  
only	   the	   fusion	  protein	  elicited	   tumour	   regression	   in	  mice.	   Lm-­‐LLO-­‐E7	  was	   tested	   in	   a	  
Phase	   I	   clinical	   trial	   on	   15	   patients	   with	   advanced	   and	   metastatic	   cervical	   cancer.	  
According	  to	  the	  authors	  this	  trial	  showed	  that	  the	  vaccine	  was	  relatively	  safe	  to	  use	  in	  
humans:	   one	   patient	   showed	   partial	   regression	   of	   lesions	  while	   seven	   showed	   stable	  
lesions,	  but	  six	  had	  progressed	  by	  the	  end	  of	  the	  trial	  (Maciag,	  Radulovic	  and	  Rothman,	  
2009).	  This	  was	  the	  first	  Lm-­‐based	  vaccine	  tested	  in	  clinical	  trials	  and	  further	  studies	  are	  
in	  progress	  in	  Phase	  I	  and	  II	  clinical	  trials	  (Advaxis,	  2014).	  
Like	   bacterial	   live	   vectors,	   live	   viral	   vectors	   have	   been	   used	   in	   numerous	   studies.	   For	  
example,	  in	  a	  Phase	  II	  clinical	  trial	  a	  recombinant	  vaccinia	  virus	  expressing	  HPV-­‐16	  and	  -­‐
18	  E6	  and	  E7	  proteins	  (TA-­‐HPV)	  was	  used.	  The	  trial	  showed	  antigen-­‐specific	  CTL	  immunity	  
in	  patients	  with	  high	  grade	  anogenital	  intraepithelial	  neoplasia.	  Of	  the	  12	  patients,	  five	  
showed	  reduction	  of	  at	  least	  50%	  of	  lesion	  diameter	  and	  one	  showed	  complete	  regression	  
of	   lesions.	  Some	  patients	   showed	   increased	  cell-­‐mediated	   responses	  while	  all	  patients	  
showed	  humoral	   responses	   to	   the	  vaccinia	   virus.	  Overall,	   the	  vaccine	   showed	  positive	  
results	  but	  needs	  to	  be	  further	  developed	  to	  increase	  its	  therapeutic	  efficacy	  (Baldwin	  et	  
al.,	  2003).	  	  
A	  highly	  attenuated	  strain	  of	  the	  vaccinia	  virus,	  the	  modified	  vaccinia	  virus	  Ankara	  (MVA),	  
was	  used	  to	  develop	  an	  E2-­‐based	  vaccine	  that	  was	  able	  to	  reduce	  overexpression	  of	  the	  
E6	   and	   E7	   oncogenes	   and	   thus	   decrease	   HeLa	   cell-­‐derived	   tumour	   growth	   in	   mice	  
(Graham	  et	  al.,	  2000).	  This	  vaccine	  has	  been	  tested	  in	  a	  Phase	  II	  clinical	  trial	   in	  women	  
with	  CIN-­‐1	  and	  -­‐2	   lesions.	  The	  MVA-­‐E2	  vaccination	  eliminated	  lesions	   in	  59%	  of	  the	  54	  
patients	  and	  41%	  showed	  up	   to	  60%	  reduction	   in	   lesion	  size	   (García-­‐Hernández	  et	  al.,	  
2006).	  Together,	  these	  studies	  show	  that	  vaccinia-­‐based	  vaccines	  are	  safe	  and	  effective.	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Gomes-­‐Gutierres	  et	  al.	  (2007)	  used	  calreticulin	  (CRT),	  which	  enhances	  MHC-­‐I	  and	  MHC-­‐II	  
antigen	  presentation	  (Basu	  and	  Srivastava,	  1999),	  fused	  to	  HPV-­‐16	  E7	  protein	  expressed	  
by	   a	   replication-­‐deficient	   adenovirus.	   This	   vaccine	  was	   referred	   to	   as	   Ad-­‐CRT/E7.	   The	  
study	   was	   conducted	   in	   mice	   and	   showed	   that	   high	   E7-­‐specific	   T-­‐cell	   activation	   and	  
proliferation,	  interferon-­‐γ	  (INF-­‐γ)	  release	  and	  CTL	  responses	  could	  be	  achieved	  leading	  to	  
both	  therapeutic	  and	  prophylactic	  activity	  of	  the	  vaccine.	  	  
Although	  live	  vectors	  are	  highly	  immunogenic,	  they	  have	  drawbacks	  since	  often	  a	  greater	  
immune	  response	  is	  elicited	  against	  the	  vector	  than	  against	  the	  target	  proteins.	  Target-­‐
specific	  responses	  are	  mostly	  humoral	  rather	  than	  cell-­‐mediated,	  while	  the	  opposite	   is	  
preferable.	  There	  is	  a	  risk	  of	  toxicity,	  since	  the	  vectors	  actively	  replicate	  inside	  the	  host.	  
Furthermore,	   there	   is	   also	   the	   possibility	   of	   pre-­‐existing	   immunity	   due	   to	   previous	  
exposure	  to	  the	  vector.	  These	  factors	  limit	  the	  use	  of	  live	  vectors	  for	  the	  presentation	  of	  
potential	  HPV	  therapeutic	  vaccines	  (Lin,	  Doolan,	  et	  al.,	  2010).	  	  
1.2.2.	  Subunit	  vaccines	  
Subunit	  vaccines	  are	  antigens	  delivered	  in	  the	  form	  of	  peptides	  or	  whole	  proteins.	  They	  
are	   regarded	   as	   safer	   than	   live	   vector	   vaccines	   for	   they	   are	   present	   in	   the	   host	   cells	  
transiently,	  decreasing	  the	  chances	  of	  toxicity.	  
Peptide	  vaccines	  are	  simple	  to	  produce,	  but	  because	  of	  their	  small	  sizes	  they	  have	  limited	  
immunogenicity	  and	  need	  to	  be	  administered	  with	  strong	  adjuvants.	  They	  also	  need	  to	  
match	   the	   receiver’s	   human	   leukocyte	   antigen	   (HLA)	   type,	   which	  makes	   this	   strategy	  
unpractical	   to	   implement	   in	   mass	   vaccinations	   (Kast	   et	   al.,	   1994;	   Hung	   et	   al.,	   2008;	  
Moscicki,	  2008).	  	  
To	  overcome	  the	  HLA	  limitation,	  synthetic	  long	  overlapping	  peptides	  (SLPs)	  that	  contain	  
all	  or	  most	  possible	  epitopes	  of	  the	  target	  protein	  can	  be	  used.	  In	  a	  Phase	  II	  clinical	  trial,	  
Kenter	  et	  al.	  (2009)	  demonstrated	  that	  vaccination	  of	  women	  positive	  for	  HPV-­‐16	  CIN-­‐3	  
with	  a	  mixture	  of	  HPV-­‐16	  E6	  and	  E7	  SLPs,	  induced	  the	  activation	  of	  CD4+	  T-­‐cells	  and	  CTL	  
responses.	   At	   the	   end	   of	   the	   trial,	   79%	  of	   the	   19	  women	   vaccinated	   showed	   positive	  
clinical	   responses	   and	   45%	   had	   complete	   regression	   of	   the	   lesions	   12	   months	   after	  
vaccination.	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In	   another	   Phase	   II	   clinical	   trial,	   patients	   that	   had	   advanced	   or	   recurrent	   HPV-­‐16	  
associated	  cervical	  cancer	  were	  treated	  with	  a	  mixture	  of	  13	  overlapping	  SLPs	  covering	  
the	  entire	  sequences	  of	  HPV-­‐16	  E6	  and	  E7.	  Of	  16	  patients	  tested,	  56%	  showed	  vaccine-­‐
induced,	   HPV-­‐specific	   T-­‐cell	   proliferation,	   and	   85%	   of	   the	   13	   patient	   tested	   showed	  
vaccine-­‐induced	   immune	   responses.	   Furthermore,	   those	   with	   a	   longer	   survival	   time	  
showed	  a	  stronger	  response	  than	  those	  that	  lived	  relatively	  shorter	  after	  vaccination,	  as	  
seen	  by	  increased	  lymphocyte	  stimulation	  and	  anti-­‐tumour	  agents	  such	  as	  INF-­‐γ	  and	  α,	  
and	  IL	  production	  (van	  Poelgeest	  et	  al.,	  2013).	  This	  suggests	  that	  this	  vaccine	  was	  able	  to	  
elicit	  effective	  CTL	  responses	  that	  prolonged	  the	  survival	  of	  women	  tested.	  	  
These	  studies	  suggest	  that	  SLP-­‐based	  vaccines	  are	  safe	  to	  use,	  since	  no	  severe	  adverse	  
events	   were	   observed,	   and	   that	   they	   can	   be	   used	   for	   the	   treatment	   of	   HPV-­‐related	  
malignancies.	  
Unlike	   peptide-­‐based	   vaccines,	   whole	   protein-­‐based	   vaccines	   contain	   all	   possible	   CTL	  
epitopes	  required	  to	  be	  recognised	  by	  any	  individual.	  However,	  some	  proteins	  are	  also	  
poorly	  immunogenic	  and	  efficient	  responses	  require	  adjuvants	  or	  fusion	  to	  immunogenic	  
carrier	  molecules	   (Kast	   et	   al.,	   1994;	   Hung	   et	   al.,	   2008;	  Moscicki,	   2008).	   Furthermore,	  
extracellular	  antigens	  are	  generally	  processed	  through	  the	  MHC-­‐II	  pathway,	  which	  leads	  
to	  the	  activation	  of	  CD4+	  T-­‐cells	  (Banchereau	  and	  Steinman,	  1998).	  Although	  this	  is	  useful	  
for	  therapeutic	  vaccines,	  CD8+	  T-­‐cell	  activation	  is	  optimal.	  For	  this,	  antigens	  can	  be	  fused	  
to	   cell	   penetrating	   peptides	   or	   to	   molecules	   that	   stimulate	   antigen	   presenting	   cells,	  
especially	   dendritic	   cells	   (DCs).	   This	   facilitates	   antigen	   processing	   through	   the	   MHC-­‐I	  
pathway	  that	   leads	  to	  the	  activation	  of	  CD8+	  T-­‐cells	   (Banchereau	  and	  Steinman,	  1998;	  
Moscicki,	  2008;	  Lin,	  Doolan,	  et	  al.,	  2010;	  Granadillo	  et	  al.,	  2011).	  	  
Granadillo	  et	  al.	  (2011)	  developed	  a	  fusion-­‐protein	  vaccine	  consisting	  of	  the	  HPV-­‐16	  E7	  
protein	   and	   a	   peptide	   derived	   from	   the	   Limulus	   polyphemus	   anti-­‐lipopolysaccharide	  
factor	   (LALF31-­‐52).	   This	   is	   a	   small	   and	   hydrophobic	   peptide	   that	   can	   penetrate	   cell	  
membranes	  and	  that	  has	  immunomodulatory	  properties	  (Vallespi	  et	  al.,	  2000).	  The	  fusion	  
to	   HPV-­‐16	   E7	   aided	   in	   the	   immunogenicity	   and	   antigen	   presentation	   of	   E7.	   In	   a	  
prophylactic	  experiment,	  vaccinated	  mice	  were	  protected	  against	  E7-­‐expressing	  TC-­‐1	  cell	  
tumour	  challenges.	  In	  a	  therapeutic	  experiment,	  tumour-­‐bearing	  mice	  showed	  tumour-­‐
specific	   immune	  responses	  and	  tumour	  regression.	  The	  tumour	  protection	  and	  tumour	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regression	  were	  significantly	  higher	  when	  compared	  to	  control	  mice	  vaccinated	  with	  E7	  
or	   LALF	  alone.	   Furthermore,	   the	  anti-­‐tumour	  effect	  of	   LALF-­‐E7	  was	   comparable	   in	   the	  
presence	  or	  absence	  of	  an	  adjuvant.	  These	  results	  confirmed	  the	  potentiating	  effect	  of	  
the	  cell-­‐penetrating	  peptide,	  and	  showed	  that	  LALF-­‐E7	  is	  promising	  as	  a	  HPV	  therapeutic	  
vaccine.	  
Tumours	   generally	   have	   immunosuppressive	   microenvironments	   which	   may	   inhibit	  
antigen-­‐specific	  CTL	  responses.	  This	   immunosuppression	   is	  mainly	  due	  to	  regulatory	  T-­‐
cells	   (Tregs),	   tumour-­‐associated	  macrophages	   (TAMs)	   and	  myeloid-­‐derived	   suppressor	  
cells	   (MDSCs)	   (Sica	   and	   Bronte,	   2007).	   Toll-­‐like	   receptor	   	   (TLR)	   agonists	   are	  
immunopotentiators	   which	   have	   been	   shown	   to	   increase	   activation	   of	   cell-­‐mediated	  
responses	  and	  viral	  clearance	  (Shen	  et	  al.,	  2015).	  Wick	  &	  Webb	  (2011)	  designed	  a	  broad-­‐
spectrum	  HPV	   therapeutic	   vaccine,	   Pentarix,	   consisting	   of	   the	   E7	   sequences	   from	   the	  
major	  hr-­‐HPV	   types	  16,	  18,	  31,	  45	  and	  52	   that	  account	   for	  more	   than	  80%	  of	   cervical	  
cancers.	  	  They	  previously	  showed	  that	  proteins	  can	  elicit	  a	  strong	  cell-­‐mediated	  response	  
extracellularly	  when	  accompanied	  by	  a	  TLR3	  agonist,	  poly(I:C)	  (Wick	  et	  al.,	  2011).	  Here	  
they	  also	  tested	  the	  TLR9	  agonist,	  CpG	  DNA.	  Mice	  vaccinated	  with	  Pentarix	  and	  either	  one	  
of	   the	   adjuvants	   showed	   regression	   of	   TC-­‐1-­‐induced	   tumours	   after	   one	   week	   of	  
vaccination.	  They	  had	  a	  complete	  tumour	  regression	  by	  week	  three	  post	  treatment	  and	  
remained	  tumour-­‐free	  for	  at	  least	  three	  months.	  Furthermore,	  they	  showed	  that	  cluster	  
immunization	  of	  mice	  with	  Pentarix	  +	  Poly(I:C)	  increased	  the	  cell-­‐mediated	  responses	  in	  
mice	  as	  well	  as	  the	  rate	  of	  tumour	  regression	  compared	  to	  mice	  vaccinated	  only	  once.	  
Their	  findings	  suggested	  that	  the	  vaccine	  was	  able	  to	  elicit	  a	  strong	  enough	  cell-­‐mediated	  
response	   capable	   of	   overcoming	   the	   immunosuppressive	   tumour	   microenvironment.	  
Pentarix	  could	  be	  used	  as	  a	  broad	  spectrum	  treatment	  for	  a	  variety	  of	  HPV-­‐related	  pre-­‐	  
and	  cancerous	  conditions	  (Wick	  and	  Webb,	  2011).	  A	  patent	  for	  Pentarix	  was	  filed	  in	  2012	  
(Pentarix.	   Novel	   HPV	   Therapeutic	   Cancer	   Vaccine,	   2012)	   however,	   no	   information	   on	  
future	  clinical	  trials	  was	  available.	  
To	   further	   enhance	   the	   potential	   of	   subunit	   vaccines,	   self-­‐adjuvating	   lipoimmunogens	  
have	  been	   linked	  to	  therapeutic	  vaccine	  candidates,	  such	  the	  case	  of	  rlipo-­‐E7m,	  which	  
consists	   of	   a	  mutant	  HPV-­‐16	   E7	   protein	   fused	   to	   a	   lipid	  moiety	   that	   has	   TLR2	   agonist	  
properties.	  The	  vaccine	  was	  administered	  to	  mice	  together	  with	  the	  TLR9	  agonist,	  CpG	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DNA.	  This	  study	  showed	  that	  rlipo-­‐E7m	  in	  combination	  with	  the	  TLR9	  agonist	  were	  able	  
to	  eradicate	  large,	  established	  solid	  TC-­‐1	  tumours	  suggesting	  an	  enhanced	  CTL	  response	  
and	  decrease	  in	  the	  immunosuppressive	  conditions	  in	  the	  tumours	  (Chang	  et	  al.,	  2014).	  
Overall,	  protein-­‐based	  vaccines	  have	  shown	  promise	  for	  future	  HPV	  therapeutic	  vaccine	  
development.	   They	   have	   the	   advantage	   over	   peptide-­‐based	   vaccines	   of	   containing	   all	  
possible	  epitopes	  for	  the	  induction	  of	  an	  effective	  immune	  response,	  and	  in	  combination	  
with	  immunopotentiators	  they	  look	  very	  promising	  for	  future	  vaccine	  designs.	  	  However,	  
they	   have	   not	   progressed	   into	   Phase	   II	   clinical	   trials,	   reflecting	   that	   development	   lags	  
compared	  to	  peptide-­‐based	  vaccines	  and	  to	  other	  strategies.	  	  
1.2.3.	  Nucleic	  acid	  vaccines	  
Another	  approach	  to	  produce	  HPV	  therapeutic	  vaccines	  is	  the	  use	  of	  nucleic	  acids	  -­‐	  DNA	  
or	  RNA,	  encoding	  for	  the	  target	  antigen.	  These	  vaccines	  are	  delivered	  intradermally	  by	  
injection	   followed	   by	   electroporation	   (EP),	   by	   gene	   gun	   or	   laser	   therapy.	   The	   target	  
antigen	  is	  then	  expressed	  in	  the	  transfected	  cells.	  This	  is	  advantageous,	  as	  antigens	  are	  
produced	  intracellularly	  and	  are	  therefore	  processed	  by	  the	  MHC-­‐I	  pathway.	  Unlike	  live	  
vector	  vaccines,	  nucleic	  acid	  vaccines	  do	  not	  contain	  or	  produce	  structural	  proteins	  which	  
can	  skew	  the	  immune	  response	  towards	  a	  humoral	  instead	  of	  a	  cell-­‐mediated	  response.	  
Therefore,	  they	  can	  be	  more	  effective	  and	  can	  be	  administered	  repeatedly.	  	  	  
1.2.3.1.	  DNA	  vaccines	  
Part	  of	  the	  attractiveness	  of	  DNA	  vaccines	  is	  their	  relatively	  low	  cost	  of	  production.	  The	  
nature	  of	  DNA	  makes	   these	  vaccines	   less	  heat	   labile	  and	   thus	  easier	   to	  be	   stored	  and	  
transported.	  They	  are	  also	  more	  stable	  and	  provide	  a	  more	  continuous	  expression	  of	  the	  
target	   antigen	   than	   RNA	   vaccines	   or	   subunit	   vaccines.	   Therefore,	   DNA	   vaccines	   could	  
overcome	  some	  limitations	  of	  other	  vaccine	  strategies	  (Hung	  et	  al.,	  2008).	  DNA	  vaccines	  
for	  HPV	   have	   been	   extensively	   studied	   and	   described,	  with	   a	   number	   of	   clinical	   trials	  
carried	  out.	  Overall	  they	  have	  proven	  to	  be	  safe,	  and	  cause	  no	  severe	  side	  effects.	  There	  
are	  also	  many	  strategies	  to	  improve	  DNA	  vaccine	  efficacy,	  immunogenicity	  and	  potency	  
(Lin,	  Roosinovich,	  et	  al.,	  2010).	  	  
To	  increase	  their	  immunogenicity,	  Massa	  et	  al.	  (2008)	  genetically	  fused	  the	  plant	  potato	  
virus	  X	  	  coat	  protein	  (PVX-­‐CP)	  to	  a	  HPV-­‐16	  E7	  mutant	  protein.	  The	  mutant	  E7,	  contained	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three	  point	  mutations	  at	   the	  pRb	  binding	  site	  where	  native	  residues	  were	  replaced	  by	  
Glycine	  residues,	  hence	  the	  name	  E7GGG.	  This	  abolished	  the	  transformative	  properties	  
of	  the	  protein	  (Smahel	  et	  al.,	  2001).	  The	  PVX-­‐CP	  was	  chosen	  as	  a	  safe	  carrier	  particle	  for	  
the	  presentation	  of	  the	  E7GGG	  antigen.	  They	  showed	  that	  mammalian	  cells	  transfected	  
with	   the	  E7GGG-­‐CP	   fusion	  DNA	  could	  drive	  protein	  expression	  and	   that	  proteins	  were	  
degraded	   through	   the	   proteasome	   pathway,	  which	   suggested	   that	   the	  MHC-­‐I	   antigen	  
processing	   pathway	   was	   preserved.	   Mice	   vaccinated	   with	   the	   E7GGG-­‐CP	   fusion	   DNA	  
showed	  E7-­‐specific	  humoral	  as	  well	  as	  cell-­‐mediated	  immunity,	  decreased	  tumour	  growth	  
rates	  and	  greater	  survival	  rates	  than	  mice	  vaccinated	  with	  the	  E7GGG	  DNA	  or	  than	  the	  
placebo	  groups.	  This	  study	  showed	  that	  CPs	  can	  be	  used	  to	  enhance	  the	  immunogenicity	  
of	  E7-­‐based	  vaccines	  and	  that	  a	  plant	  virus	  CP	  could	  be	  a	  safer	  option	  compared	  to	  other	  
strategies	  (Massa	  et	  al.,	  2008).	  
Garcia	  et	  al.	  (2004)	  synthesized	  ZYC-­‐101a,	  a	  DNA-­‐based	  vaccine	  encoding	  the	  HPV-­‐16	  and	  
-­‐18	  E6	  and	  E7	  antigens	  fused	  to	  a	  CTL	  antigen.	  The	  ZYC-­‐101a	  vaccine	  was	  used	  in	  a	  Phase	  
III	  trial,	  in	  women	  with	  CIN-­‐2	  and	  CIN-­‐3.	  Complete	  or	  partial	  regression	  of	  the	  lesions	  was	  
observed	   in	  41%	  of	  the	  vaccinated	  women.	  However,	   further	  safety	  assessment	  of	  the	  
vaccine	   is	   necessary.	  Nevertheless,	   the	   fact	   that	   the	   vaccine	  progressed	   to	   a	   Phase	   III	  
clinical	  trial,	  and	  the	  results	  obtained,	  show	  the	  potential	  of	  DNA	  vaccines.	  	  
In	   order	   to	   enhance	   antigen	   processing	   and	   presentation	   by	   DCs,	   Kim	   et	   al.	   (2014)	  
designed	  a	  DNA	  vaccine	  that	  co-­‐expressed	  the	  HPV-­‐16	  and	  -­‐18	  antigens	  E6	  and	  E7,	  and	  
the	   Fms-­‐like	   tyrosine	   kinase-­‐3	   ligand	   (Flt3L).	   The	   latter	   is	   a	   known	  DC	  activator	   and	   is	  
commonly	  used	  in	  anti-­‐cancer	  vaccine	  designs	  (Lynch	  et	  al.,	  1997;	  Barnard	  et	  al.,	  2012;	  
Riediger	  et	  al.,	  2013).	  The	  vaccine,	  GX-­‐188,	  was	  tested	   in	  a	  Phase	   I	  clinical	   trial,	  where	  
women	   with	   HPV-­‐16	   and	   -­‐18	   related	   CIN-­‐3	   were	   enrolled.	   Patients	   were	   vaccinated	  
intramuscularly,	  followed	  by	  EP	  to	  enhance	  uptake	  of	  the	  vaccine.	  GX-­‐188	  elicited	  HPV-­‐
16	  and	  -­‐18	  E6	  and	  E7	  specific	  cell-­‐mediated	  responses	  including	  IFN-­‐γ-­‐secreting	  CD8+	  and	  
CD4+	  T-­‐cells,	  as	  well	  as	  polyfunctional	  and	  proliferative	  CD8+	  T-­‐cells.	  This	  strong	  response	  
led	  to	  complete	  regression	  of	  lesions	  and	  viral	  clearance	  in	  67%	  of	  patients	  after	  12	  weeks	  
of	  treatment,	  and	  78%	  of	  patients	  after	  36	  weeks.	  This	  study	  showed	  that	  GX-­‐188	  is	  safe	  
and	  effective,	  and	  could	  be	  used	  as	  a	  non-­‐invasive	  treatment	  for	  HPV-­‐associated	  severe	  
lesions	  and	  cancer.	  Furthermore,	  it	  showed	  the	  immunopotentiator	  effect	  of	  Flt3L.	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Sun	  et	  al.	  (2015)	  tested	  the	  effects	  of	  different	  routes	  of	  vaccination	  and	  the	  effect	  of	  EP	  
on	  DNA	  vaccines	   in	  a	  pre-­‐clinical	   study.	  Mice	  were	  vaccinated	   intraperitoneally	   (IP)	  or	  
intravaginally	  (Ivag),	  with	  a	  HPV-­‐16	  E7	  sequence	  fused	  to	  CRT,	  followed	  by	  EP.	  Overall,	  EP	  
increased	   the	   CTL	   responses	   induced	   by	   both	   routes	   of	   vaccination	   compared	   to	   the	  
vaccination	  without	  EP.	  However,	  the	  Ivag	  +	  EP	  vaccination	  was	  able	  to	  elicit	  a	  strong	  E7-­‐
specific	  local	  and	  systemic	  CTL	  response,	  shown	  by	  the	  higher	  number	  of	  IFN-­‐γ	  secreting	  
CD8+	  T-­‐cells	  in	  cervicovaginal	  cells	  and	  splenocytes;	  while	  a	  strong	  CTL	  response	  of	  IP	  +	  
EP	  vaccinated	  mice	  was	  only	  shown	  in	  splenocytes	  and	  not	  in	  cervicovaginal	  cells.	  In	  the	  
same	  way,	  60%	  of	  TC-­‐1	  tumour-­‐bearing	  mice	  vaccinated	  Ivag	  +	  EP	  survived	  for	  at	  least	  80	  
days	  post	  challenge,	  while	  mice	  in	  the	  control	  and	  IP	  +	  EP	  vaccination	  groups	  died	  before	  
40	  days	  post	  challenge.	  This	  study	  showed	  that	  EP	  can	  enhance	  the	  immunogenicity	  of	  
DNA-­‐based	  vaccines	  and	  that	  the	  location	  of	  vaccination	  also	  plays	  a	  role	  in	  the	  vaccine	  
efficacy.	  	  
So	   far,	   the	  most	  successful	  HPV	  therapeutic	  vaccine	  was	  a	  synthetic	  DNA	  encoding	  for	  
HPV-­‐16	  and	   -­‐18	  E6	  and	  E7	  proteins.	  The	  vaccine,	  VGX-­‐3100,	  was	   tested	   in	  a	  Phase	   IIb	  
clinical	   trial	   (Trimble	   et	   al.,	   2015),	   where	   CIN-­‐2/3-­‐positive	   women	   were	   vaccinated	  
intramuscularly	  followed	  by	  EP.	   In	  the	  VGX-­‐3100	  group,	  49.5%	  of	  the	  105	  patients	  had	  
lesion	   regression,	   compared	   to	   30.6%	   of	   the	   36	   patients	   in	   the	   placebo	   group.	  More	  
importantly,	  40.2%	  of	  the	  patients	  had	  lesion	  regression	  accompanied	  by	  viral	  clearance	  
in	  the	  VGX-­‐3100	  group,	  compared	  to	  14.3%	  in	  the	  placebo	  group.	  The	  study	  also	  showed	  
that	  the	  vaccine	  elicited	  an	  E6-­‐specific	  cell-­‐mediated	  response	  that	  was	  reflected	  by	  lesion	  
regression,	   and	   E7-­‐specific	   responses	   which,	   however,	   did	   not	   translate	   clinically.	  
Furthermore,	  patients	  also	  showed	  anti-­‐E6	  and	  anti-­‐E7	  humoral	  responses.	  Overall,	  VGX-­‐
3100	  is	  the	  most	  advanced	  HPV	  therapeutic	  vaccine	  in	  terms	  of	  clinical	  trials,	  and	  could	  
possibly	  be	  the	  first	  approved	  vaccine	  for	  the	  treatment	  of	  HPV-­‐related	  malignancies.	  It	  is	  
expected	  to	  enter	  phase	  III	  clinical	  trials	  in	  2016	  (Inovio	  Inc.,	  2016).	  
1.2.3.2.	  RNA	  vaccines	  
DNA	  vaccines	  are	  stable	  and	  easily	  produced	  but	  they	  cannot	  proliferate	  and	  move	  from	  
cell	  to	  cell,	  which	  may	  decrease	  their	  immunogenicity.	  Additionally,	  they	  may	  impose	  a	  
risk	  of	   integrating	   in	   the	  host	   genome	  which	   could	  possibly	   cause	   cell	   transformation.	  
Although	  RNA	  vaccines	  have	  similar	  limitations	  as	  DNA	  vaccines	  and	  are	  less	  stable,	  RNA	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replicon-­‐based	  vaccines	  have	  advantages	  over	  DNA-­‐based	  ones.	  These	  can	  replicate	   in	  
various	  cell	  types,	  improving	  the	  propagation	  of	  the	  vaccine	  antigen.	  If	  derived	  from	  RNA	  
viruses	  replicating	  via	  RNA	  intermediates,	  they	  also	  lack	  the	  ability	  to	  integrate	  into	  the	  
host’s	  genome,	  decreasing	  the	  risk	  of	  cellular	  transformation.	  In	  order	  to	  counteract	  the	  
instability	  of	  RNA	  vaccines,	  a	  suicidal	  DNA	  vaccine	  encoding	  an	  RNA	  replicon	  can	  be	  used.	  
This	   DNA	   would	   be	   transcribed	   into	   the	   RNA	   replicon	   which	   would	   then	   amplify	   the	  
expression	  of	  the	  target	  antigen.	  The	  fact	  that	  the	  DNA	  is	  suicidal,	  i.e.	  it	  eventually	  induces	  
cell	  apoptosis,	  decreases	  the	  chances	  of	  it	  becoming	  integrated	  into	  the	  host’s	  genome	  
(Hung	   et	   al.,	   2008;	   Lin,	   Doolan,	   et	   al.,	   2010;	   Lin,	   Roosinovich,	   et	   al.,	   2010).	   These	  
approaches	  have	  shown	  specific	  T-­‐cell	  responses	  and	  antitumour	  effects	  (Berglund	  et	  al.,	  
1998;	   Herd	   et	   al.,	   2004;	   Hung	   et	   al.,	   2008).	   Nevertheless,	   RNA	   vaccines	   are	   more	  
complicated	  to	  produce	  and	  more	  expensive.	  Additionally,	  they	  have	  not	  progressed	  into	  
clinical	  trials.	  For	  these	  reasons	  they	  will	  not	  be	  further	  discussed	  here.	  	  
1.2.4.	  Cell-­‐based	  vaccines	  
Cell-­‐based	  vaccines	  involve	  the	  introduction	  of	  the	  major	  antigen-­‐presenting	  cells,	  DCs	  or	  
tumour	  cells,	   loaded	  with	   important	  antigens	  or	  epitopes	   that	  are	  needed	  to	   induce	  a	  
strong	  tumour-­‐specific	  CTL	  response.	  	  
The	  use	  of	  DCs	  is	  attractive	  because	  these	  cells	  are	  the	  major	  antigen	  presenting	  cells	  that	  
can	  activate	  CD4+	  and	  CD8+	  T-­‐cells	  (Banchereau	  and	  Steinman,	  1998),	  bypassing	  the	  need	  
to	  enhance	  antigen	  visibility	  that	  is	  faced	  by	  protein	  or	  DNA	  vaccines.	  Ferrara	  et	  al.	  (2003)	  
showed	  the	  safety	  of	  this	  approach	  in	  a	  clinical	  trial	  where	  cervical	  cancer	  patients	  were	  
vaccinated	  with	  DCs	  loaded	  with	  HPV-­‐16	  or	  HPV-­‐18	  E7	  proteins.	  Four	  of	  the	  11	  patients	  
showed	  E7-­‐specific	  CTL	  responses.	  However,	  these	  results	  were	  not	  reflected	  clinically,	  
maybe	  because	  of	  the	  advanced	  stages	  of	  the	  malignancies	  in	  these	  patients	  (Ferrara	  et	  
al.,	   2003).	   Handling	   human	   ex-­‐vivo	   cells	   requires	   high	   technical	   competence	   and	   DC-­‐
based	   vaccine	   production	   is	   labour-­‐intense,	   time	   consuming	   and	   costly,	   making	   this	  
strategy	   impractical	   to	   implement	   in	   large	   scale	   vaccinations	   (Lin,	   Roosinovich,	   et	   al.,	  
2010;	  Morrow,	  Yan	  and	  Sardesai,	  2013).	  	  
Using	  cancer	  cells	  allows	  the	  determination	  of	  useful	  antigens	  that	  could	  elicit	  a	  strong	  
cell-­‐mediated	  immunity.	  However,	  in	  the	  case	  of	  HPVs,	  these	  antigens	  have	  already	  been	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identified;	  therefore,	  the	  cancer	  cell	  strategy	  presents	  limited	  advantages.	  Furthermore,	  
it	  has	  similar	  limitations	  as	  the	  DC-­‐based	  strategy	  with	  the	  addition	  that	  it	  needs	  to	  be	  a	  
personalized	  vaccine,	  since	  tumour	  cells	  vary	  from	  patient	  to	  patient.	  Furthermore,	  there	  
are	   safety	   concerns	   regarding	   the	   idea	   of	   inoculating	   patients	   with	   cancer	   cells	   (Lin,	  
Roosinovich,	  et	  al.,	  2010;	  Morrow,	  Yan	  and	  Sardesai,	  2013).	  
Overall,	  cell-­‐based	  vaccines	  do	  not	  seem	  to	  be	  practical	  for	  the	  development	  of	  a	  cost-­‐
effective	  and	  wide-­‐spread	  treatment	  of	  HPV-­‐related	  malignancies.	  
1.2.5.	  Combining	  different	  therapeutic	  strategies	  
The	   diversity	   of	   current	   therapeutic	   vaccine	   candidates	   for	   HPV-­‐related	   malignancies	  
offers	   an	   opportunity	   to	   combine	   some	   of	   the	   strategies	   and	   to	   better	   exploit	   their	  
potentials.	  	  
One	  such	  strategy	  is	  the	  prime-­‐boost	  regime,	  in	  which	  the	  immune	  system	  is	  primed	  with,	  
for	  example,	  a	  DNA-­‐based	  vaccine	  and	  later	  boosted	  with	  a	  protein-­‐based	  vaccine.	  Bissa	  
et	  al.	  (2015),	  tested	  three	  prime-­‐boost	  strategies	  in	  a	  mouse	  tumour	  model:	  there	  were	  
DNA/DNA,	   DNA/viral-­‐vector	   and	   viral-­‐vector/viral-­‐vector	   regimens,	   all	   expressing	   a	  
modified	   version	   of	   the	   HPV-­‐16	   E6.	   In	   a	   therapeutic	   setting,	   80%	   of	   the	   mice	   in	   the	  
DNA/DNA	   group	   remained	   tumour-­‐free	  while	   surprisingly	   only	   20%	  of	  mice	   remained	  
tumour-­‐free	  in	  the	  other	  two	  groups.	  In	  a	  preventative	  setting,	  mice	  showed	  a	  delayed	  
development	  of	  TC-­‐1	  cell-­‐induced	  tumours.	  Although	  the	  humoral	  response	  in	  these	  mice	  
was	  very	  low,	  there	  were	  specific	  cell-­‐mediated	  responses	  which	  could	  have	  accounted	  
for	  the	  delayed	  tumour	  growth,	  highlighting	  the	  importance	  of	  this	  type	  of	  immunity	  in	  
terms	   of	   cancer	   treatment.	   This	   study	   also	   demonstrated	   the	   potential	   of	   DNA-­‐based	  
vaccines	  to	  prime	  the	  immune	  system	  and	  allow	  for	  an	  enhanced	  cell-­‐mediated	  immune	  
response	  upon	  boosting	  with	  DNA,	  viral-­‐vector	  or	  protein-­‐based	  vaccines.	  
Another	  study	  that	  showed	  the	  impact	  of	  a	  DNA	  vaccine	  priming	  followed	  by	  a	  boost	  was	  
that	  done	  by	  Radaelli	  et	  al.	  (2012).	  They	  immunized	  mice	  with	  an	  E7GGG	  DNA	  followed	  
by	  three	  boosts	  with	  an	  E7GGG-­‐expressing	  recombinant	   fowlpox	  virus	   live	  vector.	  This	  
regimen	  resulted	  in	  E7-­‐specific	  cell-­‐mediated	  immune	  responses	  that	  were	  greater	  than	  
that	  elicited	  by	  a	  live	  vector/live	  vector	  prime-­‐boost	  regimen,	  while	  the	  humoral	  immune	  
responses	  were	  comparable	  and	  low	  in	  both	  groups.	  The	  increased	  cell-­‐mediated	  immune	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response	  in	  the	  DNA/live	  vector	  group	  was	  accompanied	  by	  delayed	  tumour	  development	  
compared	  to	  the	  live	  vector/live	  vector	  and	  the	  placebo	  groups.	  	  
To	   optimize	   vaccination	   impact,	   chimaeric	   vaccines	   that	   have	   both	   prophylactic	   and	  
therapeutic	  effects	  have	  been	  studied.	  Ideally	  they	  would	  be	  able	  to	  induce	  both	  humoral	  
and	  cell-­‐mediated	  responses.	  De	  Jong	  et	  al.	  (2002)	  used	  a	  fusion	  protein	  consisting	  of	  HPV-­‐
16	   L2,	   E6	   and	  E7	   (TA-­‐CIN).	  Vaccinated	  mice	   showed	  production	  of	   E6-­‐	   and	  E7-­‐specific	  
antibodies	  as	  well	  as	  T-­‐cell	   immune	  responses.	   In	  a	  Phase	   II	   trial,	  Fiander	  et	  al.	   (2006)	  
vaccinated	   29	   women	   with	   VIN-­‐2	   and	   VIN-­‐3	   with	   TA-­‐CIN	   followed	   by	   a	   recombinant	  
vaccinia	   virus	   encoding	   HPV-­‐16	   and	   -­‐18	   E6	   and	   E7.	   Overall	   this	   prime-­‐boost	   method	  
resulted	  in	  antibody	  production	  as	  well	  as	  partial	  or	  complete	  regression	  of	  lesions.	  This	  
further	   confirmed	   that	   prime-­‐boost	   regimes	   can	   be	   useful	   in	   amplifying	   immune	  
responses,	   and	   that	   combined	   to	   chimaeric	   vaccines,	   a	   prophylactic	   as	   well	   as	   a	  
therapeutic	  effect	  can	  be	  achieved.	  This	  is	  relevant,	  as	  only	  one	  vaccine	  would	  be	  needed	  
for	  preventing	  and	  treating	  HPV-­‐related	  malignancies.	  
Pseudovirions	  (PsVs)	  consisting	  of	  a	  HPV	  VLP	  containing	  a	  plasmid	  DNA	  encoding	  for	  the	  
oncogenic	  proteins	  E6	  and	  E7	  could	  be	  used	  as	  a	  way	  of	  delivering	  DNA	  vaccines.	  HPV	  PsVs	  
would	   have	   the	   advantage	   of	   specifically	   targeting	   HPV-­‐prone	   tissues	   and	   efficiently	  
delivering	   the	   vaccine	   intracellularly,	   where	   MHC-­‐I	   pathways	   would	   be	   favoured,	  
increasing	  the	  likelihood	  of	  a	  strong	  CTL	  response.	  HPV	  PsVs	  have	  been	  used	  to	  deliver	  
gene	  therapies	  for	  different	  types	  of	  diseases,	  including	  ovarian	  cancer	  (Hung	  et	  al.,	  2012)	  
and	   respiratory	   syncytial	   virus	   (Graham	  et	   al.,	   2010;	   Çuburu	  et	   al.,	   2012;	   Kines	  et	   al.,	  
2015),	  and	  have	  been	  shown	  to	  generate	  higher	  antigen-­‐specific	  CD8+	  T	  cell	   immunity	  
than	  naked	  DNA	  (Peng	  et	  al.,	  2011).	  HPV	  PsV-­‐based	  vaccines	  could	  be	  used	  to	  also	  elicit	  
protective	  immunity,	  making	  it	  a	  chimaeric	  vaccine.	  And,	  if	  different	  HPV	  types	  were	  used	  
for	   the	   structural	   component	   of	   the	   PsVs	   and	   for	   the	   DNA	   component,	   a	   broad	   HPV	  
vaccine	  could	  be	  generated.	  
Another	  strategy	  is	  the	  combination	  of	  already	  established	  therapeutic	  treatments	  such	  
as	   chemo-­‐	   and	   radiotherapy	   with	   candidate	   vaccines	   to	   enhance	   the	   effect	   of	   one	  
another.	  For	  example,	  in	  a	  Phase	  II	  clinical	  trial,	  Daayana	  et	  al.	  (2010)	  tested	  the	  chimaeric	  
vaccine	   TA-­‐CIN	   in	   combination	  with	   imiquimod,	   an	   immunomodulatory	   topical	   agent.	  
Patients	  were	  treated	  with	  imiquimod	  for	  8	  weeks	  prior	  to	  three	  immunizations	  with	  TA-­‐
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CIN.	  Although	  the	  regimen	  did	  not	  alter	  the	  natural	  humoral	  response	  of	  the	  patients,	  by	  
week	  52	  after	  the	  last	  immunization,	  63%	  of	  patients	  had	  lesion	  clearance	  on	  histology,	  
36%	  showed	  HPV-­‐16	  clearance	  and	  79%	  were	  symptom-­‐free.	  Importantly,	  patients	  whose	  
lesion	  cleared	  had	  increased	  local	  numbers	  of	  CD4+	  and	  CD8+	  T-­‐cells	  compared	  to	  non-­‐
responders.	  	  
Chuang	  et	  al.	  (2009)	  tested	  the	  combination	  of	  apigenin,	  a	  chemotherapeutic	  agent	  that	  
enhances	  tumour	  cell	  apoptosis	  with	  a	  DNA-­‐based	  vaccine	  encoding	  for	  the	  HPV-­‐16	  E7	  
protein	   fused	   to	   the	   Mycobacterium	   tuberculosis	   HSP70.	   They	   showed	   that	   the	  
combinatorial	  vaccine	  elicited	  higher	  E7-­‐specific	  CTL	  responses	  than	  when	  apigenin	  or	  E7-­‐
HSP70	  were	  administered	  alone.	  Mice	  vaccinated	  with	  the	  combinatorial	  vaccine	  showed	  
tumour	  growth	  rates	  much	  lower	  than	  the	  other	  groups.	  In	  the	  same	  way,	  100%	  of	  mice	  
in	  the	  combinatorial	  vaccine	  group	  survived	  63	  days	  after	  challenge	  with	  TC-­‐1	  cells,	  while	  
only	  20%	  survived	  in	  the	  E7-­‐HSP70	  DNA-­‐based	  vaccine	  group	  and	  none	  in	  the	  apigenin	  
group.	  At	  the	  end	  of	  the	  experiment,	  60%	  of	  mice	  in	  the	  combinatorial	  group	  survived	  
while	   none	   survived	   in	   the	   other	   groups.	   This	   study	   showed	   the	   positive	   impact	   that	  
combining	  different	  therapeutic	  strategies	  can	  have	  in	  anti-­‐tumour	  treatments	  (Chuang	  
et	  al.,	  2009).	  	  
Finally,	  another	  possible	  strategy	  would	  be	  to	  reduce	  the	  immunosuppressive	  conditions	  
present	   in	   the	   tumour	   microenvironment.	   As	   mentioned	   before,	   this	   environment	   is	  
influenced	  by	  Tregs,	  MDSCs,	  TAMs	  between	  other	  factors.	  By	  blocking	  the	  effect	  of	  these	  
cells	   and	   factors,	   the	   potential	   of	   current	   therapeutic	   vaccine	   candidates	   could	   be	  
enhanced	  (Pittet,	  2009;	  Lin,	  Roosinovich,	  et	  al.,	  2010;	  Morrow,	  Yan	  and	  Sardesai,	  2013).	  
A	  summary	  of	  the	  mechanism	  of	  action	  of	  an	  ideal	  HPV	  therapeutic	  vaccine	  is	  shown	  in	  
Figure	  1.3.	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Figure	  1.3.	  Mechanism	  of	  an	  ideal	  therapeutic	  vaccine	  against	  HPV-­‐related	  malignancies.	  An	   ideal	  HPV	  
therapeutic	  vaccine	  would	  elicit	  a	  strong	  cell-­‐mediated	  immune	  response	  where	  CD4+	  T-­‐cells	  would	  provide	  
support	  to	  CD8+	  T-­‐cells	  by	  secreting	  cytokines	  such	  as	  IFN-­‐γ	  and	  IL2	  labelling	  infected	  and	  malignant	  cells.	  
Cytotoxic	  CD8+	  T-­‐cells	  would	  eliminate	  infected	  cells	  by	  secreting	  high	  amounts	  of	  granzyme	  B	  and	  perforin	  
which	  lead	  to	  cell	  apoptosis.	  	  The	  response	  would	  be	  effective	  even	  in	  the	  presence	  of	  immunosuppressive	  
cells	  such	  as	  Tregs.	  Adapted	  from	  Morrow	  et	  al.	  (2013).	  
	  
1.3.	  HPV	  therapeutic	  vaccines	  produced	  in	  plants	  
Developing	  countries	  carry	  the	  greatest	  burden	  of	  HPV	  infections	  and	  malignancies	  due	  
to	  their	  lack	  of	  resources	  to	  implement	  efficient	  vaccination	  and	  screening	  programmes.	  
In	  these	  areas,	  infections	  are	  generally	  detected	  at	  a	  progressed	  stage,	  and	  treatment	  and	  
follow-­‐ups	  are	  difficult	  to	  obtain.	  Despite	  the	  current	  success	  of	  several	  HPV	  therapeutic	  
vaccine	   candidates,	   including	   numerous	   clinical	   trials,	   there	   remains	   the	   concern	   that	  
Periphery	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  vector,	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conventional	   expression	  methods	  might	   result	   in	   expensive	   products	   (Giorgi,	   Franconi	  
and	  Rybicki,	  2010;	  Rybicki,	  2014).	  
Plants	  represent	  an	  attractive	  alternative	  to	  conventional	  expression	  systems	  based	  on	  
bacterial,	  yeast,	  mammalian	  and	  other	  cell	  cultures.	  Plants	  are	  not	  vulnerable	  to	  animal	  
pathogen	  contamination	  like	  mammalian	  or	  insect	  cells,	  they	  do	  not	  produce	  endotoxins	  
like	  bacterial	  cultures,	  and	  they	  are	  able	  to	  post-­‐translationally	  modify	  proteins	  in	  a	  similar	  
way	   to	   mammalian	   cells,	   making	   them	   efficient,	   safer	   and	   potentially	   far	   more	   cost-­‐
effective	  than	  conventional	  expression	  systems.	  Furthermore,	  they	  are	  highly	  scalable	  as	  
they	  can	  be	  grown	  to	  agricultural	  scale	  in	  fields,	  greenhouses	  or	  in	  vertical	  farming	  units	  
(Yusibov	  et	  al.,	  2006;	  Rybicki,	  2009;	  Merlin	  et	  al.,	  2014).	  	  
Plants	   can	   be	  modified	   to	   express	   heterologous	   proteins	   in	   a	   transgenic	   or	   transient	  
manner.	  In	  transient	  expression,	  unlike	  in	  transgenic	  expression,	  the	  gene	  of	  interest	  does	  
not	  become	  integrated	  into	  the	  plant’s	  genome.	  In	  general,	  transient	  expression	  in	  plants	  
has	  proven	  to	  be	  a	  more	  efficient	  and	  generally	  higher	  yielding	  albeit	  less	  cost-­‐effective	  
method	   than	   transgenic	   expression.	   Additionally,	   transient	   expression	   facilitates	  
biocontainment	   since	   genetically	   modified	   plants	   are	   not	   generated	   and	   no	   genetic	  
material	  such	  as	  pollen	  can	  be	  transferred	  to	  adjacent	  plants.	  Plants	  can	  be	  transiently	  
modified	  by	  Agrobacterium-­‐mediated	  gene	  delivery	  of	  Agrobacterium-­‐based	  expression	  
vectors	  or	  viral	  expression	  vectors,	  using	  vacuum	  or	  syringe	  infiltration.	  This	  method	  is	  
highly	  efficient	  and	  expression	  can	  be	  obtained	  as	  soon	  as	  3	  days	  post	  infiltration	  (Gleba,	  
Klimyuk	  and	  Marillonnet,	  2007;	  Rybicki,	  2009;	  Hefferon,	  2014).	  
Our	  group	  was	  one	  of	  the	  first	  to	  start	  developing	  HPV	  vaccines	  in	  plants,	  in	  the	  1990s	  
(Rybicki,	  2009;	  Hefferon,	  2013).	  Besides	  Biemelt	  et	  al.	  (2003),	  we	  provided	  one	  of	  the	  first	  
proofs	   that	   plant-­‐produced	   and	   L1-­‐based	   papillomavirus	   vaccines	   could	   succeed	   by	  
expressing	   the	   HPV-­‐16	   L1	   protein	   in	   transgenic	   Nicotiana	   tabacum	   and	   Solanum	  
tuberosum	  (Varsani	  et	  al.,	  2003;	  Warzecha	  et	  al.,	  2003),	  or	  the	  L1	  protein	  of	  cottontail	  
rabbit	   papillomavirus	   (CRPV)	   transiently	   in	   Nicotiana	   benthamiana	   via	   the	   use	   of	   a	  
Tobacco	  mosaic	  virus	  vector	  (Kohl	  et	  al.,	  2006).	  In	  the	  latter,	  vaccinated	  rabbits	  did	  not	  
detectably	  produce	  neutralizing	  antibodies,	  but	  were	  completely	  protected	  against	  CRPV	  
(Kohl	   et	   al.,	   2006).	   This	   work	   was	   followed	   by	   numerous	   successful	   studies	   including	  
optimization	   of	   HPV-­‐16	   L1	   antigen	   expression	   in	   terms	   of	   codon	   usage	   and	   cell	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compartment	   targeting	   (Maclean	  et	   al.,	   2007),	   as	  well	   as	   the	  development	  of	   a	   novel	  
geminivirus-­‐derived	  replicating	  DNA	  viral	  vector	  that	  further	  enhanced	  expression	  levels	  
(Regnard	  et	  al.,	  2010).	  
Although	   most	   of	   the	   HPV	   vaccine	   development	   in	   plants	   has	   focused	   on	   second	  
generation	  prophylactic	  vaccines,	  therapeutic	  vaccines	  have	  also	  been	  investigated	  more	  
recently.	  One	   of	   the	   first	   groups	   to	   attempt	   this,	   used	   a	   potato	   virus	   X	   (PVX)-­‐derived	  
vector	  to	  transiently	  express	  HPV-­‐16	  E7	  in	  N.	  benthamiana	  (Franconi	  et	  al.,	  2002).	  They	  
reported	  E7	  expression	   levels	  of	  3-­‐4	  mg/kg	  biomass.	   Leaf	  crude	  extracts	  were	  used	   to	  
immunize	   mice,	   which	   produced	   E7-­‐specific	   antibodies	   as	   well	   as	   E7-­‐specific	   CTL	  
responses.	  Mice	  showed	  both	  Th-­‐1	  and	  Th-­‐2	  immune	  responses	  with	  the	  Th-­‐1	  response	  
being	  higher.	  Forty	  per	  cent	  of	  vaccinated	  mice	  survived	  tumour	  challenges	  with	  minimal	  
tumour	  growth	  over	  the	  52	  days	  of	  the	  experiment.	  The	  same	  group	  was	  able	  to	  enhance	  
the	  expression	  levels	  of	  E7	  by	  5	  times	  by	  targeting	  it	  to	  plant	  secretory	  pathways,	  and	  the	  
increased	   levels	   of	   E7	   in	   leaf	   extracts	   enhanced	   the	   tumour	   protection	   in	  mice.	   Total	  
tumour	  protection	  was	  observed	  in	  80%	  of	  mice	  after	  50	  days	  of	  vaccination.	  They	  showed	  
that	  a	  therapeutic	  HPV	  vaccine	  candidate	  could	  be	  expressed	  in	  plants	   in	  a	  biologically	  
relevant	   way,	   although	   expression	   levels	   needed	   to	   be	   optimized.	   Furthermore,	   they	  
suggested	  that	  plant	  material	  could	  behave	  as	  a	  natural	  adjuvant	  since	  stronger	  immune	  
responses	  were	  seen	  for	  mice	  vaccinated	  with	  leaf	  extracts	  than	  in	  the	  positive	  control	  
group	  vaccinated	  with	  an	  E.	  coli-­‐derived	  E7	  and	  the	  Quil	  A	  adjuvant	  (Franconi	  et	  al.,	  2006).	  
The	   immunomodulatory	   properties	   of	   N.	   benthamiana	   leaf	   extracts	   were	   later	  
demonstrated	  by	  Di	  Bonito	  et	  al.	  (2009),	  who	  tested	  the	  effect	  of	  leaf	  extracts	  containing	  
E7	  on	  human	  monocyte	  derived	  DCs.	  The	  leaf	  extracts	  were	  able	  to	  prime	  these	  cells	  and	  
induce	  E7-­‐specific	  cytotoxic	  activity.	  	  
In	  work	  reported	  by	  Massa	  et	  al.	  (2007),	  the	  HPV-­‐16	  E7-­‐based	  mutant	  E7GGG	  was	  linked	  
to	  the	  Clostridium	  thermocellum	  beta-­‐1,3-­‐1,4-­‐glucanase	  (LicKM)	  and	  expressed	  from	  the	  
PVX-­‐based	   vector	   in	   N.	   benthamiana.	   The	   LicKM-­‐E7GGG	   vaccine	   had	   decreased	  
immunogenicity,	   but	   when	   administered	   with	   the	   Quil	   A	   adjuvant	   it	   elicited	   strong	  
humoral	  and	  cell	  mediated	  immunity	  that	  could	  prevent	  tumour	  development	  in	  100%	  of	  
vaccinated	  mice.	  They	  were	  able	  to	  purify	  LicKM-­‐E7GGG	  to	  99%	  purity	  at	  a	  yield	  of	  100	  
mg/kg	  biomass,	  representing	  a	  50%	  recovery	  rate,	  using	  immobilized	  metal-­‐ion	  affinity	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chromatography	  and	  gel	  filtration.	  They	  also	  scaled	  up	  the	  expression	  from	  50	  g	  to	  1	  kg	  of	  
biomass	   with	   very	   little	   variation	   on	   the	   purification	   results.	   This	   showed	   that	   plant-­‐
derived	  LicKM-­‐E7GGG	  and	  in	  general,	  plant-­‐derived	  E7-­‐based	  HPV	  therapeutic	  vaccines,	  
can	  be	  successfully	  expressed,	  purified	  and	  scaled-­‐up	  to	  commercially	  viable	  quantities	  
(Buyel	  et	  al.,	  2012).	  
Recently,	  the	  E7GGG	  candidate	  was	  expressed	  in	  chloroplasts	  of	  the	  well	  characterized	  
unicellular	  alga	  Chlamydomonas	   reinhardtii	   (Demurtas	  et	  al.,	   2013).	   Interestingly,	   they	  
report	  the	  expression	  of	  a	  soluble	  variant	  of	  the	  E7	  protein.	  This	  enhances	  its	  downstream	  
processing	  and	  increases	  its	  potential	  to	  be	  a	  cost-­‐effective	  product	  compared	  to	  other	  
E7	  derived	  proteins	  that	  are	  normally	  very	  insoluble	  (Giorgi,	  Franconi	  and	  Rybicki,	  2010).	  
Sixty	  per	  cent	  of	  immunized	  mice	  remained	  tumour-­‐free	  at	  the	  end	  of	  the	  experiment	  and	  
the	   mice	   that	   developed	   tumours	   showed	   delayed	   tumour	   appearance	   compared	   to	  
control	   mice	   vaccinated	   with	   an	   E.	   coli-­‐derived	   E7GGG,	   showing	   that	   this	   vaccine	  
candidate	  expressed	  in	  an	  algal	  system	  retained	  its	  therapeutic	  relevance	  	  (Demurtas	  et	  
al.,	  2013).	  	  
Recently,	  Whitehead	  et	   al.	   (2014)	   expressed	   another	  HPV-­‐16	   E7	  mutant	   protein	   in	  N.	  
benthamiana,	   that	   had	   its	   pRb-­‐binding	   ability	   eliminated	   by	   shuffling	   the	   protein	  
sequence	  while	  retaining	  all	  possible	  CTL	  epitopes.	  This	  vaccine	  candidate,	  16E7SH,	  was	  
previously	   tested	   as	   a	   DNA-­‐based	   vaccine	   with	   successful	   protective	   and	   therapeutic	  
results	  in	  mouse	  models	  (Öhlschläger	  et	  al.,	  2006).	  Here,	  16E7SH	  was	  linked	  to	  the	  Zera®	  
signal	   peptide	   (ERA	  Biotech,	   Spain),	   derived	   from	   the	  maize	   γ-­‐zein	   protein,	  which	   can	  
naturally	  form	  large	  membrane-­‐bound	  protein	  bodies.	  The	  Zera®-­‐16E7SH	  fusion	  protein	  
was	  expressed	  at	  very	  high	  levels,	  1.1	  g/kg	  biomass,	  while	  when	  expressed	  without	  the	  
Zera®	  peptide,	  16E7SH	  was	  not	  detectable.	  Furthermore,	  Zera®-­‐E7SH	  protein	  bodies	  were	  
easily	  purified	  to	  a	  yield	  of	  50	  mg/kg	  biomass.	  Vaccinated	  mice	  showed	  strong	  cellular	  
immunity	   similar	   to	   that	   elicited	   by	   the	   DNA-­‐based	   counterpart,	   as	   determined	   by	  
Granzyme	  B	  levels	  and	  IFN-­‐γ	  levels.	  This	  was	  independent	  of	  the	  presence	  of	  incomplete	  
Freud’s	  adjuvant,	  showing	  a	  potential	  immunostimulatory	  role	  of	  the	  Zera®	  peptide.	  Mice	  
were	   protected	   against	   tumours	   in	   prophylactic	   experiments,	   and	   showed	   tumour	  
regression	  in	  therapeutic	  experiments	  in	  a	  similar	  way	  as	  mice	  immunized	  with	  the	  DNA-­‐
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based	  counterpart.	  These	  results	  were	  very	  promising	  and	  have	  the	  potential	  to	  be	  further	  
enhanced	  by	  a	  DNA/fusion	  protein	  prime-­‐boost	  regimen	  (Whitehead	  et	  al.,	  2014).	  
Finally,	   our	   group	   has	   recently	   expressed	  HPV-­‐16	   PsVs	   in	  N.	   benthamiana,	   capable	   of	  
infecting	   mammalian	   cells	   and	   efficiently	   delivering	   a	   functional	   reporter-­‐expressing	  
plasmid	   (Lamprecht	  et	  al.,	  2016).	  This	  opens	   the	  possibility	  of	  producing	  plant-­‐derived	  
HPV	  PsVs	  encoding	  for	  therapeutic	  DNA	  vaccines,	  which	  would	  be	  considerably	  more	  cost-­‐
effective	   than	   conventional	   PsVs	   that	   are	   currently	   produced	   in	   mammalian	   cells.	  
Therefore,	  it	  is	  evident	  that	  plant	  expression	  systems	  can	  be	  used	  to	  produce	  biologically	  
relevant	  products	  with	  potential	  important	  pharmaceutical	  applications.	  
	  
1.4.	  Conclusions	  
The	  future	  of	  HPV	  therapeutic	  vaccine	  development	  will	  probably	  be	  more	  focused	  on	  
DNA	  and	  protein-­‐based	  strategies,	  since	  these	  have	  been	  most	  successful	  and	  safer	  than	  
use	  of	  live	  vaccine	  vectors.	  Protein	  and	  DNA-­‐based	  vaccines	  are	  also	  simpler	  to	  produce,	  
therefore	  less	  costly	  compared	  to	  the	  other	  strategies.	  They	  will	  probably	  be	  designed	  to	  
incorporate	   molecules	   that	   improve	   CD8+	   T-­‐cell	   responses	   by	   facilitating	   uptake	   by	  
professional	  antigen	  presenting	  cells	  by	  fusion	  to	  cell	  penetrating	  peptides,	  TLR-­‐3	  and	  -­‐9	  
agonists,	  and	  engineered	  to	  overcome	  the	  immunosuppressive	  conditions	  in	  the	  tumour	  
microenvironment.	   	   Furthermore,	   they	   will	   probably	   be	   more	   extensively	   studied	   in	  
combination	  with	  other	  cancer	  treatments.	  	  
Until	  now	  there	  has	  been	  no	  therapeutic	  vaccine	  commercially	  released	  for	  the	  treatment	  
of	  HPV	  infections	  and	  related	  malignancies.	  Nevertheless,	  there	  are	  numerous	  successful	  
pre-­‐clinical	  results	  and	  ever-­‐increasing	  clinical	  results	  for	  a	  variety	  of	  candidate	  vaccines.	  
The	  most	  promising,	  in	  terms	  of	  clinical	  trial	  progression,	  is	  the	  Inovio	  VGX-­‐3100.	  With	  the	  
increased	  accumulation	  of	  knowledge	  due	  to	  the	  detailed	  study	  of	  cancer	  pathways	  and	  
characterisation	   of	   immune	   responses	   (especially	   cell-­‐mediated),	   the	   design	   of	  
therapeutic	  vaccines	  can	  only	  improve.	  More	  clinical	  studies	  will	  be	  done,	  and	  hopefully	  
a	  HPV	  therapeutic	  vaccine	  is	  not	  too	  far	  in	  the	  future,	  even	  if	  it	  is	  one	  that	  only	  improves	  
the	  life	  of	  those	  affected	  by	  the	  virus.	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1.5.	  Project	  aims	  and	  objectives	  
The	   first	   aim	   of	   this	   study	   was	   to	   optimize	   the	   expression	   of	   the	   candidate	   HPV	  
therapeutic	  vaccine,	  LALF-­‐E7	  (Granadillo	  et	  al.,	  2011),	  in	  Nicotiana	  benthamiana	  leaves.	  
This	   fusion	  protein	  was	  previously	  expressed	   in	  plants,	  but	  was	  difficult	   to	  detect	   and	  
could	  not	  be	  purified	   (M.	  Granadillo	  and	  R.	   Lamprecht,	  unpublished	  data).	   In	  order	   to	  
increase	  the	  expression	  of	  LALF-­‐E7	  I	  used	  our	  in-­‐house	  self-­‐replicating	  expression	  vector	  
pRIC3.0	   (Regnard	   et	   al.,	   2010),	   which	   was	   shown	   to	   increase	   expression	   levels	   by	  
increasing	   gene	   copy	   numbers.	   To	   further	   increase	   LALF-­‐E7	   accumulation	   in	   N.	  
benthamiana	   leaves,	   I	   targeted	   it	   to	   the	   chloroplasts.	  We	  hypothesised	   that	   targeting	  
proteins	  to	  cell	  compartments	  could	  increase	  their	  yields	  by	  increasing	  their	  stability	  and	  
decreasing	   proteolytic	   degradation.	   Furthermore,	   I	   investigated	   the	   effect	   of	   silencing	  
suppressors	  on	  the	  expression	  of	  LALF-­‐E7.	  	  
The	   second	   aim	   was	   to	   determine	   the	   subcellular	   localization	   of	   LALF-­‐E7	   in	   N.	  
benthamiana	  leaves	  by	  fluorescence	  microscopy.	  For	  this	  I	  fused	  it	  to	  the	  enhanced	  green	  
fluorescent	  protein	  (EGFP).	  I	  wanted	  to	  see	  whether	  LALF-­‐E7	  was	  indeed	  targeted	  to	  the	  
chloroplasts	   and	   if	   it	   remained	   associated	   to	   these	   organelles.	   Since	   LALF	   is	   a	   cell	  
membrane-­‐penetrating	  peptide,	   it	   could	  be	  possible	   that	  LALF-­‐E7	  would	  be	  associated	  
with	  the	  plants’	  cell	  membranes	  or	  that	  it	  could	  in	  fact	  exit	  the	  plant	  cells.	  
The	  third	  aim	  was	  to	  scale-­‐up	  the	  production	  of	  LALF-­‐E7	  and	  develop	  an	  extraction	  and	  
purification	  strategy	  for	  it.	  Different	  crude	  extraction	  strategies	  were	  tested	  to	  pre-­‐purify	  
the	  plant-­‐derived	  LALF-­‐E7.	  This	  was	  followed	  by	  an	  automated	  affinity	  chromatography	  
step	  using	  the	  ÄKTA	  system.	  	  
Finally,	  I	  aimed	  at	  comparing	  the	  plant-­‐derived	  LALF-­‐E7	  to	  the	  E.	  coli-­‐derived	  counterpart	  
for	  its	  ability	  to	  elicit	  tumour	  regression	  in	  C57BL/6	  mice.	  I	  hypothesized	  that	  the	  plant-­‐
derived	  LALF-­‐E7	  could	  drive	   tumour	   regression	   in	  a	  comparable	  manner	  as	   the	  E.	  coli-­‐
derived	  LALF-­‐E7.	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Chapter	  2:	  Expression	  optimization	  of	  LALF-­‐E7	  in	  Nicotiana	  
benthamiana	  leaves	  
	  
2.1.	  Introduction	  	  
Recombinant	  proteins	  have	  a	  wide	  range	  of	  applications	  in	  the	  industrial,	  biomedical	  and	  
biological	  research	  fields.	  There	  is	  a	  high	  demand	  for	  recombinant	  proteins,	  which	  in	  turn	  
requires	   efficient	   and	   scalable	   production	   systems.	   Current	   methods	   to	   produce	  
recombinant	  proteins	  are	  based	  on	  mammalian,	  insect	  or	  microbial	  cell	  cultures,	  and	  rely	  
on	  the	  use	  of	  bioreactors	  and	  expensive	  growth	  media.	  As	  mentioned	  in	  Chapter	  1,	  plants	  
provide	   an	   alternative	   platform	   for	   the	   expression	   of	   recombinant	   proteins	   which	   is	  
potentially	  more	  cost-­‐effective	  than	  conventional	  methods,	  and	  highly	  scalable	  	  (Yusibov	  
et	  al.,	  2006;	  Sainsbury	  et	  al.,	  2008;	  Rybicki,	  2009;	  Pogue	  and	  Holzberg,	  2012).	  	  
Plants	   can	  be	  modified	   by	  Agrobacterium	   tumefaciens-­‐mediated	   gene	  delivery,	  where	  
bacterial	   cultures	   transformed	  with	   an	   appropriate	   expression	   vector	   are	   vacuum-­‐	   or	  
syringe-­‐infiltrated	  into	  the	  plant	  leaves,	  a	  process	  termed	  agroinfiltration.	  A.	  tumefaciens	  
is	  a	  plant	  pathogen	  that	  is	  able	  to	  deliver	  genetic	  information	  into	  the	  plant	  cells	  nuclei	  
via	  its	  Ti-­‐plasmid.	  This	  plasmid	  contains	  a	  region	  flanked	  by	  25	  bp	  direct	  repeats,	  called	  
the	  T-­‐DNA.	  Any	  DNA	  sequence	  contained	  between	  these	  borders	  is	  transferred	  into	  the	  
plant	   cells	   nuclei	   by	   a	   bacterially-­‐mediated	   transport	   process	   involving	   linear	   single-­‐
stranded	  T-­‐DNA,	  after	  which	  it	  can	  be	  integrated	  into	  the	  host’s	  genomic	  DNA.	  By	  cloning	  
an	  expression	  cassette	  into	  the	  T-­‐DNA,	  transgenic	  plants	  can	  be	  generated	  that	  express	  a	  
protein	  of	  interest	  (Kapila	  et	  al.,	  1997;	  Zupan	  et	  al.,	  2000;	  Gelvin,	  2003).	  	  
However,	  not	  all	  T-­‐DNAs	  become	  integrated:	  probably	  more	  often,	  T-­‐DNA	  remains	  as	  a	  
linear	  or	  circularised	  dsDNA	  episome.	  These	  episomal	  T-­‐DNAs	  can	  drive	  gene	  expression	  
in	  a	  transient	  way.	  This	  has	  been	  preferentially	  exploited	  as	  a	  more	  rapid	  and	  simple	  way	  
of	  expressing	  recombinant	  proteins	  in	  plants.	  Transient	  expression	  is	  not	  influenced	  by	  
insertion	   position	   and	   does	   not	   require	   the	   challenging	   techniques	   faced	   when	  
regenerating	   transgenic	   plants	   (Kapila	   et	   al.,	   1997;	   Zupan	   et	   al.,	   2000;	   Gelvin,	   2003).	  
Transient	  expression	  also	  facilitates	  biocontainment	  since	  genetically	  modified	  plants	  are	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not	  generated	  and	  no	  genetic	  material	  can	  be	  transferred	  to	  other	  	  plants	  via,	  for	  example,	  
pollen	  (Gleba	  et	  al.,	  2007;	  Hefferon,	  2014;	  Rybicki,	  2009;	  Yusibov	  et	  al.,	  2006).	  	  
The	  choice	  of	  expression	  vectors	  plays	  an	  important	  role	  in	  the	  expression	  of	  recombinant	  
proteins	   in	  plants.	   The	  use	  of	   plant	   viral	   vectors	  has	  often	  been	   favoured	   in	   transient	  
expression	  over	  other	  methods,	  as	  they	  offer	  various	  advantages.	  Plant	  viruses	  have	  small	  
genomes	  which	  allow	  them	  to	  be	  easily	  manipulated,	  especially	  in	  the	  case	  of	  the	  circular	  
single	  stranded	  (ss)	  DNA	  geminiviruses.	  Plant	  infection	  with	  these	  viral	  vectors	  is	  simple	  
and	  inexpensive,	  and	  a	  wide	  range	  of	  hosts	  can	  potentially	  be	  used	  (Cañizares,	  Nicholson	  
and	  Lomonossoff,	  2005;	  Rybicki	  and	  Martin,	  2011).	  Agrobacterium-­‐mediated	  delivery	  of	  
the	  viral	  vectors	  encoded	  within	  the	  Agrobacterium	  T-­‐DNA	  benefits	  from	  the	  advantages	  
of	  three	  important	  biological	  systems:	  the	  Agrobacterium	  provides	  transfection	  efficiency	  
and	  systemic	  delivery	  of	  the	  viral	  construct;	  the	  viral	  vector	  provides	  speed	  to	  the	  process	  
since	  it	  contains	  elements	  that	  can	  enhance	  the	  expression	  of	  target	  genes	  encoded	  in	  its	  
backbone;	  and	  the	  plant	  provides	  the	  correct	  processing	  of	  the	  proteins	  of	  interest	  as	  well	  
as	  low	  production	  costs	  (Gleba	  et	  al.,	  2007;	  Hefferon,	  2012;	  Hefferon,	  2014).	  	  	  
In	  this	  study	  I	  used	  pRIC3.0,	  a	  proprietary	  replicating	  plant	  expression	  vector.	  This	  vector	  
is	  based	  on	  the	  mild	  strain	  of	  the	  bean	  yellow	  dwarf	  virus	  (BeYDV),	  a	  ssDNA	  geminivirus	  
belonging	  to	  the	  genus	  Mastrevirus.	  It	  consists	  of	  the	  BeYDV	  genome	  between	  two	  viral	  
large	   intergenic	   regions	   (LIRs)	  within	  which	   two	  copies	  of	   the	   cauliflower	  mosaic	   virus	  
(CaMV)	  35S	  constitutive	  promoter	  and	  the	  gene	  of	  interest	  replace	  the	  viral	  capsid	  protein	  
and	  movement	  protein	  genes.	  This	  expression	  cassette	   is	  placed	  between	  the	   left	  and	  
right	  borders	  of	  the	  A.	  tumefaciens	  T-­‐DNA	  and	  includes	  the	  viral	  replication-­‐associated	  
genetic	  elements	  (Rep	  and	  RepA)	  expressed	  in	  cis	  from	  its	  backbone.	  It	  also	  contains	  the	  
bla	   gene	   for	   antibiotic	   selection,	   as	   well	   as	   origins	   of	   replication	   for	   E.	   coli	   and	  
Agrobacterium.	   Upon	   infiltration	   the	   T-­‐DNA	   is	   released	   and	   re-­‐circularizes	   forming	   a	  
replicon.	  Using	  the	  host’s	  replication	  machinery	  and	  specially	  the	  Rep	  and	  RepA	  proteins,	  
the	  replicon	  is	  continuously	  amplified	  by	  rolling	  circle	  replication.	  In	  this	  way,	  a	  high	  copy	  
number	  of	  the	  gene	  of	  interest	  is	  obtained,	  which	  leads	  to	  an	  increase	  in	  expression	  levels.	  
Regnard	  et	  al.	  (2010)	  and	  Rybicki	  and	  Martin	  (2011)	  give	  a	  full	  description	  of	  this	  vector	  
and	  discuss	  the	  use	  of	  geminiviruses	  and	  other	  ssDNA	  plant	  viruses	  as	  plant	  expression	  
vectors.	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pRIC	   was	   originally	   compared	   to	   the	   non-­‐replicative	   Ti	   plasmid-­‐based	   vector	   pTRAc	  
(Regnard	  et	  al.,	  2010).	  The	  pTRAc	  vector	  is	  similar	  to	  the	  pRIC	  vector,	  except	  it	  does	  not	  
contain	  the	  BeYDV	  replicative	  elements.	  Instead,	  the	  gene	  of	  interest	  and	  the	  two	  copies	  
of	   the	   CaMV	   35S	   promoter	   are	   in	   between	   the	   left	   and	   right	   borders	   of	   the	   T-­‐DNA,	  
resembling	  a	  Ti-­‐plasmid	  (Maclean	  et	  al.,	  2007),	  as	  seen	  in	  Figure	  2.1.	  	  
	  
Figure	  2.1.	  Comparison	  between	  the	  non-­‐replicative	  pTRAc	  and	  the	  replicative	  pRIC	  expression	  vectors.	  
The	  circularized	  pRIC	  replicon	  released	  from	  T-­‐DNA	  is	  shown	  on	  the	  bottom.	  ColE1	  ori,	  origin	  of	  replication	  
for	  E.	  coli;	  RK2	  ori,	  origin	  of	  replication	  for	  A.	  tumefaciens;	  bla,	  ampicillin/carbenicillin	  resistance	  gene;	  LB	  
and	  RB,	  left	  and	  right	  borders	  for	  T-­‐DNA	  integration;	  SAR,	  scaffold	  attachment	  region	  of	  the	  tobacco	  Rb7	  
gene;	   P35SS,	   CaMV	  35S	  promoter	  with	   duplicated	   transcriptional	   enhancer;	   CHS,	   chalcone	   synthase	   5’-­‐
untranslated	  region;	  pA35S,	  CaMV	  35S	  polyadenylation	  signal;	  LIR,	  BeYDV	  long	  intergenic	  region;	  SIR,	  BeYDV	  
short	  intergenic	  region;	  rep,	  BeYDV	  rep	  gene.	  The	  T-­‐DNA	  transferred	  into	  the	  plant	  cells	  is	  shown	  by	  the	  
grey	  bar	  inside	  the	  plasmid	  maps.	  Kindly	  provided	  by	  Regnard	  et	  al.	  (2010).	  
	  
Regnard	  et	  al.,	  (2010)	  obtained	  higher	  cytoplasmic	  expression	  levels	  of	  HPV-­‐16	  L1	  and	  two	  
other	  non-­‐related	  proteins	  than	  previously	  described	  (Maclean	  et	  al.,	  2007	  and	  Meyers	  et	  
al.,	  2008).	  HPV-­‐16	  L1	  yields	  were	  1.6	  fold	  higher	  when	  using	  pRIC	  (550	  mg/kg	  biomass)	  
than	  when	  using	  the	  pTRAc	  (337	  mg/Kg	  biomass).	  However,	  the	  increase	  in	  expression	  
levels	  was	  far	  smaller	  than	  the	  increase	  in	  gene	  copy	  number,	  which	  was	  100	  fold	  for	  HPV-­‐
16	  L1.	  
Subcellular	   localization	  can	  have	  a	  dramatic	  effect	  on	  expression	  levels	  of	  recombinant	  
proteins.	   It	  has	  been	  shown	   in	  numerous	  cases	  that	   targeting	  proteins	  not	  only	   to	  the	  
chloroplasts,	  but	   also	   to	   the	  endoplasmic	   reticulum	   (ER)	  or	   the	  apoplast,	   can	   increase	  
their	  accumulation	  (Streatfield	  et	  al.,	  2003;	  Maclean	  et	  al.,	  2007;	  Meyers	  et	  al.,	  2008;	  Karg	  
and	  Kallio,	  2009).	  Significantly	  high	  levels	  of	  HPV-­‐16	  L1,	  up	  to	  11%	  of	  total	  soluble	  proteins	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(TSP)	  using	  the	  pTRAc	  vector,	  were	  obtained	  when	  targeting	  proteins	  to	  the	  chloroplasts	  
compared	  to	  cytoplasmic	  localization.	  This	  was	  done	  using	  the	  chloroplast	  transit	  peptide	  
(cTP)	   derived	   from	   the	   potato	   rbcS1	   gene	   of	   the	   ribulose-­‐1,5-­‐bisphosphate	  
carboxylase/oxygenase	  (RuBisCO)	  small	  subunit.	  It	  is	  known	  that	  targeting	  proteins	  to	  cell	  
compartments	   increases	   protein	   accumulation	   possibly	   because	   proteins	  may	   be	   less	  
prone	   to	   degradation	   than	   in	   the	   cytoplasm	   (Maclean	   et	   al.,	   2007).	   It	   was	   therefore	  
hypothesized	  that	  expression	  by	  the	  pRIC	  vector	  could	  be	  further	  enhanced	  by	  targeting	  
proteins	  to	  the	  chloroplasts	  of	  the	  plant	  cells,	  as	  these	  might	  tolerate	  greater	   levels	  of	  
accumulation.	  
As	  mentioned	  in	  Chapter	  1,	  the	  expression	  of	  the	  HPV-­‐16	  therapeutic	  vaccine	  candidate	  
LALF-­‐E7	  (Granadillo	  et	  al.,	  2011)	  in	  N.	  benthamiana	  was	  previously	  attempted	  using	  pTRAc	  
and	  the	  cowpea	  mosaic	  virus-­‐derived	  pEAQ-­‐HT	  expression	  vectors,	  but	  with	  low	  success	  
(M.	  Granadillo	  and	  R.	  Lamprecht,	  unpublished	  data).	  In	  this	  project	  I	  aimed	  at	  increasing	  
the	   expression	   levels	   of	   LALF-­‐E7	   by	   using	   the	   self-­‐replicating	   vector	   pRIC3.0	   and	   by	  
targeting	  it	  to	  the	  chloroplasts	  using	  the	  rbcs1-­‐cTP.	  
It	  is	  also	  well	  known	  that	  posttranscriptional	  gene	  silencing	  (PTGS)	  negatively	  affects	  the	  
expression	  of	   recombinant	  proteins	   in	  plants.	  PTGS	   is	  a	  mechanism	  of	  defence	  against	  
foreign	  RNAs	  in	  eukaryotes.	  In	  plants,	  PTGS	  is	  an	  anti-­‐viral	  defence	  mechanism.	  Foreign	  
RNA	  forms	  such	  as	  double-­‐stranded	  and	  replication	  intermediate	  RNAs	  are	  recognized	  by	  
the	   plant	   host	   as	   aberrant	   RNAs.	   The	   plant	   responds	   by	   producing	   homologous	   small	  
interfering	  RNAs	  (siRNAs).	  This	   leads	  to	  a	  decrease	   in	  protein	  expression.	  Several	  plant	  
viruses	  have	  developed	  silencing	  suppressor	  proteins	  to	  counteract	  the	  host’s	  PTGS	  by	  
binding	  to	  and	  blocking	  the	  effect	  of	  siRNAs	  (reviewed	  by	  Qu	  and	  Morris,	  2005).	  Two	  well-­‐
known	  silencing	  suppressors	  are	  the	  tomato	  spotted	  wilt	  virus	  NSs	  protein	  (Takeda	  et	  al.,	  
2002)	  and	  the	  tomato	  bushy	  stunt	  virus	  P19	  protein	  (Voinnet	  et	  al.,	  2003).	  The	  expression	  
of	  recombinant	  proteins	  was	  dramatically	  increased	  when	  plants	  were	  co-­‐infiltrated	  with	  
such	  silencing	  suppressors.	  Therefore,	   I	  also	  investigated	  the	  effect	  of	  co-­‐expression	  of	  
silencing	  suppressors	  on	  the	  accumulation	  levels	  of	  LALF-­‐E7	  in	  N.	  benthamiana.	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2.2.	  Materials	  and	  Methods	  
2.2.1.	  Bacterial	  strains	  and	  culture	  conditions	  
2.2.1.1.	  Escherichia	  coli.	  All	  constructs	  were	  maintained	  in	  DH5-­‐α	  chemically	  competent	  
E.	  coli	  cells	  (E.	  cloni™,	  Lucigen).	  Cells	  containing	  pRIC3.0-­‐LALF-­‐E7	  and	  pRIC3.0-­‐cTP-­‐BFDV	  
were	   kindly	   provided	   by	   Renate	   Lamprecht	   and	   Guy	   Regnard	   respectively,	   and	   were	  
obtained	  from	  the	  culture	  collection	  of	  the	  Biopharming	  Research	  Unit	  at	  the	  Department	  
of	  Molecular	  and	  Cell	  Biology	  (MCB),	  University	  of	  Cape	  Town	  (UCT).	  These	  were	  streaked	  
onto	  Luria-­‐Bertani	  (LB)	  agar	  [1.0	  %	  tryptone,	  0.5	  %	  yeast	  extract,	  1.0	  %	  NaCl,	  1.5	  %	  agar,	  
pH	  7.0]	  plates.	  Liquid	  cultures	  were	  grown	  in	  LB	  broth	  with	  agitation	  at	  120	  revolutions	  
per	  minute	  (rpm),	  at	  37	  °C,	  for	  16	  to	  18	  h.	  Antibiotic	  selection	  was	  done	  using	  100	  µg/ml	  
ampicillin.	  
2.2.1.2.	  Agrobacterium	  tumefaciens.	  For	  pTRAc,	  pRIC3.0	  and	  pRIC3.0-­‐cTP	  constructs,	  A.	  
tumefaciens	  strain	  GV3101	  containing	  the	  helper	  plasmid	  pMP90RK,	  was	  used.	  For	  pEAQ-­‐
HT	  and	  pBIN	  constructs,	  A.	  tumefaciens	  strain	  LBA4404	  was	  used.	  Cells	  were	  grown	  in	  LB	  
broth,	  with	  agitation	  at	  120	  rpm,	  at	  27	  °C	  for	  2-­‐3	  days.	  Antibiotic	  selection	  was	  done	  using	  
50	   µg/ml	   carbenicillin	   (only	   used	   for	   recombinant	   GV3101::pMP90RK	   cells),	   50	   µg/ml	  
rifampicin	   and	   30	   µg/ml	   kanamycin.	   To	   prevent	   clumping	   of	   LBA4404	   cultures,	   liquid	  
media	  were	  supplemented	  with	  MgSO4	  to	  a	  final	  concentration	  of	  2	  mM.	  
2.2.2.	  Construct	  generation	  
2.2.2.1.	   pRIC3.0-­‐LALF-­‐E7.	  The	   sequence	   encoding	   LALF-­‐E7	  was	   kindly	   provided	   by	   our	  
Cuban	   collaborator,	  M.	  Granadillo	   (Centre	   for	  Genetic	   Engineering	   and	  Biotechnology,	  
Havana,	  Cuba).	  The	  E7	  sequence	  was	  previously	  modified	  to	  contain	  a	  base	  substitution	  
(T/G)	  in	  the	  codon	  encoding	  for	  the	  first	  cysteine	  to	  abolish	  the	  carcinogenic	  effect	  of	  the	  
protein.	  The	  LALF	  sequence	  encodes	  a	  small	  linear	  peptide	  containing	  residues	  32	  to	  51	  
from	  the	  original	  LALF	  protein	  (Granadillo	  et	  al.,	  2011;	  Vallespi	  et	  al.,	  2000).	  The	  LALF-­‐E7	  
sequence	   was	   codon-­‐optimized	   for	   expression	   in	   N.	   benthamiana,	   synthesized	   by	  
GenScript	   (USA)	  and	  provided	   in	  the	  cloning	  vector	  pUC57.	  The	  LALF-­‐E7	  sequence	  was	  
excised	   from	  pUC57	  using	   the	   restriction	  enzymes	   (REs)	  NcoI/XhoI.	   The	   sequence	  was	  
inserted	  into	  the	  expression	  vector	  pRIC3.0	  by	  R.	  Lamprecht	  (Biopharming	  Research	  Unit,	  
MCB,	  UCT)	  using	  the	  RE	  sites	  AflIII/XhoI.	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2.2.2.2.	  Subcloning	  of	  LALF-­‐E7	  into	  pRIC3.0-­‐cTP.	  The	  vector	  pRIC3.0-­‐cTP-­‐BFDV,	  was	  kindly	  
provided	   by	   G.	   Regnard	   (Biopharming	   Research	   Unit,	   MCB,	   UCT)	   with	   the	   beak	   and	  
feather	  disease	  virus	  capsid	  protein	  (BFDV)	  inserted	  between	  the	  MluI	  and	  XhoI	  restriction	  
sites.	  To	  confirm	  insertions,	  pRIC3.0-­‐cTP-­‐BFDV	  and	  pRIC3.0-­‐LALF-­‐E7	  were	  digested	  with	  
EcoRV.	   To	   subclone	   the	   LALF-­‐E7	   sequence	   from	   pRIC3.0	   into	   pRIC3.0-­‐cTP,	   a	   MluI	  
restriction	  site	  was	  added	  at	  the	  5’-­‐end	  of	  the	  sequence	  by	  PCR	  using	  the	  LALF-­‐E7	  primers	  
(Table	  2.1).	  The	  PCR	  was	  carried	  out	  using	  the	  Pfu	  polymerase,	  a	  final	  concentration	  of	  4	  
mM	  MgSO4,	  determined	  by	  MgSO4	  titration,	  and	  1	  µM	  of	  each	  primer.	  The	  PCR	  profile	  
was	  initial	  denaturation	  at	  95	  °C	  for	  5	  min;	  30	  cycles	  of	  denaturation	  at	  95	  °C	  for	  30	  s,	  
annealing	  at	  63	  °C	  for	  30	  s	  and	  extension	  at	  72	  °C	  for	  1	  min;	  and	  final	  extension	  for	  7	  min.	  
LALF-­‐E7	  amplicons	  were	  gel-­‐extracted	  using	  the	  QIAQuick®	  Gel	  extraction	  kit	  (QIAGEN®)	  
according	   to	   manufacturer	   instructions,	   and	   ligated	   into	   pJET1.2/blunt	   cloning	   vector	  
overnight,	  at	  4	  °C,	  using	  the	  T4	  ligase	  with	  a	  1:4	  vector	  to	  insert	  ratio.	  E.	  cloni	  cells	  were	  
transformed	  with	  pJET-­‐LALF-­‐E7,	  as	  per	  manufacturer’s	  protocol.	  Clones	  were	  confirmed	  
by	  MluI	  RE	  digestion.	  Five	  µg	  of	  pJET-­‐LALF-­‐E7	  DNA	  were	  RE-­‐digested	  with	  XhoI	  and	  MluI	  
in	  order	  to	  excise	  LALF-­‐E7.	  To	  linearize	  pRIC3.0-­‐cTP	  while	  excising	  the	  BFDV-­‐CP	  sequence	  
from	  it,	  2	  µg	  of	  pRIC3.0-­‐cTP-­‐BFDV	  were	  RE-­‐digested	  with	  the	  same	  enzymes.	  The	  DNA	  
fragments	  of	  interest	  were	  gel-­‐extracted	  and	  ligated.	  E.	  cloni	  cells	  were	  transformed	  with	  
pRIC3.0-­‐cTP-­‐LALF-­‐E7	   and	   putative	   recombinants	  were	   then	   confirmed	   by	   RE	   digestion	  
using	   EcoRV.	   The	   constructs	   pRIC3.0-­‐LALF-­‐E7	   and	   pRIC3.0-­‐cTP-­‐LALF-­‐E7	   were	   further	  
confirmed	  by	  sequence	  analysis	  (Macrogen	  Inc.)	  using	  the	  pTRAkc	  primers	  (Table	  2.1).	  All	  
REs,	  the	  DNA	  polymerase	  and	  ligase	  as	  well	  as	  pJET1.2/blunt	  used	  here	  were	  provided	  by	  
Thermo	  Scientific.	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Figure	  2.2.	  Construct	  generation	  for	  the	  expression	  of	  LALF-­‐E7	  in	  N.	  benthamiana.	  The	  LALF-­‐E7	  sequence	  
(dark-­‐blue	  boxes)	  was	  plant	  codon-­‐optimized	  and	  synthesised	  by	  GenScript.	  To	  generate	  pRIC3.0-­‐cTP-­‐
LALF-­‐E7,	   a	   5’-­‐end	  MluI	   restriction	   site	   was	   added	   to	   the	   LALF-­‐E7	   sequence	   by	   PCR	   amplification	   from	  
pRIC3.0-­‐LALF-­‐E7.	  The	  LALF-­‐E7	  amplicon	  was	  cloned	  into	  pJET1.2/blunt	  to	  give	  the	  intermediary	  construct,	  
pJET-­‐LALF-­‐E7.	   pRIC3.0-­‐cTP-­‐BFDV	   and	   pJET-­‐LALF-­‐E7	   were	   digested	   with	  MluI/XhoI	   REs	   and	   the	   LALF-­‐E7	  
fragment	  and	  pRIC3.0-­‐cTP	  vector	  were	  ligated	  to	  create	  pRIC3.0-­‐cTP-­‐LALF-­‐E7.	  Light-­‐blue	  arrows,	  RE	  sites.	  
Black	   boxes,	   the	   cauliflower	   mosaic	   virus	   35S	   constitutive	   promoter.	   Light-­‐blue	   boxes,	   LALF-­‐E7	   hexa-­‐
histidine	  tag.	  Green	  box,	  the	  rbcs1-­‐cTP.	  Not	  drawn	  to	  scale.	  
	  
2.2.3.	  Electroporation	  of	  A.	  tumefaciens	  	  
Electro-­‐competent	  A.	  tumefaciens	  cultures	  were	  prepared	  as	  described	  by	  Wen-­‐jun	  and	  
Forde,	   (1989)	   and	   electroporated	   as	   described	   by	   Maclean	   et	   al.,	   (2007).	  
GV3101::pMP90RK	   cells	   were	   electroporated	   with	   pRIC3.0-­‐LALF-­‐E7	   and	   pRIC3.0-­‐cTP-­‐
LALF-­‐E7	  in	  this	  study.	  The	  construct	  pRIC3.0	  empty	  vector	  in	  GV3101::pMP90RK	  cells	  was	  
kindly	   provided	   by	   J.	   Els	   and	   the	   constructs	   pTRAc-­‐LALF-­‐E7	   and	   pRIC3.0-­‐LALF-­‐E7	   in	  
GV3101::pMP90RK	   cells	   as	   well	   as	   pEAQ-­‐HT-­‐LALF-­‐E7	   in	   LBA4404	   cells	   were	   kindly	  
provided	   by	   R.	   Lamprecht	   (both	   in	   the	   Biopharming	   Research	   Unit,	   MCB,	   UCT).	   The	  
constructs	  pEAQ-­‐HT	  which	  contains	  the	  p19	  expression	  cassette,	  and	  pBIN-­‐NSs,	  both	  in	  
LBA4404	   cells	   were	   obtained	   from	   the	   Biopharming	   Research	   Unit	   culture	   collection.	  
Recombinant	  A.	  tumefaciens	  pRIC3.0-­‐LALF-­‐E7	  and	  pRIC3.0-­‐cTP-­‐LALF-­‐E7	  were	  confirmed	  
by	   colony	   PCR	   using	   the	   pTRAkc	   primers	   (provided	   by	   R.	   Lamprecht;	   Table	   2.1)	   and	  
GoTaq®	   Flexi	   DNA	   Polymerase	   (Promega).	   The	   I	   PCR	   conditions	   were	   an	   initial	  
denaturation	  cycle	  at	  95	  °C	  for	  5	  minutes,	  subsequent	  30	  cycles	  of	  denaturation	  for	  30	  s,	  
annealing	  at	  50	  °C	  for	  30	  s	  and	  extension	  at	  72	  °C	  for	  1	  min,	  followed	  by	  a	  final	  extension	  
cycle	  for	  7	  min.	  
pRIC3.0-­‐LALF-­‐E7	  
pRIC3.0-­‐cTP-­‐LALF-­‐E7	  
CAMV-­‐promoter	   LALF-­‐E7	   6xHIS	  
EcoRV	   EcoRV	   XhoI	  
LALF-­‐E7	   6xHIS	  
EcoRV	   XhoI	  MluI	  
CAMV-­‐promoter	   LALF-­‐E7	   6xHIS	  cTP	  
EcoRV	   EcoRV	   XhoI	  MluI	  
pJET-­‐LALF-­‐E7	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Table	  2.1.	  Primers	  used	  in	  this	  work	  
Name	   Sequence	   Feature	   Application	  
LALF-­‐E7-­‐Fw	   5’	   AAA	   CGC	   GTT	   AGG	  
TGC	  ATG	  GCC	  GAG	  TTT	  
CAT	  TAC	  AG	  3’	  
Contains	  the	  MluI	  site.	   PCR	   amplification	   and	  
addition	   of	   the	   MluI	  
restriction	  site.	  
LALF-­‐E7-­‐Rv	   5’	   AAT	   CGA	   GGG	   TCT	  
CAT	  TAG	  TGG	  TGG	  TGG	  
TGA	  TGG	  TGA	  G	  3’	  
N.A.	   PCR	  amplification.	  
pTRAkc-­‐Fw	   5’	   CAT	   TTC	   ATT	   TGG	  
AGA	  GGA	  CAC	  G	  3’	  
Complementary	   to	  
pRIC3.0	   and	   pRIC3.0-­‐
cTP	  backbone.	  
Sequencing	   insertions	   and	  
confirmation	  of	  recombinant	  
A.	   tumefaciens	  
GV3101::pMP90RK.	  
pTRAkc-­‐Rv	   5’	   GAA	   CTA	   CTC	   ACA	  
CAT	  TAT	  TCT	  GG	  3’	  
Complementary	   to	  
pRIC3.0	   and	   pRIC3.0-­‐
cTP	  backbone.	  
Sequencing	   insertions	   and	  
confirmation	  of	  recombinant	  
A.	   tumefaciens	  
GV3101::pMP90RK.	  
LALF-­‐E7	  primers	  were	  designed	  using	  the	  CLC-­‐Main	  Workbench	  6	  (QIAGEN®	  Bioinformatics)	  and	  synthesised	  
by	  the	  DNA	  Synthesis	  Unit	  (MCB,	  UCT).	  N.A.,	  not	  applicable.	  
	  
2.2.4.	  Agroinfiltration	  and	  transient	  expression	  of	  LALF-­‐E7	  in	  N.	  benthamiana	  leaves	  	  
2.2.4.1.	  Determination	  of	   the	  optimal	   conditions	   for	   the	  expression	  of	   LALF-­‐E7	   in	  N.	  
benthamiana	  leaves.	  Recombinant	  A.	  tumefaciens	  cultures	  were	  prepared	  for	  small	  scale	  
agroinfiltration	   as	  described	  by	  Maclean	  et	  al.,	   (2007).	   Two	  plants	  per	   construct	  were	  
syringe-­‐infiltrated	  using	  A.	  tumefaciens	  cultures	  at	  different	  optical	  densities	  of	  0.25,	  0.5,	  
1.0	  and	  1.5	  at	  600	  nm	  (OD600),	  to	  determine	  the	  optimal	  OD600	  for	  the	  expression	  of	  LALF-­‐
E7.	  A	  time	  trial	  was	  performed	  to	  determine	  the	  accumulation	  profile	  of	  LALF-­‐E7.	  This	  was	  
done	  by	  harvesting	  3	  x	  leaf	  clippings	  (obtained	  using	  the	  lid	  of	  a	  1.5	  ml	  microcentrifuge	  
tube)	   on	   3,	   5	   and	   7	   days	   post	   infiltration	   (dpi).	   The	   control,	   pEAQ-­‐HT-­‐LALF-­‐E7,	   was	  
infiltrated	   at	   an	   OD600	   of	   0.75	   as	   previously	   determined	   by	   M.	   Granadillo	   (2013;	  
unpublished	  data).	  The	  negative	  control,	  pRIC3.0-­‐empty,	  was	  infiltrated	  at	  an	  OD600	  of	  1.0.	  
Thereafter,	   the	   time	   trial	   was	   repeated	   three	   times	   independently,	   using	   the	   optimal	  
OD600,	  three	  plants	  per	  construct	  and	  vacuum	  infiltration.	  The	  construct	  pTRAc-­‐LALF-­‐E7	  
was	   used	   as	   a	  more	   appropriate	   positive	   control,	   as	   its	   backbone	   is	   similar	   to	   that	   of	  
pRIC3.0.	   For	   vacuum	   infiltration,	  Agrobacterium	   cultures	  were	   grown	   as	   described	   by	  
Maclean	  et	  al.,	   (2007)	   in	  LBB	  enriched	  medium	  [0.25	  %	  tryptone,	  1.25	  %	  yeast	  extract,	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0.50	   %	   NaCl,	   10	   mM	   2-­‐(N-­‐Morpholino)	   ethanesulfonic	   acid	   (MES),	   pH	   5.6],	   induced	  
overnight	   with	   20	   µM	   acetosyringone	   and	   diluted	   to	   the	   desired	   final	   OD600	   in	  
resuspension	  solution	  [5	  mM	  MES,	  20	  mM	  MgCl2,	  0.2	  mM	  acetosyringone].	  	  
2.2.4.2.	  Investigating	  the	  effect	  of	  silencing	  suppressors	  on	  the	  expression	  of	  LALF-­‐E7.	  
Plants	  were	  vacuum	  infiltrated	  with	  pRIC3.0-­‐LALF-­‐E7,	  pRIC3.0-­‐cTP-­‐LALF-­‐E7	  and	  pRIC3.0-­‐
empty,	  with	  or	  without	  a	  silencing	  suppressor-­‐containing	  constructs:	  LBA4404-­‐pEAQ-­‐HT-­‐
P19	  and	  LBA4404-­‐pBIN-­‐NSs.	  All	  A.	  tumefaciens	  cultures	  were	  set	  to	  an	  OD600	  of	  1.0.	  Three	  
plants	  per	  construct	  were	  vacuum	  infiltrated.	  One	  leaf	  per	  plant	  was	  harvested	  on	  3,	  5	  
and	  7	  dpi,	  giving	  a	  total	  of	  3	  leaves	  per	  construct.	  This	  set	  of	  experiments	  was	  repeated	  
twice,	  independently.	  
2.2.5.	  Preparation	  of	  plant	  crude	  extracts	  
2.2.5.1.	  Small	  scale	  expression	  studies.	  Samples	  of	  three	  or	  six	  leaf	  discs	  were	  harvested	  
by	  clipping	  the	  leaves	  with	  a	  1.5	  ml	  microcentrifuge	  tube	  lid.	  Samples	  were	  flash-­‐frozen	  
in	   liquid	   nitrogen,	   ground	  with	   a	   pestle	   and	   suspended	   in	   200	  µl	   or	   400	  µl	   8	  M	   urea	  
extraction	  buffer	  [8	  M	  urea	  in	  1	  mM	  carbonate-­‐bicarbonate	  buffer,	  pH	  10.6],	  respectively.	  
Extracts	  were	  clarified	  by	  centrifugation	  at	  13,000	  rpm	  for	  10	  min.	  	  The	  supernatant	  was	  
prepared	  for	  SDS-­‐PAGE	  or	  stored	  at	  -­‐20	  °C.	  
2.2.5.2.	  Medium	   scale	   expression	   studies.	   For	   vacuum-­‐infiltrated	   plants,	   leaves	   were	  
weighed	  immediately	  after	  being	  harvested.	  Leaves	  were	  flash-­‐frozen	  in	  liquid	  nitrogen	  
and	  ground	  up	  using	  a	  mortar	  and	  pestle.	  Crude	  extracts	  were	  prepared	  by	  homogenizing	  
leaves	  in	  2	  v/w	  of	  extraction	  buffer	  using	  a	  T25	  digital	  ULTRA-­‐TURRAX®	  homogenizer	  (IKA).	  
Extracts	  were	  clarified	  by	  centrifugation	  at	  13,000	  rpm	  (BeckmanT	  Coulter	  Avanti®	  J25TI	  
centrifuge)	  for	  10	  min.	  	  
2.2.6.	  Total	  soluble	  protein	  (TSP)	  and	  %	  TSP	  determination	  
Total	   soluble	   protein	   concentrations	   of	   crude	   extracts	  were	   determined	   using	   the	  DC	  
Protein	  Assay	  (Bio-­‐Rad).	  A	  serial	  dilution	  of	  1	  mg/ml	  to	  0.06	  mg/ml	  bovine	  serum	  albumin	  
(BSA;	  Sigma-­‐Aldrich)	  was	  used	  as	  standard.	  Crude	  extracts	  were	  diluted	  to	  fall	  within	  the	  
range	   of	   the	   standard.	   The	   A750	   of	   the	   samples	  was	   determined	   using	   the	  microplate	  
spectrophotometer	   PowerWave	   XS™	   (BioTek®).	   The	   output	   data	   were	   analysed	   by	  
Microsoft®	  Excel	  2015.	  For	  %TSP	  determination,	  western	  blot	  densitometry	  was	  used.	  The	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plant-­‐derived	   LALF-­‐E7	   was	   quantified	   using	   the	   6xHis	   Protein	   Ladder	   (QIAGEN®)	   as	   a	  
protein	  standard.	  The	  anti-­‐Histidine	  and	  goat	  anti-­‐mouse	  IgG	  whole	  molecules	  conjugated	  
to	   alkaline	   phosphatase	   (AP;	   Sigma-­‐Aldrich)	   were	   used	   at	   a	   dilution	   of	   1:2,000.	   The	  
Syngene	   Gene	   Genius	   imaging	   system	   (Artisan	   Technology	   Group)	   and	   GeneTools	  
software	  (Syngene)	  were	  used.	  The	  %TSP	  fold	  change	  was	  calculated	  using	  the	  equation	  
bellow,	  where	  values	  above	  1	  indicated	  increase,	  a	  value	  of	  1	  indicated	  no	  change	  and	  a	  
value	  below	  1	  indicated	  decrease.	  
𝐹𝑜𝑙𝑑	  𝑐ℎ𝑎𝑛𝑔𝑒	   =
%	  𝑇𝑆𝑃	  𝑝𝑅𝐼𝐶3.0 − 𝑐𝑇𝑃 − 𝐿𝐴𝐿𝐹 − 𝐸7
%	  𝑇𝑆𝑃	  𝑝𝑅𝐼𝐶3.0 − 𝐿𝐴𝐿𝐹 − 𝐸7 	  	  
	  
2.2.7.	  SDS-­‐PAGE	  and	  western	  blotting	  
Crude	  extracts	  were	  mixed	  with	  6x	  SDS	  sample	  application	  buffer	  [25	  %	  (v/v)	  glycerol,	  0.5	  
M	  DDT,	  5	  %	  (w/v)	  bromothymol	  blue]	  to	  a	  final	  concentration	  of	  1x	  and	  boiled	  at	  90	  °C	  for	  
10	  min.	  Fifteen	  per	  cent	  SDS-­‐PAGE-­‐gels	  were	   loaded	  and	  electrophoresed	   in	  a	  Bio-­‐Rad	  
Tetra	  Cell	  system	  at	  120	  volts.	  Gels	  were	  stained	  with	  Aqua	  StainTM	  (Vacutec)	  for	  1	  h,	  at	  
37	   °C.	   Protein	   sizes	  were	   estimated	   using	   PageRuler™	   Plus	   Prestained	   Protein	   Ladder	  
(Thermo	  Scientific)	  or	  with	  the	  Colour	  Prestained	  Protein	  Standard,	  Broad	  Range	  (11–245	  
kDa)	  (NEB).	  	  
For	   western	   blots,	   proteins	   were	   transferred	   from	   SDS-­‐PAGE-­‐gels	   to	   nitrocellulose	  
membranes	  using	  a	  Bio-­‐Rad	  Trans-­‐Blot®	  Semi-­‐dry	  transfer	  cell	  at	  15	  volts,	   for	  1	  h.	  The	  
primary	  and	  secondary	  antibodies	  used	  were	  the	  polyclonal	  anti-­‐HPV-­‐16-­‐E7	  rabbit	  serum	  
(I.	  Hitzeroth,	  Biopharming	  Research	  Unit,	  MCB,	  UCT)	  and	  the	  goat	  anti-­‐Rabbit	  IgG	  whole	  
molecules-­‐AP	   (Sigma-­‐Aldrich).	   Blots	   were	   visualized	   with	   NBT/BCIP	   substrate	   (Sigma-­‐
Aldrich).	  	  
2.2.8.	  Bacterial	  expression	  of	  LALF-­‐E7	  	  
To	  be	  used	  as	  positive	  control	  for	  plant-­‐derived	  LALF-­‐E7	  expression,	  the	  LALF-­‐E7	  sequence	  
was	   cloned	   into	   the	   bacterial	   expression	   vector	   pPROEX-­‐HTb	   (Addgene).	   LALF-­‐E7	  was	  
expressed	  in	  E.	  coli	  according	  to	  the	  pPROEX-­‐HTb	  Prokaryotic	  Expression	  System	  protocol.	  
LALF-­‐E7	  was	  partially	  purified	  using	  the	  BugBuster®	  Protein	  Extraction	  Reagent	  (Novagen)	  
protocol	  for	   inclusion	  body	  purification	  with	  additional	  3	  x	  washes	  with	  0.1§%	  Triton	  X	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100	  (Sigma-­‐Aldrich)	  in	  phosphate	  buffered	  saline	  [PBS;	  137	  mM	  NaCl,	  2.7	  mM	  KCl,	  10	  mM	  
PO43−	  (0.144	  %	  Na2HPO4	  and	  0.024	  %	  KH2PO4),	  pH	  7.4].	  
	  
2.3.	  Results	  
2.3.1.	  Construct	  generation	  	  
Initial	   constructs	  were	   confirmed	  by	  RE	  digestion	  with	  EcoRV.	  The	  DNA	  band	  patterns	  
obtained	  were	  as	  expected,	  1	  kb	  and	  5.84	  kb	  for	  pRIC3.0-­‐cTP-­‐BFDV,	  and	  0.45	  kb	  and	  5.85	  
kb	   for	   pRIC3.0-­‐LALF-­‐E7	   (not	   shown).	   For	   subcloning	   into	   the	   chloroplast-­‐targeting	  
expression	  vector,	  pRIC3.0-­‐cTP,	  the	  restriction	  site	  for	  MluI	  was	  added	  at	  the	  5’-­‐end	  of	  
LALF-­‐E7	   by	   PCR	   amplification.	   Gel-­‐extracted	   amplicons	   were	   first	   ligated	   into	   the	  
pJET1.2/blunt	   cloning	   vector	   to	   produce	   pJET-­‐LALF-­‐E7,	   in	   order	   to	   confirm	   that	   the	  
amplicons	  were	  positive	  for	  the	  MluI	  restriction	  site.	  Plasmid	  DNA	  from	  11	  clones	  were	  
digested	  with	  MluI	  and	  9	  were	  determined	  MluI-­‐positive	  by	  obtaining	  the	  expected	  3.4	  kb	  
band	  (Figure	  2.3A).	  One	  clone	  was	  selected	  to	  proceed	  with	  subcloning.	  The	  constructs	  
pJET-­‐LALF-­‐E7	   and	   pRIC3.0-­‐cTP-­‐BFDV	   were	   digested	   with	   XhoI	   and	  MluI.	   Gel-­‐extracted	  
fragments	   of	   interest	   were	   ligated,	   resulting	   in	   pRIC3.0-­‐cTP-­‐LALF-­‐E7.	   All	   recombinant	  
pRIC3.0-­‐cTP-­‐LALF-­‐E7	  clones	  selected	  were	  successfully	  confirmed	  by	  RE	  digestion	  using	  
EcoRV	  that	  resulted	  in	  a	  band	  pattern	  of	  0.6	  Kb	  and	  5.9	  Kb	  (Figure	  2.3B).	  	  The	  constructs	  
of	   interest,	  pRIC3.0-­‐LALF-­‐E7	  and	  pRIC3.0-­‐cTP-­‐LALF-­‐E7,	  were	  sequenced	  and	   the	   results	  
agreed	  with	  predicted	  sequences	  on	  CLC	  Main	  Workbench	  6.	  A.	  tumefaciens	  cells	  were	  
successfully	  electroporated	  with	  these	  constructs	  as	  shown	  by	  positive	  colony	  PCRs	  using	  
the	  pTRAkc	  primers.	  These	  primers	  amplified	  products	  of	  0.6	  kb	  for	  pRIC3.0-­‐LALF-­‐E7	  and	  
0.75	  kB	  for	  pRIC3.0-­‐cTP-­‐LALF-­‐E7	  which	  were	  as	  expected	  (Figure	  2.3C).	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Figure	  2.3.	  pRIC3.0-­‐cTP-­‐LALF-­‐E7	  construct	  generation	  and	  A.	  tumefaciens	  transformation.	  (A)	  pJET-­‐LALF-­‐
E7	  screening	  by	  MluI	  RE	  digestion	  of	  DNA	   isolated	   from	  11	  single	  colonies	   (Lanes	  1-­‐11).	   Lane	  12,	  no	  RE	  
added.	  Band	  pattern	  expected:	  3.4	  kb	  linearized	  plasmids.	  (B)	  pRIC3.0-­‐cTP-­‐LALF-­‐E7	  screening	  by	  EcoRV	  RE	  
digestion.	   	   Lane	  1,	  no	  RE	  added.	   Lanes	  2-­‐8,	  digested	  DNA	   isolated	   from	  7	   single	   colonies.	  Band	  pattern	  
expected:	  0.6	  kB	  +	  5.9	  kb.	  (C)	  Confirming	  recombinant	  A.	  tumefaciens	  by	  colony	  PCR.	  (+)	  positive	  control,	  
1.5	  kb.	  (-)	  negative	  control,	  PCR	  mixture	  with	  no	  DNA	  added.	  Lanes	  1	  and	  2:	  pRIC3.0-­‐LALF-­‐E7,	  0.6	  kb.	  Lanes	  
3-­‐7,	  pRIC3.0-­‐cTP-­‐LALF-­‐E7,	  0.75	  kB.	  For	  all	  images:	  (M),	  1kb	  DNA	  molecular	  weight	  marker.	  (kb),	  sizes	  shown	  
in	  kilobases.	  Arrows	  point	  at	  relevant	  bands.	  
	  
2.3.2.	  Optimization	  of	  LALF-­‐E7	  transient	  expression	  in	  N.	  benthamiana	  
To	  determine	  the	  optical	  density	  (OD600)	  of	  recombinant	  A.	  tumefaciens	  that	  resulted	  in	  
highest	   expression	   levels,	   plants	   were	   syringe-­‐infiltrated	   using	   recombinant	  
GV3101::pMP90RK-­‐pRIC3.0-­‐LALF-­‐E7	   and	   –pRIC3.0-­‐cTP-­‐LALF-­‐E7	   cultures	   at	   different	  
OD600s.	  Two	  plants	  were	  syringe-­‐infiltrated	  per	  OD600,	  per	  construct	  and	  the	  plants	  were	  
monitored	   over	   7	   days.	   pRIC3.0-­‐empty	   vector	   and	   pEAQ-­‐HT-­‐LALF-­‐E7	   were	   used	   as	  
negative	  and	  positive	  controls,	  respectively.	  Leaf	  clippings	  were	  collected	  on	  3,	  5	  and	  7	  
dpi.	  On	  3dpi,	  all	  plants	  infiltrated	  with	  pRIC3.0	  constructs	  presented	  signs	  of	  infection.	  By	  
5	  dpi	  these	  plants	  showed	  signs	  of	  damage	  which	  became	  severe	  by	  7	  dpi,	  including	  brittle	  
leaves	  and	  chlorosis	  (data	  not	  shown	  for	  syringe-­‐infiltrated	  plants).	  In	  the	  plants	  infiltrated	  
with	  pEAQ-­‐HT-­‐LALF-­‐E7	  the	  severe	  symptoms	  were	  delayed,	  only	  appearing	  by	  the	  end	  of	  
the	  time	  trial	  (data	  not	  shown).	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Anti-­‐E7	  polyclonal	  antibody	  western	  blots	  showed	  that	   the	  expression	  of	  LALF-­‐E7	  (»22	  
kDa)	   using	   vectors	   pRIC3.0	   and	   pRIC3.0-­‐cTP	   was	   successful	   (Figure	   2.4).	   LALF-­‐E7	   was	  
absent	  or	  poorly	  detected	  for	  some	  pRIC3.0	  samples	  (Figure	  2.4,	  upper	  panel)	  but	  it	  was	  
detected	  in	  all	  pRIC3.0-­‐cTP	  samples	  (Figure	  2.4,	  bottom	  panel).	  The	  expression	  of	  LALF-­‐E7	  
in	  pRIC3.0	  appeared	  strongest	  at	  an	  OD600	  between	  1.0	  and	  1.5,	  on	  3	  dpi.	  The	  expression	  
in	  pRIC3.0-­‐cTP	  appeared	  strongest	  at	  an	  OD600	  between	  0.5	  and	  1.0,	  also	  on	  3	  dpi.	  The	  
expression	   of	   LALF-­‐E7	   when	   using	   the	   positive	   control,	   pEAQ-­‐HT	   was	   also	   detected,	  
however,	  it	  appeared	  to	  be	  lower	  than	  that	  when	  using	  pRIC3.0	  and	  pRIC3.0-­‐cTP.	  No	  LALF-­‐




Figure	  2.4.	  Small-­‐scale	  detection	  of	  LALF-­‐E7	  expression	  in	  N.	  benthamiana	  leaves.	  Western	  blots	  (1:1,000)	  
of	  equal	  volumes	  of	  crude	  extracts	   from	  N.	  benthamiana	   leaves	  syringe-­‐infiltrated	  with	  pRIC3.0-­‐LALF-­‐E7	  
(top)	   and	   pRIC3.0-­‐cTP-­‐LALF-­‐E7	   (bottom).	   Different	   recombinant	  Agrobacterium	  OD600s	   were	   used.	   Leaf	  
clippings	  were	  harvested	  on	  3,	  5	  and	  7	  dpi.	  Mw,	  Page	  Ruler™	  molecular	  weight	  marker.	  Band	  sizes	  (kDa)	  are	  
indicated	   on	   the	   left-­‐hand-­‐side.	   (-­‐),	   pRIC3.0-­‐empty	   vector,	   harvested	   on	   5	   dpi.	   (+),	   pEAQ-­‐HT-­‐LALF-­‐E7,	  
harvested	  on	  5	  dpi.	  	  E,	  purified	  E.	  coli-­‐derived	  HPV-­‐16	  E7	  provided	  by	  M.	  Granadillo.	  Arrows	  indicate	  the	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2.3.3.	  Comparing	  the	  accumulation	  of	  LALF-­‐E7	  in	  the	  cytoplasm	  versus	  the	  chloroplasts	  
In	   order	   to	   better	   compare	   the	   accumulation	   of	   LALF-­‐E7	   in	   the	   cytoplasm	   versus	   the	  
chloroplasts,	  the	  set	  of	  experiments	  described	  in	  section	  3.2.	  were	  repeated	  three	  times,	  
independently	  and	  at	  a	  larger	  scale.	  Three	  plants	  were	  vacuum-­‐infiltrated	  with	  pRIC3.0-­‐
LALF-­‐E7	  and	  pRIC3.0-­‐CTP	  LALF-­‐E7,	  using	  the	  overlapping	  optimum	  OD600	  of	  1.0.	  pRIC3.0-­‐
empty	  vector	  and	  pTRAc-­‐LALF-­‐E7	  were	  used	  as	  controls.	  pTRAc-­‐LALF-­‐E7	  was	  chosen	  as	  a	  
more	   appropriate	   control	   than	   pEAQ-­‐HT-­‐LALF-­‐E7	   as	   its	   backbone	   is	   similar	   to	   that	   of	  
pRIC3.0.	  Plants	  were	  monitored	  for	  7	  days	  and	  leaves	  were	  harvested	  on	  3,	  5	  and	  7	  dpi.	  
All	  plants	  showed	  similar	  but	  less	  severe	  symptoms	  as	  described	  in	  section	  2.3.2.	  (Figure	  
2.5A).	  Plants	  infiltrated	  with	  pTRAc-­‐LALF-­‐E7	  showed	  delayed	  and	  less	  severe	  symptoms	  
than	  plants	  infiltrated	  with	  pRIC3.0	  constructs	  (data	  not	  shown).	  	  
Equal	   volume	   western	   blots	   showed	   how	   LALF-­‐E7	   was	   almost	   undetectable	   when	  
expressed	  from	  pTRAc,	  even	  when	  using	  concentrated	  antibodies	  (1:1,000;	  Figure	  2.5B,	  
left	   hand	   side).	   However,	   large	   molecular	   weight	   aggregates	   were	   detected	   in	   these	  
samples	   at	   approximately	   46	   and	   58	   kDa.	   The	   total	   soluble	   protein	   (TSP)	   content	   of	  
pRIC3.0-­‐LALF-­‐E7	  and	  pRIC3.0-­‐cTP-­‐LALF-­‐E7	  crude	  extracts	  was	  determined	  by	  Bradford’s	  
assay.	   In	   order	   to	   normalize	   for	   any	   variation	   in	   protein	   extraction	   efficiency,	   equal	  
amounts	  of	  TSP	  were	  used	  to	  analyse	  the	  accumulation	  of	  LALF-­‐E7	  in	  the	  cytoplasm	  versus	  
the	   chloroplasts	   (Figure	   2.5B,	   right	   hand	   side).	   Unlike	   in	   the	   small-­‐scale	   expression	  
experiments,	  when	  expressed	  in	  pRIC3.0,	  LALF-­‐E7	  peaked	  on	  5	  dpi	  and	  was	  undetectable	  
on	  3	  and	  7	  dpi.	  No	  LALF-­‐E7	  was	  detected	  in	  pRIC3.0-­‐empty	  vector	  extracts.	  As	  determined	  
by	  western	  blot	  densitometry,	  it	  accounted	  for	  up	  to	  0.017	  %	  TSP	  in	  the	  extracts	  analysed	  
(Figure	  2.5C).	  On	  the	  other	  hand,	  LALF-­‐E7	  accumulation	  when	  expressed	  in	  pRIC3.0-­‐cTP	  
fluctuated	  less	  than	  in	  pRIC3.0,	  peaking	  on	  3	  and	  5	  dpi.	  This	  accounted	  for	  up	  to	  0.56%	  
TSP,	   however	   on	   average	   this	   was	   0.44%	   TSP.	   The	   accumulation	   of	   LALF-­‐E7	   in	   the	  
chloroplasts	  was	  26.8	  fold	  higher	  than	  the	  accumulation	   in	  the	  cytoplasm	  when	  taking	  










Figure	  2.5.	  Comparing	  the	  effects	  of	  expression	  vector	  and	  subcellular	  localization	  on	  the	  expression	  of	  
LALF-­‐E7.	   (A),	   Leaf	   physiology	   monitored	   over	   time	   after	   vacuum	   infiltration	   with	   pRIC3.0-­‐LFLF-­‐E7	   and	  
pRIC3.0-­‐cTP-­‐LFLF-­‐E7.	  	  All	  cultures	  used	  were	  set	  to	  an	  OD600	  of	  1.0.	  Shown	  are	  representative	  leaves	  on	  3,	  5	  
and	  7	  dpi.	  pRIC3.0-­‐empty	  vector	  was	  used	  as	  a	  negative	  control.	  Shown	  here	  are	  representative	  images	  of	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three	   independent	   repeats.	   (B)	   The	  effect	  of	   expression	   vector	  on	   LALF-­‐E7	  expression.	   (Left	  hand	   side),	  
equal	  volume	  western	  blots	  (1:1,000)	  of	  LALF-­‐E7	  expression	  from	  pTRAc.	  (+),	  purified	  E.	  coli-­‐derived	  LALF-­‐
E7,	  provided	  by	  M.	  Granadillo.	   (-­‐),	  pRIC3.0-­‐empty	  vector	  crude	  extract.	  Mw,	  weight	  marker.	  Black	  arrow	  
indicates	  the	  expected	  position	  of	  LALF-­‐E7,	  ≈22	  kDa.	  Blue	  arrows	  show	  higher	  molecular	  weight	  aggregates.	  	  
(Right	  hand	  side),	  analysis	  of	  50	  µg	  of	  TSP	  of	  pRIC3.0-­‐LALF-­‐E7	  and	  pRIC3.0-­‐cTP-­‐LALF-­‐E7	  crude	  extracts.	  Top	  
panel:	  western	  blot	  (1:5,000).	  Bottom	  panel:	  corresponding	  AquaStained	  SDS-­‐PAGE	  gels	  showing	  a	  native	  
protein	  of	  approximately	  50	  kDa	  as	  an	  internal	  control	  for	  equal	  TSP	  loading.	  Mw,	  molecular	  weight	  marker.	  
(-­‐)	  pRIC3.0-­‐empty	  vector	  crude	  extract.	   (+),	  E.	  coli-­‐derived	  LALF-­‐E7	   inclusion	  bodies.	  Arrow	   indicates	   the	  
position	  of	  LALF-­‐E7,	  ≈22	  kDa.	  Shown	  here	  are	  representative	  images	  of	  three	  independent	  repeats.	  (C)	  The	  
effect	  of	  subcellular	  localization	  on	  LALF-­‐E7	  expression	  determined	  by	  the	  %TSP.	  	  
	  
2.3.4.	  Investigating	  the	  effect	  of	  silencing	  suppressors	  on	  the	  expression	  of	  LALF-­‐E7	  
To	   determine	   the	   effect	   of	   silencing	   suppressors	   on	   the	   expression	   of	   LALF-­‐E7	   in	   N.	  
benthamiana,	   leaves	   were	   co-­‐infiltrated	   with	   pRIC3.0-­‐LALF-­‐E7	   or	   pRIC3.0-­‐cTP-­‐LALF-­‐E7	  
and	   P19	   or	   NSs.	   pRIC3.0-­‐empty	   vector	   was	   used	   as	   a	   negative	   control.	   This	   set	   of	  
experiments	   was	   done	   twice	   independently,	   by	   vacuum	   infiltration.	   The	   plants	   were	  
monitored	   over	   a	   period	   of	   7	   days.	   Symptoms	   were	   as	   described	   in	   section	   2.3.2.	  
However,	  signs	  of	  necrosis	  were	  exacerbated	  by	  the	  co-­‐infiltration	  with	  P19,	  and	  seemed	  
to	  be	  attenuated	  by	  co-­‐infiltration	  with	  NSs	  (Figure	  2.6A).	  
Western	   blot	   analysis	   of	   leaf	   extracts	   from	   each	   construct	   and	   silencing	   suppressor	  
combination	  showed	  that	  LALF-­‐E7	  in	  pRIC3.0	  peaked	  on	  5	  dpi,	  with	  or	  without	  silencing	  
suppressor,	  which	  was	  consistent	  with	  previous	  experiments.	  The	  best	  day	  for	  pRIC3.0-­‐
cTP	  was	  3	  dpi,	  except	  when	  in	  the	  presence	  of	  P19,	  in	  which	  case	  it	  was	  5	  dpi.	  No	  LALF-­‐E7	  
was	  detected	  from	  pRIC3.0-­‐empty	  vector	  leaf	  extracts	  (data	  not	  shown).	  
Based	  on	  the	  above	  results,	  TSP	  content	  of	  the	  leaf	  extracts	  from	  the	  best	  expression	  day	  
of	  each	  combination	  was	  determined.	  Fifty	  µg	  TSP	  per	  sample	  were	  used	  to	  compare	  the	  
effect	  of	  silencing	  suppressors	  on	  the	  expression	  of	  LALF-­‐E7	  	  (Figure	  2.6B).	  The	  expression	  
of	   LALF-­‐E7	   in	   pRIC3.0	   did	   not	   seem	   to	   change	   in	   the	   presence	   of	   either	   silencing	  
suppressor.	   It	  was	  not	  possible	  to	  accurately	  quantify	  these	  samples	  due	  to	  their	  poor	  
detection.	  The	  expression	  of	  LALF-­‐E7	  in	  pRIC3.0-­‐cTP	  only	  increased	  in	  the	  presence	  of	  P19,	  
on	   average	   by	   1.3	   fold,	   while	   it	   seemed	   to	   decrease	   by	   on	   average	   0.92	   fold	   in	   the	  
presence	  of	  NSs.	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Figure	  2.6.	  The	  effects	  of	  silencing	  suppressors	  on	  the	  expression	  of	  LALF-­‐E7.	  (A)	  Leaf	  physiology	  monitored	  
over	   time	   after	   vacuum	   co-­‐infiltration	   with	   pRIC3.0-­‐LFLF-­‐E7	   and	   pRIC3.0-­‐cTP-­‐LFLF-­‐E7	   with	   silencing	  
suppressors.	  	  All	  cultures	  used	  were	  set	  to	  an	  OD600	  of	  1.0.	  Shown	  are	  representative	  leaves	  on	  3,	  5	  and	  7	  
dpi.	  pRIC3.0-­‐empty	  vector	  was	  used	  as	  a	  negative	  control.	  (B)	  Analysis	  of	  50	  µg	  of	  TSP	  crude	  extracts	  of	  
leaves	  vacuum-­‐infiltrated	  with	  or	  without	  a	   silencing	   suppressor	  on	   the	  best	  expression	  dpi.	   Top	  panel:	  
western	  blot	  (1:5,000).	  Bottom	  panel:	  corresponding	  AquaStained	  SDS-­‐PAGE	  gel	  showing	  a	  native	  protein	  
of	  approximately	  50	  kDa	  as	  an	   internal	  control	   for	  equal	  TSP	   loading.	  Mw,	  molecular	  weight	  marker.	   (-­‐)	  
pRIC3.0-­‐empty	   vector	   crude	   extract.	   (+),	   E.	   coli-­‐derived	   LALF-­‐E7	   inclusion	   bodies.	   Arrow	   indicates	   the	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2.4.	  Discussion	  
The	  fusion	  protein	  LALF-­‐E7	  is	  a	  potential	  therapeutic	  vaccine	  candidate	  for	  HPV-­‐16.	  It	  was	  
previously	  expressed	  in	  E.	  coli	  and	  was	  successful	  in	  eliciting	  tumour	  regression	  in	  trials	  in	  
animal	   model	   (Granadillo	   et	   al.,	   2011,	   2013).	   However,	   it	   would	   be	   potentially	   more	  
economical	  to	  use	  plant	  expression	  systems	  to	  produce	  this	  candidate	  vaccine,	  given	  that	  
the	  expression	  is	  sufficiently	  high	  (Fischer	  et	  al.,	  2004;	  Rybicki,	  2010).	  LALF-­‐E7	  has	  been	  
expressed	   in	  N.	   benthamiana	   leaves	   before,	   using	   the	   expression	   vectors	   pTRAc	   and	  
pEAQ-­‐HT	  (Granadillo	  and	  Lamprecht,	  unpublished	  data).	  However,	  the	  expression	  level	  
was	  very	  low.	  	  
In	  order	  to	  determine	  whether	  the	  plant-­‐derived	  LALF-­‐E7	  has	  similar	  immunogenic	  effects	  
in	  animal	  models	  as	  its	  bacterial-­‐derived	  counterpart,	  I	  aimed	  at	  increasing	  and	  optimising	  
the	  expression	  of	  LALF-­‐E7	  in	  N.	  benthamiana.	  This	  was	  done	  by	  expressing	  LALF-­‐E7	  in	  the	  
self-­‐replicating	   viral-­‐based	   expression	   vector	   pRIC3.0	   (Regnard	   et	   al.,	   2010).	   We	   also	  
compared	  the	  accumulation	  of	  LALF-­‐E7	  when	  targeted	  to	  the	  chloroplast	  by	  the	  potato	  
rbcs1	  chloroplast	  targeting	  peptide	  (cTP),	  to	  that	  when	  localized	  in	  the	  cytoplasm.	  And	  
finally,	  I	  tested	  whether	  silencing	  suppressors	  would	  affect	  the	  accumulation	  of	  LALF-­‐E7	  
in	  the	  cytoplasm	  and	  in	  the	  chloroplasts.	  
The	  expression	  of	  LALF-­‐E7	  as	  detected	  by	  western	  blots	  was	  successful	  using	  both	  pRIC3.0	  
and	   pRIC3.0-­‐cTP	   vectors.	   The	   expression	   of	   LALF-­‐E7	   in	   pRIC3.0	   and	   pRIC3.0-­‐cTP	   was	  
notably	  higher	  compared	  to	  pEAQ-­‐HT	  and	  pTRAc.	  This	  agreed	  with	  the	  results	  of	  Regnard	  
et	  al.	  (2010),	  in	  that	  increasing	  gene	  copy	  number	  can	  lead	  to	  increase	  in	  expression	  of	  
recombinant	   proteins.	   Several	   other	   studies	   have	   also	   shown	   that	   using	   replicating	  
vectors,	  especially	  those	  derived	  from	  geminiviruses,	  can	  lead	  to	  high	  expression	  levels	  
(Kim	  et	  al.,	  2007;	  Huang	  et	  al.,	  2009,	  2010;	  Dugdale	  et	  al.,	  2013).	  	  
It	  was	  noted	  that	  LALF-­‐E7	  appeared	  at	  »	  22	  kDa	  in	  western	  blots,	  while	  its	  predicted	  size	  
is	  »	  15	  kDa.	  This	  was	  consistent	  with	  observations	  by	  Granadillo	  et	  al.,	  (2011).	  The	  net	  
negative	  charge	  of	  E7	  is	  known	  to	  influence	  the	  migration	  of	  this	  protein	  in	  SDS-­‐PAGE	  gels,	  
making	  it	  appear	  larger	  (Armstrong	  and	  Roman,	  1993).	  This	  has	  also	  been	  observed	  with	  
other	  E7-­‐based	  fusion	  proteins,	  like	  16E7SH	  (Whitehead	  et	  al.,	  2014).	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It	   was	   observed	   that	   using	   the	   self-­‐replicating	   vector	   induced	   strong	   infection-­‐like	  
symptoms	  in	  the	  plants,	  even	  when	  no	  insert	  was	  present.	  Other	  studies	  have	  reported	  
that	   the	   Rep	   proteins	   of	   other	   geminiviruses	   can	   induce	   hypersensitive	   responses	   in	  
plants	  (Van	  Wezel	  et	  al.,	  2002):	  it	  could	  be	  that	  the	  presence	  of	  the	  BeYDV	  Rep	  and	  RepA	  
proteins	   induces	  the	  symptoms	  observed.	  Alternatively,	  the	  high	   level	  of	  replication	  of	  
the	  pRIC3.0	  vector	  could	  induce	  a	  hypersensitive	  response	  in	  the	  plant	  cells,	  especially	  in	  
later	   stages	   of	   infection.	   However,	   the	   protein	   expression	   levels	   were	   not	   negatively	  
affected	  by	  these	  strong	  symptoms,	  even	  on	  7	  dpi,	  compared	  to	  the	  expression	  obtained	  
from	  non-­‐replicative	  vectors.	  The	  strong	  symptoms	  could	  also	  be	  a	  result	  of	  the	  high	  OD600	  
used.	  
The	   choice	  of	   subcellular	   localization	   for	   the	  expression	  of	   recombinant	  proteins	   is	   an	  
important	  factor	  to	  be	  considered	  (Fischer	  et	  al.,	  2004;	  Benchabane	  et	  al.,	  2008;	  Daniell	  
et	  al.,	  2009).	  This	  has	  been	  demonstrated	  in	  previous	  studies	  from	  our	  lab.	  The	  highest	  
expression	  levels	  of	  HPV-­‐16	  L1	  variants	  where	  obtained	  when	  these	  were	  targeted	  to	  the	  
chloroplasts,	  compared	  to	  cytoplasmic	  localization.	  On	  the	  other	  hand,	  the	  same	  proteins	  
were	   hardly	   detectable	  when	   targeted	   to	   the	   endoplasmic	   reticulum	   (Maclean	   et	   al.,	  
2007).	  Meyers	  et	  al.	  (2008)	  obtained	  similar	  results	  for	  a	  human	  immunodeficiency	  virus	  
type	   1	   (HIV-­‐1)	   Gag-­‐derived	   antigen	   by	   targeting	   it	   to	   the	   same	   cell	   compartments.	  
However,	  a	  5-­‐fold	  increase	  in	  expression	  levels	  of	  HPV-­‐16	  E7	  in	  N.	  benthamiana	   leaves	  
was	   reported	  when	  E7	  was	   targeted	   to	   the	  plant	   secretory	   pathways	   (Franconi	  et	   al.,	  
2002,	  2006),	  suggesting	  that	  the	  effect	  of	  cell	  compartment	  targeting	  varies	  from	  protein	  
to	  protein.	  	  	  
To	  properly	  compare	  the	  accumulation	  of	  LALF-­‐E7	  in	  the	  cytoplasm	  to	  that	  in	  chloroplasts,	  
the	  preliminary	  set	  of	  experiments	  was	  repeated	  three	  times.	  The	  total	  soluble	  protein	  
(TSP)	   content	  was	  determined	   for	  each	  sample	  and	  accounted	   for	  when	  analysing	   the	  
expression	  of	  LALF-­‐E7.	   	  The	  accumulation	  of	  LALF-­‐E7	  in	  the	  cytoplasm	  peaked	  on	  5	  dpi	  
and	  it	  was	  undetectable	  on	  3	  and	  7	  dpi.	  On	  the	  other	  hand,	  the	  accumulation	  detected	  in	  
the	   chloroplasts	   did	   not	   fluctuate	   and	   represented	   the	   highest	   accumulation	   levels	   of	  
LALF-­‐E7.	  The	  increase	  in	  %	  TSP	  of	  26.8-­‐fold	  agrees	  with	  the	  hypothesis	  that	  proteins	  in	  cell	  
compartments	  are	  less	  prone	  to	  degradation.	  It	  is	  thought	  that	  protease	  concentrations	  
are	  lower	  in	  these	  than	  in	  the	  cytoplasm	  (Fischer	  et	  al.,	  2004;	  Maclean	  et	  al.,	  2007;	  Meyers	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et	  al.,	  2008).	  The	  higher	  accumulation	  of	  LALF-­‐E7	  in	  the	  chloroplasts	  seen	  here	  	  could	  also	  
be	  due	  to	  the	  cTP	  signal	  increasing	  the	  stability	  of	  the	  LALF-­‐E7	  transcripts	  in	  the	  cytoplasm,	  
making	  it	  less	  prone	  to	  PTGS	  (Maclean	  et	  al.,	  2007).	  To	  confirm	  this,	  quantitative	  reverse	  
transcription	  PCR	  (qRT-­‐PCR)	  could	  be	  done	  on	  pRIC3.0-­‐LALF-­‐E7	  and	  pRIC3.0-­‐cTP-­‐LALF-­‐E7	  
samples	  from	  different	  time	  points	  post	  infiltration.	  	  
The	  fact	  that	  targeting	  LALF-­‐E7	  to	  the	  chloroplasts	  dramatically	  increased	  its	  expression	  
compared	  to	  localizing	  it	  in	  the	  cytoplasm,	  suggest	  that	  subcellular	  localization	  played	  a	  
greater	   role	   in	   the	   accumulation	   of	   LALF-­‐E7	   than	   the	   increase	   in	   gene	   copy	   number	  
provided	  by	   the	   self-­‐replicating	   vector.	   This	   agrees	  with	   the	   findings	  of	   Regnard	  et	   al.	  
(2010),	  in	  that	  the	  increase	  in	  gene	  copy	  number	  was	  not	  proportional	  to	  the	  fold	  increase	  
in	  protein	  expression.	  Therefore,	   it	  would	  not	  be	  surprising	   if	  comparable	  results	  were	  
obtained	   if	   expressing	   LALF-­‐E7	   from	   pTRAc	   versus	   pTRA-­‐cTP;	   although	   higher	   A.	  
tumefaciens	  OD600	  would	  probably	  be	  needed.	  	  
Previous	  work	  with	  ZERA-­‐16E7SH	  expressed	  using	  pTRAc	  (Whitehead	  et	  al.,	  2014)	  showed	  
that	  the	  accumulation	  of	  this	  protein	  was	  enhanced	  in	  the	  presence	  of	  the	  NSs	  protein.	  
This	  suggested	  that	  PTGS	  could	  play	  a	  role	  in	  the	  accumulation	  of	  E7-­‐based	  recombinant	  
proteins.	   To	   determine	   whether	   PTGS	   does	   play	   a	   role	   in	   LALF-­‐E7	   accumulation,	   N.	  
benthamiana	  plants	  were	  co-­‐infiltrated	  with	  pRIC3.0-­‐LALF-­‐E7	  or	  pRIC3.0-­‐cTP-­‐LALF-­‐E7	  and	  
NSs	   or	   P19	   silencing	   suppressors.	   It	   was	   shown	   that	   co-­‐infiltration	   with	   silencing	  
suppressors	  did	  not	  have	  a	  big	  impact	  on	  the	  expression	  of	  LALF-­‐E7,	  as	  the	  increase	  was	  
only	   1.3-­‐fold:	   this	   can	   be	   considered	   insignificant	   when	   compared	   to	   the	   26.8-­‐fold	  
increase	   seen	  when	   targeting	   to	   the	   chloroplast	   alone	   versus	   cytoplasmic	   localization.	  
These	   results	  were	   consistent	  with	   those	  of	  Maclean	  et	   al.	   (2007),	  who	   reported	   that	  
targeting	  hL1	  to	  the	  chloroplasts	  allowed	  for	  its	  detection	  in	  western	  blots,	  while	  it	  was	  
undetectable	  when	  localized	  in	  the	  cytoplasm,	  even	  in	  the	  presence	  of	  NSs.	  	  
The	   only	   instances	   where	   silencing	   suppressors	   did	   seem	   to	   have	   an	   effect	   on	   the	  
expression	  of	  LALF-­‐E7	  were	  when	  looking	  at	  7	  dpi	  samples	  (data	  not	  shown).	  This	  is	  not	  
surprising	  as	  PTGS	  takes	  place	  in	  later	  stages	  of	  infection.	  However,	  the	  expression	  levels	  
at	  7	  dpi	  in	  the	  presence	  of	  silencing	  suppressors	  were	  still	  lower	  than	  on	  days	  3	  and	  5	  with	  
or	   without	   silencing	   suppressors.	   The	   replication	   of	   geminivirus-­‐based	   vectors	   is	   very	  
rapid	  and	  high	  expression	  levels	  are	  often	  obtained	  before	  the	  onset	  of	  PTGS	  (Chen	  et	  al.,	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2011).	  Furthermore,	  the	  poor	  expression	  of	  LALF-­‐E7	  in	  pEAQ-­‐HT,	  which	  encodes	  for	  the	  
P19	  silencing	  suppressor,	  further	  suggests	  that	  amplification	  of	  gene	  copy	  number	  by	  the	  
replicative	  vectors	  can	  have	  a	  greater	  impact	  on	  expression	  levels	  than	  that	  of	  silencing	  
suppressors.	  	  
In	  conclusion,	  I	  was	  able	  to	  enhance	  the	  expression	  of	  LALF-­‐E7	  in	  N.	  benthamiana	  leaves	  
over	  previous	   studies.	   I	   found	   that	   subcellular	   localization	  of	   LALF-­‐E7	  played	   the	  most	  
important	   role	   in	   increasing	   its	   accumulation	   levels.	   Furthermore,	   this	   allowed	  me	   to	  
proceed	  to	  expressing	  LALF-­‐E7	  in	  large	  scales	  to	  test	  it	  in	  animal	  models.	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Chapter	  3:	  Subcellular	  localization	  of	  LALF-­‐E7	  in	  Nicotiana	  
benthamiana	  leaves	  
3.1.	  Introduction	  
The	  green	   fluorescent	  protein	   (GFP)	   and	   its	   derivatives	   are	   flexible	  proteins	   that	  have	  
been	  used	  for	  numerous	  applications	  in	  cell	  biology,	  including	  plant	  imaging.	  They	  have	  
facilitated	   the	   study	   of	   subcellular	   localization	   and	   trafficking	   visualization	   of	   diverse	  
proteins,	  and	  have	  helped	  elucidate	  different	  cellular	  pathways.	  Therefore,	  fluorescent	  
proteins	   have	   gained	   great	   importance	   as	   cell	   biology	   tools	   (Tsien,	   1998;	  Hanson	   and	  
Köhler,	  2001).	  	  
In	  our	  group,	  the	  use	  of	  the	  rbcS1	  gene-­‐derived	  chloroplast	  transit	  peptide	  (cTP),	  from	  the	  
RuBisCO	  small	  subunit	  of	  Solanum	  tuberosum,	  has	  proven	  useful	   (Maclean	  et	  al.	  2007;	  
Meyers	  et	  al.	  2008).	  In	  Chapter	  2	  it	  was	  seen	  that	  the	  highest	  accumulation	  level	  of	  LALF-­‐
E7	  was	  obtained	  when	  targeted	  to	  the	  chloroplasts	  by	  the	  same	  cTP.	  This	  was	  26.8-­‐fold	  
higher	  than	  when	  LALF-­‐E7	  was	  not	  targeted	  to	  any	  cell	  compartment.	  It	  is	  not	  likely	  that	  
this	  difference	  is	  due	  to	  a	  difference	  in	  gene	  copy	  numbers,	  since	  the	  same	  replicative	  
vector	  was	  used	  for	  cytoplasmic	  and	  chloroplast-­‐targeted	  LALF-­‐E7	  expression.	  	  In	  order	  to	  
show	  whether	  my	  protein	  of	  interest	  was	  in	  fact	  being	  targeted	  to	  the	  chloroplasts,	  I	  fused	  
LALF-­‐E7	  to	  the	  enhanced	  GFP	  (EGFP).	  In	  this	  way,	  I	  aimed	  to	  determine	  the	  subcellular	  
localization	  of	  LALF-­‐E7	  by	  indirectly	  imaging	  it	  using	  confocal	  laser	  scanning	  microscopy	  
(CLSM).	  	  
N.	  benthamiana	  leaves	  expressing	  fluorescent	  proteins	  can	  easily	  be	  visualized	  by	  CLSM	  
in	   vivo	  without	   the	  need	   for	   fixation	  or	   staining	  procedures	   (Fang	  and	  Spector,	  2010).	  
Furthermore,	  the	  autofluorescence	  of	  chlorophylls	  can	  be	  used	  as	  a	  means	  of	  detecting	  
the	   plant	   chloroplasts.	   The	   advances	   in	   confocal	  microscopy,	   the	   autofluorescence	   of	  
chlorophylls	  and	  the	  properties	  of	  GFP	  make	  the	  latter	  an	  appropriate	  tag	  candidate	  to	  
determine	  the	  subcellular	  localization	  of	  LALF-­‐E7.	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3.2.	  Materials	  and	  Methods	  
3.2.1.	  Bacterial	  strains	  and	  growth	  conditions	  
Refer	  to	  section	  2.2.1.	  
3.2.2.	  Construct	  generation	  
3.2.2.1.	  Modification	  of	  LALF-­‐E7.	   In	  order	  to	   fuse	  LALF-­‐E7	  to	  EGFP,	   the	  DNA	  sequence	  
encoding	  LALF-­‐E7	  (section	  2.2.2.1)	  was	  modified	  to	  remove	  the	  hexa-­‐histidine	  (His)-­‐tag	  
and	   the	   stop	   codon,	   to	   add	   appropriate	   restriction	   enzyme	   (RE)	   sites	   to	   be	   used	   in	   a	  
stepwise	  cloning	  strategy,	  and	  to	  insert	  a	  linker	  between	  the	  two	  peptides.	  The	  RE	  sites	  
BamHI,	  MluI	  and	  NcoI	  were	  added	  at	  the	  5’-­‐end	  of	  the	  LALF-­‐E7	  open	  reading	  frame	  (ORF),	  
while	  a	  rigid	  linker,	  Proline(P)-­‐Alanine(A)-­‐P-­‐A-­‐P,	  and	  the	  restriction	  site	  BspHI	  were	  added	  
to	   the	   3’-­‐end	   (Figure	   3.1).	   The	   modified	   LALF-­‐E7	   was	   plant	   codon-­‐optimized	   and	  
synthesized	  by	  GenScript	  (USA),	  and	  provided	  in	  a	  pUC57	  plasmid.	  
3.2.2.2	  Subcloning	  the	  modified	  LALF-­‐E7	  into	  plant	  expression	  vectors.	  The	  pUC57	  vector	  
containing	  the	  modified	  LALF-­‐E7	  and	  the	  pEGFP	  plasmid	  were	  digested	  with	  BamHI/BspHI.	  
The	  relevant	  fragments,	  428	  bp	  and	  3,340	  bp,	  respectively,	  were	  gel-­‐extracted	  and	  ligated	  
as	   described	   in	   section	   2.2.2.2.	   The	  plasmid	   generated,	   pLALF-­‐E7-­‐EGFP	   (pLG),	  was	  RE-­‐
digested	  with	  BamHI/NotI	  to	  excise	  the	  fusion	  sequence	  LALF-­‐E7-­‐EGFP	  (LG;	  1,100	  bp).	  This	  
fusion	  fragment	  was	  ligated	  into	  pPROEX-­‐HTb	  previously	  linearized	  using	  the	  same	  REs.	  
The	  pPROEX-­‐HTb-­‐LALF-­‐E7-­‐EGFP	  (pX-­‐LG)	  plasmid	  was	  digested	  with	  NcoI/XhoI	  to	  insert	  LG	  
into	  pRIC3.0	  using	  the	  restriction	  sites	  NcoI/AflIII,	  generating	  pRIC3.0-­‐LALF-­‐E7-­‐EGFP	  (pR-­‐
LG).	   To	   insert	   LG	   into	   pRIC3.0-­‐cTP,	   the	   plasmids	   pX-­‐LG	   and	   pRIC3.0-­‐cTP-­‐BFDV	   were	  
digested	   with	   MluI/XhoI,	   thereby	   excising	   the	   beak	   and	   feather	   disease	   virus	   (BFDV)	  
capsid	   protein	   sequence	   and	   inserting	   the	   LG	   sequence	   into	   pRIC3.0-­‐cTP,	   generating	  
pRIC3.0-­‐cTP-­‐LALF-­‐E7-­‐EGFP	  (pT-­‐LG;	  Figure	  3.1	  and	  table	  3.1).	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Figure	  3.1.	  Representation	  of	  the	  relevant	  constructs	  used	  in	  this	  work.	  pEGFP,	  contains	  the	  target	  EGFP	  
sequence	  (light-­‐green	  box)	  to	  be	  fused	  to	  LALF-­‐E7,	  and	  contains	  a	  stop	  codon	  (black	  stars).	  pUC57-­‐LALF-­‐E7	  
contains	   the	   plant	   codon-­‐optimized	   LALF-­‐E7	   sequence	   (dark-­‐blue	   box),	   appropriate	   restriction	   sites	   for	  
subcloning	  (shown	  by	  the	  light-­‐blue	  arrows),	  a	  rigid	  linker	  (PAPAP,	  red	  box)	  and	  no	  His-­‐tag	  or	  stop	  codons.	  
The	  final	  constructs	  pR-­‐LG	  and	  pT-­‐LG	  were	  generated	  in	  a	  stepwise	  manner,	  having	  the	  p-­‐LG	  and	  pX-­‐LG	  as	  
intermediates	  (not	  shown).	  Also	  shown	  are	  the	  cauliflower	  mosaic	  virus	  (CAMV)	  35	  S	  constitutive	  promoter	  
(black	  box),	  and	  the	  chloroplast	  targeting	  peptide	  (cTP,	  dark-­‐green	  box).	  Not	  drawn	  to	  scale.	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For	  all	  steps,	  E.	  cloni	  cells	  were	  transformed	  as	  described	  in	  section	  2.2.2.2.	  Colonies	  were	  
screened	   by	   PCR	   using	   the	   LALF-­‐E7-­‐GenScript	   primers	   (Table	   3.2).	   The	   KapaTaq	   HiFi	  
HotStart	  ReadyMix	  PCR	  kit	  (Kapa	  Biosystems)	  was	  used	  according	  to	  the	  manufacturer’s	  
instructions.	  The	  PCR	  profile	  used	  was	  one	  cycle	  of	  initial	  denaturation	  at	  95	  °C	  for	  3	  min;	  
25	  cycles	  of	  denaturation	  at	  98	  °C	  for	  20	  s,	  annealing	  at	  65	  °C	  for	  15	  s,	  and	  extension	  at	  72	  
°C	  for	  15	  s;	  and	  one	  cycle	  of	  final	  extension	  at	  72	  °C	  for	  7	  min.	  The	  expected	  size	  of	  the	  
PCR	  product	  was	  403	  bp.	  Putative	  positive	  colonies	  were	  then	  confirmed	  by	  RE	  digestion.	  
All	  REs	  used	  were	  provided	  by	  Thermo	  Scientific,	  except	  for	  AflIII	  (New	  England	  Biolabs).	  
One	  µg	  of	  plasmid	  DNA	  was	  used	  for	  sub-­‐cloning	  steps	  and	  300-­‐500	  ng	  of	  DNA	  were	  used	  
for	  confirmation	  of	  putative	  recombinant	  colonies.	  The	  final	  constructs	  pR-­‐LG	  and	  pT-­‐LG	  
were	  further	  confirmed	  by	  sequence	  analysis	  (Macrogen	  Inc.)	  using	  the	  pTRAkc	  primers	  
(Table	  3.2).	  	  
3.2.3.	  Electroporation	  of	  A.	  tumefaciens	  
Electrocompetent	   A.	   tumefaciens	   GV3101::pMP90RK	   cultures	   were	   prepared	   and	  
electroporated	  as	  described	  in	  section	  2.2.3.	  Recombinant	  A.	  tumefaciens	  pR-­‐LG	  and	  pT-­‐
LG	  were	  confirmed	  by	  colony	  PCR	  using	  the	  KapaTaq	  ReadyMix	  PCR	  kit	  (Kapa	  Biosystems)	  
and	  the	  pTRAkc	  primers	  (Table	  3.2).	  The	  PCR	  profile	  used	  was	  as	  in	  section	  2.2.3.	  with	  the	  
annealing	  temperature	  being	  at	  54	  °C	  and	  extension	  period	  for	  1	  min.	  The	  pRIC3.0	  empty	  
vector	  DNA	  was	  used	  as	  positive	  control	  and	  a	  no	  template	  reaction	  was	  used	  as	  negative	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Table	  3.2.	  Primers	  used	  in	  this	  work	  
Name	   Sequence	   Feature	   Application	  
Fw-­‐LALF-­‐E7-­‐GenScript	   5’	  aaT	  CCA	  TGG	  CCG	  
AGT	  TCC	  ATT	  3’	  
Complementary	   to	  
the	  modified	  LALF-­‐E7	  
sequence.	  
E.	  cloni	  colony	  PCR	  screening.	  
Rv-­‐LALF-­‐E7-­‐GenScript	   5’	   ttc	   tcg	  agt	   tat	   taA	  
GCA	  CGG	  CTA	  3’	  
Complementary	   to	  
the	  modified	  LALF-­‐E7	  
sequence.	  
E.	  cloni	  colony	  PCR	  screening.	  
pTRAkc-­‐Fw	   5’	   CAT	   TTC	  ATT	   TGG	  
AGA	  GGA	  CAC	  G	  3’	  
Complementary	   to	  
pRIC3.0	   and	   pRIC3.0-­‐
cTP	  backbone.	  
Sequencing	   insertions	   and	  
confirmation	  of	   recombinant	  
A.	  tumefaciens.	  
pTRAkc-­‐Rv	   5’	  GAA	  CTA	  CTC	  ACA	  
CAT	  TAT	  TCT	  GG	  3’	  
Complementary	   to	  
pRIC3.0	   and	   pRIC3.0-­‐
cTP	  backbone.	  
Sequencing	   insertions	   and	  
confirmation	  of	   recombinant	  
A.	  tumefaciens.	  
LALF-­‐E7-­‐GenScript	  primers	  were	  designed	  using	  the	  CLC-­‐Main	  Workbench	  6	  (QIAGEN	  Bioinformatics)	  and	  
synthesised	  by	  the	  DNA	  Synthesis	  Unit	  (MCB,	  UCT).	  
	  
3.2.4.	  Agroinfiltration	  of	  N.	  benthamiana	  leaves	  
Recombinant	  A.	  tumefaciens	  cultures	  were	  prepared	  for	  agroinfiltration	  as	  described	  in	  
section	  2.2.4.1.	  For	  small	  scale	  expression	  studies,	  A.	  tumefaciens	  cultures	  were	  diluted	  
in	  infiltration	  medium	  to	  final	  OD600s	  of	  0.25,	  0.50	  and	  1.00	  to	  determine	  the	  optimal	  OD	  
for	  the	  expression	  of	  LG.	  Two	  plants	  were	  used	  per	  construct:OD600	  combination.	  A	  time	  
trial	  was	   done	   to	   determine	   the	   expression	   profile	   of	   pR-­‐LG	   and	   pT-­‐LG,	   as	  well	   as	   to	  
monitor	  leaf	  symptoms.	  This	  was	  done	  by	  visualizing	  infiltrated	  leaves	  under	  white	  light	  
and	  ultraviolet	  light	  (Spectroline	  Long	  Life	  ™	  Filter,	  set	  at	  365	  nm)	  on	  3,	  5	  and	  7	  days	  post	  
infiltration	  (dpi),	  and	  harvesting	  plant	  tissue	  on	  3	  and	  5	  dpi.	  The	  construct	  pRIC3.0-­‐EGFP	  
was	  used	  as	  a	  positive	  control	  at	  an	  OD600	  of	  0.25	  as	  determined	  by	  Regnard	  et	  al.	  (2010).	  
As	  negative	  control,	  the	  pRIC3.0	  empty	  vector	  was	  used	  at	  an	  OD600	  of	  0.5.	  One	  plant	  was	  
used	  per	  control.	  
For	   fluorescence	   CLSM,	   young	  N.	   benthamiana	   plants,	   3-­‐4	   weeks	   old,	   were	   vacuum-­‐
infiltrated	  with	  A.	  tumefaciens	  cultures	  at	  an	  OD600	  of	  0.25	  as	  described	  in	  section	  2.2.4.1.	  
The	  pR-­‐LG	  construct	  was	  also	  vacuum-­‐infiltrated	  at	  an	  OD600	  of	  0.5.	  
3.2.5.	  Fluorescence	  confocal	  laser	  scanning	  microscopy	  (CLSM)	  
3.2.5.1.	  Sample	  preparation.	  Vacuum-­‐infiltrated	  leaves	  were	  manually	  sectioned	  with	  a	  
razor	  blade	  into	  very	  fine	  strips	  and	  mounted	  in	  distilled	  water	  on	  a	  glass	  slide.	  A	  cover	  
slip	  was	  placed	  on	  top	  of	  the	  sections	  for	  visualization.	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3.2.5.2.	  Data	  collection.	  Thin	  leaf	  sections	  were	  imaged	  using	  a	  Zeiss	  LSM	  510	  Meta	  NLO	  
multiphoton	   confocal	  microscope	   and	   the	   ZEN	  2009	   software	   (Zeiss).	   The	   lenses	   used	  
included	  a	  20x	  air	  lens	  and	  a	  40×	  water	  immersion	  lens	  (numerical	  aperture	  of	  1.1).	  The	  
EGFP	  was	  excited	  by	  an	  argon	  laser	  at	  488	  nm	  and	  the	  emission	  was	  detected	  at	  500-­‐550	  
nm.	  The	  chloroplasts	  were	  indirectly	  detected	  by	  exciting	  the	  chlorophyll	  by	  a	  DPSs	  laser	  
at	  561	  nm	  and	  the	  emission	  was	  detected	  at	  650-­‐710	  nm.	  Imaging	  parameters	  were	  fixed	  
for	  all	  data	  acquisition	  for	  both	  rounds	  of	  microscopy	  done.	  
For	   colocalization	   studies,	   images	   obtained	   during	   sample	   visualization	  were	   analysed	  
using	   the	   colocalization	   set-­‐up	   on	   the	   ZEN	   software.	   To	   accurately	   set	   the	   crosshairs,	  
single	   label	  control	  samples	  must	  be	  prepared.	  For	  the	  red	  label	  sample	  (chloroplasts),	  
the	  negative	  control	  was	  used.	  Due	  to	  the	  nature	  of	  the	  samples,	  I	  did	  not	  have	  a	  green	  
single	  label.	  Therefore,	  the	  positive	  control	  was	  used.	  These	  controls	  were	  imaged	  with	  
the	  same	  microscope	  settings	  as	  the	  experimental	  sample.	  All	  imaging	  settings,	  including	  
the	  crosshair	  positions,	  were	  kept	  fixed	  throughout	  the	  colocalization	  analysis.	  	  
3.2.6.	  Preparation	  of	  plant	  crude	  extracts	  and	  western	  blot	  detection	  of	  LG	  	  
For	  the	  small	  scale	  expression	  optimization,	  crude	  extracts	  were	  prepared	  as	  described	  in	  
section	  2.2.5.1.	  For	  plants	  used	  for	  CLSM,	  vacuum-­‐infiltrated	  leaves	  were	  harvested	  and	  
crude	  extracts	  were	  prepared	  as	  described	  in	  section	  2.2.5.2.	  after	  the	  visualization	  was	  
done.	  	  
Samples	   were	   prepared	   for	   SDS-­‐PAGE	   electrophoresis	   as	   described	   in	   section	   2.2.7.	  
Twenty	  µl	  of	  crude	  extracts	  were	  used	  per	  sample.	  Crude	  extracts	  from	  plants	  infiltrated	  
with	  pRIC3.0-­‐EGFP	  and	  pRIC3.0	  empty	  vector	  were	  used	  as	  positive	  and	  negative	  controls,	  
respectively.	  The	  primary	  and	  secondary	  antibodies	  used	  were	  mouse	  monoclonal	  anti-­‐
GFP	   (Sigma-­‐Aldrich)	   and	   goat	   anti-­‐Mouse	   IgG	  whole	  molecules	   conjugated	   to	   alkaline	  
phosphatase	  (AP;	  Sigma-­‐Aldrich),	  respectively.	  Both	  were	  used	  at	  a	  dilution	  of	  1:5,000.	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3.3.	  Results	  
3.3.1.	  LALF-­‐E7-­‐EGFP	  fusion	  construct	  generation	  
The	  original	  sequence	  of	  LALF-­‐E7	  was	  modified	  to	  generate	  the	  fusion	  protein	  LALF-­‐E7-­‐
EGFP	  (LG).	  The	  His-­‐tag	  and	  stop	  codons	  were	  removed,	  while	  adding	  appropriate	  RE	  sites	  
and	  a	   rigid	   linker	   sequence	   to	   separate	   the	   two	  peptides	   (Figure	  3.1).	  The	   rigid	   linker,	  
PAPAP	  (Zhao	  et	  al.,	  2008;	  Chen,	  Zaro	  and	  Shen,	  2013),	  was	  chosen	  to	  prevent	  interactions	  
between	  LALF-­‐E7	  and	  EGFP,	  and	  therefore	  prevent	  possible	  misfolding	  of	  the	  EGFP,	  since	  
LALF-­‐E7	  is	  highly	  hydrophobic	  and	  could	  associate	  with	  hydrophobic	  patches	  on	  the	  EGFP.	  
The	  modified	  LALF-­‐E7	  sequence	  was	  successfully	  cloned	  into	  the	  pEGFP	  plasmid	  (Figure	  
3.2A).	  The	  LG	  fusion	  was	  subcloned	  into	  pPROEX-­‐HTb	  in	  order	  to	  place	  a	  XhoI	  RE	  site	  at	  
the	  3’-­‐end	  of	  the	  sequence	  which	  was	  used	  in	  subsequent	  cloning	  steps	  (see	  section	  3.2.2.	  
and	  Figure	  3.2B).	  From	  pPROEX-­‐HTb,	  LG	  was	  subcloned	  into	  the	  final	  vectors	  pRIC3.0	  and	  
pRIC3.0-­‐cTP,	   generating	   pR-­‐LG	   and	   pT-­‐LG	   respectively	   (Figure	   3.2C).	   Furthermore,	   the	  
sequencing	   results	   of	   the	   final	   constructs	   coincided	  with	   predicted	   sequences	   on	   CLC	  
Main	   Workbench	   6.	   These	   constructs	   were	   subsequently	   electroporated	   into	   A.	  
tumefaciens	  cells	  and	  recombinant	  colonies	  were	  confirmed	  by	  PCR	  (Figure	  3.2D).	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Figure	   3.2.	   Confirming	   recombinant	   E.	   cloni	   and	   A.	   tumefaciens	   containing	   LALF-­‐E7-­‐EGFP	   fusion	  
constructs.	  (A-­‐C),	  Screening	  putative	  positive	  E.	  cloni	  colonies	  by	  RE	  digestion.	  REs	  used	  are	  shown	  above	  
each	  image.	  	  U,	  undigested	  plasmid.	  Mw,	  1	  kb	  DNA	  molecular	  weight	  marker.	  Relevant	  molecular	  weight	  
marker	  band	  sizes	  are	  shown.	  (D),	  Screening	  putative	  positive	  A.	  tumefaciens	  GV3101::pMP19RK-­‐pR-­‐LG	  and	  
-­‐pT-­‐LG	  by	  colony	  PCR.	  Shown	  are	  representatives	  of	  10	  and	  30	  colonies	  selected,	  respectively.	  
	  
3.3.2.	  Optimization	  of	  LG	  expression	  in	  N.	  benthamiana	  leaves	  
In	  order	  to	  determine	  the	  best	  OD600	  and	  dpi	  for	  the	  expression	  of	  the	  EGFP-­‐tagged	  LALF-­‐
E7,	  plants	  were	  syringe-­‐infiltrated	  with	  pR-­‐LG	  and	  pT-­‐LG	  at	  different	  OD600s.	  The	  plants	  
were	  visualized	  under	  UV-­‐light	  on	  3,	  5	  and	  7	  dpi.	  The	  positive	  control	  fluoresced	  green	  
throughout	  the	  experiment	  as	  expected	  (Figure	  3.3);	  however,	  due	  to	  tissue	  necrosis	  by	  
7	  dpi,	   the	  fluorescence	  decreased	  at	  this	  time	  point	   (not	  shown).	  The	  negative	  control	  
fluoresced	  red,	  except	  in	  areas	  of	  leaf	  damage,	  such	  as	  at	  the	  points	  of	  infiltration	  and	  
areas	  affected	  by	  necrosis.	  Therefore,	  a	  white-­‐blue	  fluorescence	  was	  seen	  on	  5	  and	  7	  dpi.	  
Experimental	  plants,	  pR-­‐LG	  and	  pT-­‐LG,	  expressed	  LG	  on	  3	  and	  5	  dpi	  regardless	  of	  the	  OD600	  
used.	  However,	  higher	  OD600	  and	  longer	  incubation	  periods	  were	  associated	  with	  more	  
necrotic	   symptoms	   and	   lower	   green	   fluorescence.	   For	   fluorescence	   CLSM,	   healthy,	  
undamaged	   leaf	   tissue	  was	   desirable,	   since	   these	   are	   easier	   to	   handle	   during	   sample	  
preparation	  and	  unspecific	  fluorescence	  is	  prevented.	  Therefore,	  OD600	  of	  0.25-­‐0.5,	  and	  3	  
dpi	  were	  considered	  to	  be	  the	  optimal	  conditions	  for	  LG	  expression	  from	  both	  vectors.	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Figure	  3.3.	  Optimization	  of	  LALF-­‐E7-­‐EGFP	  expression	  in	  syringe-­‐infiltrated	  N.	  benthamiana	  leaves.	  Plants	  
infiltrated	  with	  pRIC3.0-­‐EGFP	  and	  pRIC3.0	  empty	  vector	  were	  used	  as	  positive	  (+)	  and	  negative	  (-­‐)	  controls,	  
respectively.	  Experimental	  plants	  were	  infiltrated	  with	  pR-­‐LG	  and	  pT-­‐LG	  at	  different	  OD600.	  Shown	  here	  is	  a	  
representative	  picture	  of	  each	  vector:OD600	  combination	  under	  UV-­‐light	  (top)	  and	  white	  light	  (bottom).	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3.3.3.	  Subcellular	  localization	  of	  LG	  by	  fluorescence	  CLSM	  	  
Once	   the	   optimal	   conditions	   were	   determined	   for	   the	   expression	   of	   LG,	   plants	   were	  
vacuum-­‐infiltrated	   and	   leaves	   were	   visualized	   under	   a	   confocal	   laser	   scanning	  
microscope.	  Young	  plants	  were	  used	  as	  their	  leaves	  are	  thinner	  than	  that	  of	  older	  plants.	  
This	  allowed	  for	  appropriate	  leaf	  sectioning	  and	  better	  visualization.	  
In	   cells	   expressing	   the	   positive	   control,	   the	   green	   fluorescence	   could	   be	   seen	   evenly	  
distributed	  in	  the	  cytoplasm.	  No	  green	  fluorescence	  was	  detected	  inside	  the	  chloroplasts	  
as	   they	  were	  seen	  as	  black	  or	  empty	  spheres	   in	   the	  green	  channel	  and	  no	  yellow	  was	  
detected	   when	   the	   green	   and	   red	   channels	   were	  merged.	   This	   represented	   a	   typical	  
cytoplasm-­‐localized	  protein	   (Figure	  3.4A).	   In	   samples	  of	   the	  negative	  controls,	  pRIC3.0	  
empty	  vector	  and	  uninfiltrated	  leaves,	  no	  green	  fluorescence	  was	  observed,	  as	  expected,	  
and	  only	  chloroplasts	  were	  detected	  (Figure	  3.4B).	  
The	   fluorescence	  pattern	   in	   the	  pR-­‐LG	  samples	   resembled	  that	  of	   the	  positive	  control,	  
however	   it	   was	   less	   intense	   (Figure	   3.4C),	   as	   also	   seen	   during	   the	   optimisation	  
experiments.	  Besides	  the	  evenly	  spread	  green	  fluorescence	  within	  the	  plant	  cells,	  large	  
and	  bright	   globular	   structures	   could	  also	  be	   seen	   that	   resembled	  protein	  bodies	   (PBs;	  
Figure	  3.4D,	  yellow	  arrows).	  	  
Interestingly,	  cells	  expressing	  pT-­‐LG	  presented	  a	  very	  different	  fluorescence	  pattern.	  The	  
LG	  in	  these	  samples	  were	  seen	  as	  numerous	  bright	  small	  dots	  also	  resembling	  PBs,	  but	  
smaller	  and	  much	  more	  abundant	  than	  those	  seen	  in	  some	  pR-­‐LG	  samples	  (Figure	  3.4E-­‐
F).	  The	  pattern	  formed	  by	  these	  PB-­‐like	  structures	  followed	  the	  pattern	  formed	  by	  the	  
chloroplasts	  and	  appeared	  yellow	  when	  seen	  at	  a	  lower	  magnification	  (Figure	  3.4F,	  white	  
arrows).	  On	  the	  other	  hand,	  the	  LG	  PB-­‐like	  structures	  did	  not	  appear	  to	  overlap	  or	  to	  be	  
within	   the	   chloroplasts	   when	   seen	   at	   a	   higher	   magnification.	   They	   appeared	   rather	  
associated	  to	  the	  surface	  of	  the	  chloroplasts	  (Figure	  3.4E,	  blue	  arrow).	  However,	  no	  LG	  
was	  seen	  separated	  from	  chloroplasts,	  even	  though	  chloroplasts	  that	  did	  not	  have	  a	  LG	  
PB-­‐like	  structures	  attached	  to	  them	  could	  be	  seen.	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Figure	  3.4.	  Fluorescence	  CLSM	  images	  of	  the	  subcellular	  localization	  of	  LG.	  N.	  benthamiana	  leaves	  were	  
vacuum-­‐infiltrated	  with	  the	  relevant	  constructs.	  On	  3	  dpi	  live	  leaf	  sections	  were	  prepared	  for	  visualization.	  
(A),	  positive	  control,	  pRIC3.0-­‐EGFP.	  (B),	  negative	  control,	  pRIC3.0	  empty	  vector.	  (C-­‐D),	  cytoplasmic	  pR-­‐LG.	  
(E-­‐F),	   chloroplast-­‐targeted	   pT-­‐LG.	   Green	   channel,	   EGFP	   fluorescence.	   Red	   channel,	   chlorophyl	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Red	   Merged	  
Green	   DIC	  
Red	   Merged	  
Green	   DIC	  
Red	   Merged	  
Green	   DIC	  
Red	   Merged	  
Green	   DIC	  
Red	   Merged	  
(A)	   (B)	  
(C)	  
Green	   DIC	  
Red	   Merged	  
(D)	  
(F)	  (E)	  
	   55	  
autofluorescence.	  DIC,	  differential	   interference	  contrast.	  Merged,	  an	  overlap	  of	   the	  Green,	  Red	  and	  DIC	  
channel	   images.	  For	  A-­‐C	  and	  E:	  scale	  bar	  =	  20	  µm,	  magnification	  =	  40x.	  For	  D	  and	  F:	  scale	  bar	  =	  50	  µm,	  
magnification	  =	  20x.	  Shown	  here	  are	  representative	  images	  of	  several	  images	  taken	  over	  two	  independent	  
sets	  of	  experiments.	  
	  
Images	  taken	  during	  the	  fluorescence	  microscopy	  were	  analysed	  using	  the	  colocalization	  
settings	  of	  the	  Zeiss’	  Zen	  software.	  Shown	  in	  Figure	  3.5	  are	  representative	  images	  of	  the	  
colocalization	  profiles	  obtained.	  Overall,	  the	  pattern	  seen	  for	  the	  positive	  control	  was	  that	  
as	   the	  green	   fluorescence	  curve	   increased,	   the	   red	   fluorescence	  curve	  decreased,	  and	  
vice-­‐versa	  (Figure	  3.5A).	  Overlapping	  of	  the	  red	  and	  green	  fluorescence	  curves	  was	  not	  
common,	  as	  expected,	  indicating	  that	  the	  EGFP	  was	  not	  localized	  inside	  the	  chloroplast.	  
The	  negative	   control	   contained	  only	  a	   red	   fluorescence	  curve	   (Figure	  3.5B).	   The	  curve	  
pattern	  for	  the	  cytoplasmic	  pR-­‐LG	  was	  similar	  to	  that	  of	  the	  positive	  control,	  except	  that	  
the	  green	  fluorescence	  was	   lower	  (Figure	  3.5C).	  On	  the	  other	  hand,	  the	  green	  and	  red	  
fluorescence	   curves	   for	   chloroplast-­‐targeted	  pT-­‐LG	   followed	   the	   same	  pattern,	   as	   one	  
increased	  so	  did	  the	  other.	  This	  indicated	  that	  pT-­‐LG	  was	  associated	  with	  the	  chloroplasts	  
(Figure	  3.5D).	  Here,	  the	  green	  fluorescence	  curve	  was	  at	  times	  very	  high,	  suggesting	  that	  
the	  PB-­‐like	  structures	  seen	  for	  pT-­‐LG	  were	  very	  concentrated.	  	  
	  
Figure	  3.5.	  Colocalization	  profiles	  of	  LG	  and	  chloroplasts.	  Colocalization	  profiles	  were	  generated	  using	  the	  
colocalization	  feature	  of	  the	  Zeiss	  Zen	  software.	  (A),	  positive	  control,	  pRIC3.0-­‐EGFP.	  (B),	  negative	  control,	  
pRIC3.0	   empty	   vector.	   (C),	   cytoplasmic	   pR-­‐LG.	   (D),	   chloroplast-­‐targeted	   pT-­‐LG.	   Green	   and	   red	   curves	  
correspond	  to	  EGFP	  fluorescence	  and	  the	  chlorophyl	  autofluorescence,	  respectively.	  White	  bars	  represent	  
the	  area	  used	  to	  generate	  the	  colocalization	  profiles.	  Magnification	  of	  40X.	  Shown	  here	  are	  representatives	  
of	  several	  images	  taken	  over	  two	  independent	  sets	  of	  experiments.	  
(A)	   (B)	  
(C)	   (D)	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After	  fluorescence	  confocal	  microscopy,	  the	  remaining	  leaves	  were	  harvested	  from	  the	  
vacuum-­‐infiltrated	  plants.	   The	  western	  blots	  of	   the	   resulting	   crude	  extracts	   confirmed	  
that	  LALF-­‐EGFP	  was	  expressed	  in	  these	  plants.	  Cytoplasmic	  and	  chloroplast-­‐targeted	  LG	  
formed	  the	  same	  banding	  patterns,	  showing	  high	  molecular	  weight	  aggregates	  that	  were	  
not	  disrupted	  by	  boiling	  with	  SDS	  and	  beta-­‐mercaptoethanol	  and	  that	  were	  larger	  than	  
190	  kDa.	  Furthermore,	   the	  most	  distinct	  band	  for	  both	  samples	  appeared	  at	   the	  same	  
molecular	  weight,	  of	  approximately	  50	  kDa	  (Figure	  3.6).	  	  
	  
	  Figure	  3.6.	  Western	  blot	  of	  leaf	  crude	  extracts	  of	  samples	  viewed	  under	  the	  fluorescence	  CLSM.	  Crude	  
extracts	  were	  prepared	  after	   visualizing	  vacuum-­‐infiltrated	  N.	  benthamiana	   leaves.	   (+),	   positive	   control,	  
pRIC3.0-­‐EGFP.	   (-­‐),	   negative	   control,	   pRIC3.0	   empty	   vector.	   pR-­‐LG,	   cytoplasmic	   LG.	   pT-­‐LG,	   chloroplast-­‐
targeted	  LG.	  Mw,	  NEB	  protein	  molecular	  weight	  marker.	  Sizes	  are	  shown	  on	  the	  left	  hand	  side	  in	  kilodaltons	  
(kDa).	  Arrows	  point	  at	  the	  position	  of	  LG	  ≈	  50	  kDa	  and	  EGFP	  ≈	  25	  kDa.	  Primary	  and	  secondary	  antibodies:	  
1:5,000	  monoclonal	  anti-­‐GFP	  and	  anti-­‐mouse,	  respectively.	  
	  
3.4.	  Discussion	  
LALF-­‐E7,	   accumulated	   to	   the	   highest	   levels	   when	   targeted	   to	   the	   chloroplasts	   of	   N.	  
benthamiana	  leaves	  than	  when	  not	  targeted	  to	  any	  cell	  compartment.	  In	  order	  to	  prove	  
whether	   this	  protein	  was	   indeed	  being	   targeted	  to	   the	  plant	  chloroplasts,	   I	   fused	   it	   to	  
EGFP	   and	   determined	   its	   subcellular	   localization	   by	   fluorescence	   CLSM.	   LALF	   is	   a	   cell	  
membrane-­‐penetrating	   peptide	   (Vallespi	   et	   al.,	   2000),	   therefore	   I	   also	   wanted	   to	  
determine	  whether	  LALF-­‐E7	  interacted	  with	  the	  plant	  cell	  membranes.	  
The	  predicted	  molecular	  weight	  of	  the	  EGFP-­‐tagged	  LALF-­‐E7	  (LG),	  was	  42	  kDa,	  however,	  
it	   appeared	   in	  western	   blots	   at	   50	   kDa.	   This	   observation	   is	   therefore	   consistent	  with	  
previous	  expression	  of	  LALF-­‐E7	  and	  other	  HPV-­‐16	  E7-­‐based	  proteins	  which	  run	  higher	  on	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acrylamide	  gels	  than	  predicted	  by	  their	  molecular	  weight	  (Armstrong	  and	  Roman,	  1993;	  
Granadillo	  et	  al.,	  2011;	  Whitehead	  et	  al.,	  2014).	  
The	  optimal	  OD600	  for	  the	  expression	  of	  LG	  was	  lower	  than	  that	  for	  the	  untagged	  LALF-­‐E7.	  
This	  was	  because,	  here	  it	  was	  desirable	  to	  detect	  LG	  via	  fluorescence	  while	  maintaining	  
minimum	   leaf	   symptoms,	   unlike	   in	   Chapter	   2	  where	   the	   optimization	  was	   focused	  on	  
reaching	  high	  expression	  levels.	  The	  leaf	  symptom	  development	  after	  agroinfiltration	  with	  
the	  pRIC3.0	  constructs	  was	  consistent	  with	  that	  seen	  in	  previous	  expression	  experiments	  
in	  Chapter	  2,	  this	  suggested	  that	  they	  are	  mainly	  due	  to	  the	  expression	  vector,	  rather	  than	  
the	  target	  protein.	  However,	  a	  toxic	  effect	  of	  the	  target	  protein	  cannot	  be	  ruled	  out.	  
From	  the	  images	  taken	  during	  fluorescence	  CLSM,	  it	  could	  be	  seen	  that	  LG	  expressed	  from	  
pRIC3.0	  behaved	  similarly	  to	  the	  positive	  control,	  a	  typical	  cytoplasmic	  protein.	  It	  could	  
often	  also	  be	   seen	   that	   the	   cytoplasmic	   LG	   formed	   large	  PB-­‐like	  aggregates,	  however,	  
these	   were	   less	   common	   and	   more	   heterogeneous	   than	   those	   seen	   in	   chloroplast-­‐
targeted	  LG	  samples.	  It	  has	  been	  shown	  that	  LALF-­‐E7	  forms	  inclusion	  bodies	  in	  E.	  coli	  cells	  
and	   that	   it	   forms	   large	   molecular	   weight	   aggregates	   of	   varying	   sizes,	   even	   after	   its	  
purification	  (Granadillo	  et	  al.,	  2011,	  2013).	  However,	  these	  PB-­‐like	  aggregates	  were	  not	  
associated	  with	   the	   chloroplasts.	   This	   sample	   also	   showed	  a	   less	   intense	   fluorescence	  
than	  the	  chloroplast-­‐targeted	  LG,	  agreeing	  with	  previous	  accumulation	   levels	  obtained	  
for	  the	  untagged	  cytoplasmic	  LALF-­‐E7.	  	  
The	  fluorescence	  patterns	  seen	  for	  the	  chloroplast-­‐targeted	  LG	  was	  distinctively	  different	  
from	  that	  of	  the	  cytoplasmic	  LG.	  The	  small	  spherical	  structures	  seen	  for	  pT-­‐LG	  samples	  
clearly	   formed	  the	  same	  pattern	  as	   the	  chloroplasts,	  confirming	   they	  were	  associated.	  
These	  spherical	  structures	  were	  comparable	  in	  shape	  and	  size	  to	  the	  PBs	  formed	  by	  the	  
chloroplast-­‐targeted	   γ-­‐Zein-­‐DsRed	   fusion	   protein	   seen	   by	   Hofbauer	   et	   al.	   (2014).	   This	  
group	  demonstrated	  that	  PBs	  can	  form	  in	  different	  subcellular	  localizations,	  not	  only	  in	  
the	   ER.	   This	   suggested	   that	   LALF-­‐E7	   could	   form	   PBs,	   not	   only	   when	   targeted	   to	   the	  
chloroplasts.	   However,	   the	   chloroplast-­‐targeted	   LG	   PB-­‐like	   structures	   appeared	   more	  
concentrated	  and	  abundant.	  Unlike	  in	  the	  cytoplasm,	  no	  other	  form	  of	  LG	  was	  seen	  when	  
targeted	   to	   the	   chloroplasts.	   A	   similar	   punctuated	   pattern	   was	   also	   seen	   by	  
immunofluorescence	  microscopy	   of	   mammalian	   cells	   incubated	   with	   E.	   coli-­‐produced	  
LALF-­‐E7	  (Granadillo	  et	  al.,	  2011).	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Scatter	   plots	   of	   the	   colocalization	   of	   EGFP	   or	   LALF-­‐E7-­‐EGFP	   and	   chloroplasts	   were	  
generated.	  These	  showed	  colocalization	  for	  all	  samples,	  except	  for	  the	  negative	  control,	  
which	   was	   not	   surprising,	   since	   the	   cytoplasmic	   EGFP	   and	   LG	   were	   within	   the	   cells,	  
surrounding	  the	  chloroplasts	  and	  other	  organelles.	  Furthermore,	  the	  chloroplast-­‐targeted	  
LG	  was	  not	  localized	  within	  the	  chloroplasts,	  at	  least	  not	  within	  the	  stroma,	  making	  the	  
colocalization	   scatter	   plots	   unreliable	   for	   this	   particular	   study.	   Fluorescence	   profiles	  
proved	  to	  be	  more	  useful.	  These	   further	   illustrate	  that,	  as	  expected,	   the	  LG	  expressed	  
from	  pRIC3.0-­‐cTP	  was	  associated	  with	  chloroplasts,	  while	  no	  association	  was	  seen	  for	  the	  
same	  protein	  expressed	  from	  pRIC3.0.	  	  
Taken	   together	   the	  microscopy	   results	   obtained,	   I	   showed	   that	   the	   cTP	   signal	   indeed	  
targeted	   LALF-­‐E7	   to	   the	   chloroplasts.	   This	   agreed	   with	   immunogold	   labelling	   studies	  
previously	   conducted	   in	   our	   laboratory	   [Maclean	   et	   al.	   (2007),	   unpublished	   data].	  
Furthermore,	  I	  am	  confident	  that	  LALF-­‐E7	  entered	  the	  chloroplasts,	  as	  in	  western	  blots	  it	  
was	  detected	  at	  the	  same	  molecular	  weight	  as	  the	  cytoplasmic	  LALF-­‐E7,	  showing	  that	  the	  
cTP	  signal	  peptide	  was	  cleaved	  during	  the	  membrane	  translocation	  into	  the	  chloroplasts.	  
The	  same	  was	  observed	  for	  cytoplasmic	  and	  chloroplast-­‐targeted	  LG.	  
Chlorophyll	   pigments	   are	   located	   within	   the	   thylakoid	   membranes	   in	   the	   stromal	  
compartment	   of	   chloroplasts.	   At	   the	   resolution	   power	   at	  which	   the	   fluorescent	   CLSM	  
images	   were	   taken	   here,	   it	   is	   not	   possible	   to	   differentiate	   between	   the	   chloroplast	  
compartments.	  However,	   if	   LG	  was	   located	  within	   the	  stroma,	  where	   it	   is	   targeted	   to,	  
most	  of	   the	  higher	  magnification	   images	  would	  show	  yellow	  PB-­‐like	  structures.	  As	  this	  
was	  not	  the	  case,	  I	  hypothesize	  that	  LG	  is	  located	  on	  the	  surface	  or	  in	  the	  intermembrane	  
space	  of	  the	  chloroplast	  envelope.	  It	  was	  not	  possible	  to	  determine	  whether	  the	  PB-­‐like	  
structures	  were	  membrane-­‐bound.	  For	  that,	  transmission	  electron	  microscopy	  or	  higher	  
resolution	  CLSM	  imaging	  would	  be	  necessary,	  as	  done	  by	  Hofbauer	  et	  al.	  (2014).	  	  
I	   further	   hypothesize	   a	  mechanism	   that	   leads	   to	   the	   formation	   of	   the	   protein	   PB-­‐like	  
structures	  seen	  here	  (Figure	  3.7).	  The	  LALF-­‐E7	  genetically	  fused	  to	  the	  cTP	  is	  expressed	  in	  
the	  plant	  cell	  cytoplasm.	  It	  is	  targeted	  to	  the	  chloroplasts	  by	  the	  cTP	  signal.	  It	  enters	  the	  
chloroplasts	   stroma	   through	   the	   translocon	   at	   the	   outer	   envelope	   membrane	   of	  
chloroplasts/translocon	   at	   the	   inner	   envelope	   membrane	   of	   chloroplasts	   (TOC/TIC)	  
pathway	  (Li	  and	  Chiu,	  2010).	  In	  the	  stroma,	  the	  cTP	  signal	  is	  cleaved	  by	  stromal	  processing	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peptidases.	  Thereafter,	  the	  LALF	  portion	  of	  LALF-­‐E7	  mediates	  the	  exit	  from	  the	  chloroplast	  
stroma.	  Alternatively,	  LALF-­‐E7	  exits	  the	  chloroplasts	  by	  an	  unknown	  mechanism.	  PBs	  or	  
protein	  aggregates	  are	  subsequently	  formed	  either	  in	  the	  envelope	  intermembrane	  space	  
or	  on	  the	  surface	  of	  the	  outer	  envelope	  membrane.	  Furthermore,	  it	  is	  possible	  that	  the	  
PB-­‐like	  structures	  seen	  are	  membrane-­‐bound.	  	  
	  
Figure	  3.7.	  Hypothesized	  mechanism	  by	  which	  LALF-­‐E7	  forms	  protein	  body-­‐like	  structures	  when	  targeted	  
to	  the	  chloroplsts.	  (1)	  cTP-­‐LALF-­‐E7	  is	  expressed	  in	  the	  cytoplasm.	  (2)	  The	  cTP	  signal	  targets	  LALF-­‐E7	  to	  the	  
chloroplasts	   where	   it	   interacts	   with	   TOC	   complex.	   cTP-­‐LALF-­‐E7	   enters	   the	   chloroplast	   stroma	   via	   the	  
TOC/TIC	   pathway.	   (3)	   In	   the	   stroma,	   the	   cTP	   signal	   is	   proteolitically	   processed	   	   by	   stromal	   processing	  
peptidases.	  (4)	  LALF-­‐E7	  interacts	  with	  the	  chloroplast	  envelope	  membranes	  mediated	  by	  the	  LALF	  peptide.	  
(5)	  LALF-­‐E7	  exits	  the	  stroma	  and	  forms	  protein	  bodies	  that	  could	  be	  membrane	  bound.	  These	  are	  located	  
in	  IMS	  of	  the	  chloroplast	  envelope,	  or	  on	  its	  surface	  (but	  remaining	  in	  close	  association).	  cTP,	  chloroplast	  
transit	  peptide.	  TOC,	  translocon	  at	  the	  outer	  envelope	  membrane	  of	  chloroplasts.	  TIC,	  translocon	  at	  the	  
inner	  envelope	  membrane	  of	  chloroplasts.	  IMS,	  intermembrane	  space.	  
	  
Overall,	  I	  have	  shown	  how	  LALF-­‐E7	  probably	  forms	  PBs	  when	  targeted	  to	  the	  chloroplasts,	  
which	  are	  more	  concentrated	  and	  abundant	  than	  for	  the	  cytoplasmic	  LALF-­‐E7.	  Besides	  
other	  reasons	  stated	  in	  Chapter	  2,	  these	  results	  could	  explain	  why	  LALF-­‐E7	  accumulated	  
to	  much	  higher	  levels	  when	  targeted	  to	  the	  chloroplasts	  than	  when	  left	  in	  the	  cytoplasm.	  
This	   further	   confirms	   the	   importance	   of	   cellular	   localization,	   and	   highlights	   that	  
chloroplasts	  are	  a	  useful	  compartment	  to	  target	  proteins	  to.	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Chapter	  4:	  Large-­‐scale	  production	  of	  LALF-­‐E7	  and	  
Immunogenicity	  studies	  
4.1.	  Introduction	  
4.1.1.	   Scaling-­‐up	   plant	   production	   and	   purification	   of	   plant-­‐produced	   recombinant	  
proteins	  	  
Plant	  expression	  systems	  offer	  an	  advantage	  over	  other	  expression	  systems	  in	  terms	  of	  
lower	  upstream	  production	  costs	  (Fischer	  et	  al.,	  2004;	  Rybicki,	  2010;	  Sack	  et	  al.,	  2015).	  
Plant	   produced	   antigens	   have	   been	   shown	   to	   elicit	   immune	   responses,	   showing	   that	  
plants	  can	  be	  used	  to	  produce	  biologically	  functional	  pharmaceuticals	   (Di	  Bonito	  et	  al.,	  
2009;	  BioTherapeutics,	  2010;	  Whitehead	  et	  al.,	  2014;	  Beiss	  et	  al.,	  2015).	  However,	   the	  
downstream	  processing	  of	  plant-­‐produced	  proteins	  has	   similar	   costs	   to	   those	  of	  other	  
expression	   systems,	   these	   accounting	   for	   the	   bulk	   of	   production	   costs.	   Therefore	   it	   is	  
important	  to	  optimize	  their	   large	  scale	  expression,	  extraction	  and	  purification	   (Rybicki,	  
2009;	  Fischer,	  2013;	  Sabalza,	  Christou	  and	  Capell,	  2014).	  
In	   the	   case	   of	   plant-­‐produced	   proteins,	   scaling	   up	   expression	   does	   not	   represent	   the	  
challenge	  it	  does	  in	  other	  systems.	  A	  large	  number	  of	  plants	  can	  be	  used,	  depending	  on	  
the	  requirements,	  without	  changing	  the	  expression	  conditions,	  since	  the	  expression	  unit	  
continues	  to	  be	  the	  plant	   leaf.	  This	   is	   in	  contrast	   to	  cell	  culture	  expression	  systems,	   in	  
which	   the	   conditions	   change	   as	   the	   volumes	   increase,	   which	   can	   therefore	   be	   more	  
difficult	  to	  scale	  up	  (Rybicki,	  2009).	  
In	  terms	  of	  protein	  extraction	  from	  plant	  leaves,	  the	  optimization	  depends	  on	  the	  nature	  
of	  the	  recombinant	  protein	  and	  its	  localization	  (Fischer,	  2013).	  Proteins	  targeted	  to	  the	  
apoplast	  can	  be	  easily	  extracted	  without	  the	  disruption	  of	  the	  plant	  cells.	  This	  is	  useful,	  as	  
it	  minimizes	  the	  presence	  of	  host	  contaminant	  proteins	  in	  the	  final	  crude	  sample.	  On	  the	  
other	  hand,	  proteins	  localized	  within	  the	  plant	  cells	  require	  the	  breakage	  of	  these	  cells	  
(Łojewska	  et	  al.,	  2016).	  	  
Protein	  solubility	   is	  also	  an	   important	  factor	   in	  purification.	   If	   the	  protein	  of	   interest	   is	  
insoluble,	  there	  is	  the	  possibility	  of	  removing	  soluble	  host	  proteins	  before	  solubilizing	  the	  
target	  protein.	  This	  is	  advantageous,	  since	  most	  host	  proteins	  are	  soluble,	  including	  the	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well-­‐known	   and	   common	   plant	   contaminant,	   ribulose-­‐1,5-­‐bisphosphate	  
carboxylase/oxygenase	   (RuBisCO),	   that	   is	   known	   to	   associate	   with	   numerous	  
recombinant	   proteins	   expressed	   in	   plants	   and	   adds	   to	   the	   difficulty	   of	   purifying	   the	  
protein	  of	  interest	  (Buyel,	  Twyman	  and	  Fischer,	  2015).	  	  
There	   are	   different	   strategies	   to	   purify	   plant-­‐produced	   proteins,	   ranging	   from	  density	  
gradient	   ultracentrifugation	   techniques	   to	   precipitation	   ammonium	   sulphate	   (A.S.)	  
treatment,	   to	   the	   more	   sophisticated	   metal	   ion	   affinity	   chromatography.	   The	   first	  
mentioned	  method	  is	  the	  most	  widely	  used	  laboratory-­‐scale	  technique	  for	  the	  purification	  
of	  virus-­‐like	  particles	  (VLPs).	  Ammonium	  sulphate	  can	  be	  used	  to	  salt	  out	  subunit	  proteins	  
according	  to	  their	  solubility	  at	  different	  A.S.	  percentages,	  and	  is	  commonly	  useful	  for	  the	  
removal	  of	  host	  proteins	  in	  pre-­‐purification	  steps.	  Lastly,	  affinity	  chromatography	  can	  be	  
used	   to	   specifically	  purify	   the	  protein	  of	   interest,	   resulting	   in	  good	   recovery	   rates	  and	  
purity	  levels	  (Buyel	  et	  al.,	  2012;	  Atkinson	  et	  al.,	  2016;	  Łojewska	  et	  al.,	  2016).	  
The	  hexa-­‐histidine	  (His)-­‐tag	  binds	  to	  immobilized	  nickel	  ions	  (Ni2+)	  and	  is	  a	  widely	  used	  
affinity	  tag	  for	  the	  purification	  of	  recombinant	  proteins.	  Nickel	  column	  chromatography	  
is	  a	  highly	  specific	  method	  that	  can	  lead	  to	  low	  protein	  loss,	  and	  often	  leads	  to	  significant	  
enrichment	  of	   the	  protein	  of	   interest.	  Ni2+	  resins	  can	  withstand	  flexible	  conditions	  and	  
numerous	  regeneration	  cycles,	  making	  them	  practical	  and	  relatively	  inexpensive	  to	  use	  
(Schmitt,	  Hess	  and	  Stunnenberg,	  1993;	  Waugh,	  2005).	  They	  can	  also	  support	  denaturing	  
conditions,	  which	   is	   advantageous	   for	   the	   purification	   of	   highly	   hydrophobic	   proteins,	  
which	  is	  the	  case	  for	  LALF-­‐E7.	  
When	  expressed	  in	  E.	  coli	  cells,	  LALF-­‐E7	  could	  be	  purified	  using	  a	  single	  step	  of	  Ni2+	  affinity	  
chromatography	   (Granadillo	   et	   al.,	   2011,	   2013).	   In	   the	   previous	   chapters	   of	   this	  
dissertation,	  it	  was	  shown	  how	  the	  expression	  of	  LALF-­‐E7	  in	  N.	  benthamiana	  leaves	  was	  
optimized.	   Subsequently,	   it	   was	   desirable	   to	   scale-­‐up	   its	   production	   and	   develop	   a	  
purification	   strategy	   to	   obtain	   enough	   of	   the	   candidate	   vaccine	   to	   test	   in	   animal	  
experiments.	  For	  this,	  I	  optimized	  the	  extraction	  of	  LALF-­‐E7	  from	  leaf	  material	  and	  used	  
Ni2+	  affinity	  chromatography	  to	  purify	  it.	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4.1.2.	  Evaluation	  of	  HPV	  therapeutic	  vaccine	  candidates	  
The	  propagation	  of	  HPVs	   in	  mammalian	  cells	  has	  been	  difficult,	  which	  complicates	  the	  
characterization	  of	  HPV	  vaccines	  in	  vitro.	  HPV	  vaccine	  development	  has	  benefited	  from	  
the	  development	  and	  use	  of	  tumourigenic	  mouse	  cell	  lines,	  such	  as	  C3	  (Feltkamp	  et	  al.,	  
1993)	  and	  TC-­‐1	  (Lin	  et	  al.,	  1996)	  cells,	  that	  express	  the	  HPV-­‐16	  oncogenes	  E6	  and	  E7.	  The	  
C3	  line	  is	  one	  of	  the	  most	  commonly	  used	  tumour	  cell	  lines	  and	  contains	  the	  entire	  HPV-­‐
16	  genome,	  whereas	  the	  TC-­‐1	  cell	   line	  only	  contains	  the	  HPV-­‐16	  E6	  and	  E7	  oncogenes.	  
Another	  important	  difference	  between	  the	  two	  cell	  lines	  is	  that	  in	  C3	  cells,	  the	  HPV	  genes	  
are	  under	  the	  control	  of	  their	  natural	  promoters,	  whereas	  in	  TC-­‐1,	  the	  E6	  and	  E7	  genes	  
are	  under	  the	  control	  of	  a	  heterologous	  retroviral	  promoter.	  
The	   most	   well	   studied	   animal	   models	   used	   for	   HPV-­‐induced	   tumours	   are	   based	   on	  
challenging	   immunised	   female	   C57BL/6	   mice	   with	   these	   tumour	   cells,	   or	   looking	   for	  
regression	  of	  established	  tumours	  after	  therapeutic	  immunisation.	  These	  are	  suitable	  pre-­‐
clinical	  tumour	  models	  for	  the	  evaluation	  of	  HPV	  therapeutic	  vaccines	  targeting	  E6	  and	  E7	  
oncogenic	  proteins,	  since	  the	  above	  tumourigenic	  cell	  lines	  were	  derived	  from	  these	  mice.	  	  
The	  candidate	  HPV-­‐16	  therapeutic	  vaccine	  LALF-­‐E7	  produced	  in	  E.	  coli	  cells	  was	  originally	  
evaluated	  in	  pre-­‐clinical	  studies	  using	  the	  TC-­‐1	  cell	  line	  (Granadillo	  et	  al.,	  2011),	  and	  clearly	  
elicited	  strong	  specific	  cell-­‐mediated	  immune	  responses	  capable	  of	  inducing	  both	  tumour	  
regression	  and	  tumour	  protection.	  Similar	   immune	  responses	  were	  obtained	  when	  the	  
same	  vaccine	  was	  tested	  in	  C3	  cell	  line-­‐induced	  tumours	  by	  the	  detection	  of	  interferon-­‐g-­‐
producing	  cytotoxic	  cells	  identified	  by	  Enzyme-­‐Linked	  ImmunoSpot	  (ELISPOT)	  assays	  (M.	  
Granadillo	  and	  R.	  Lamprecht,	  2015,	  unpublished	  data).	  	  
It	   was	   hypothesized	   that	   the	   plant-­‐produced	   LALF-­‐E7	   would	   have	   comparable	   anti-­‐
tumour	  properties	  as	  the	  E.	  coli-­‐produced	  counterpart.	  Therefore,	  the	  second	  aim	  of	  the	  
work	   reported	   in	   this	   chapter	   was	   to	   test	   the	   plant-­‐produced	   LALF-­‐E7	   in	   a	   tumour	  
regression	  study	  using	  female	  C57BL/6	  mice	  as	  animal	  model	  and	  C3	  cells	  as	  HPV-­‐induced	  
tumour	  models.	  This	  was	  a	  proof	  of	  concept	  study	  to	  show	  that	  plant	  produced	  LALF-­‐E7	  
can	  result	  in	  tumour	  regression,	  which	  would	  then	  lead	  to	  a	  follow-­‐up	  study	  with	  a	  tumour	  
challenge	  experiment.	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4.2.	  Methods	  
4.2.1.	  Large	  scale	  agroinfiltration	  of	  N.	  benthamiana	  leaves	  
For	   large	   scale	   expression	   and	   purification	   of	   LALF-­‐E7,	   20-­‐40	   plants	   were	   vacuum-­‐
infiltrated	  with	  A.	  tumefaciens	  GV3101::pMP90RK	  –	  pRIC3.0-­‐cTP-­‐LALF-­‐E7	  cultures	  diluted	  
to	  an	  OD600	  of	  1.0	  as	  described	  in	  section	  2.2.4.1.	  Leaves	  were	  harvested	  on	  3	  days	  post	  
infiltration	  (dpi)	  and	  stored	  at	  -­‐80	  °C	  until	  needed.	  	  
4.2.2.	  Preparation	  of	  LALF-­‐E7	  crude	  extracts	  
4.2.2.1.	  Protocol	  1.	  Leaf	  material	  was	  homogenized	  with	  8	  M	  urea	  extraction	  buffer	  [8	  M	  
urea	  in	  1	  mM	  carbonate-­‐bicarbonate	  buffer,	  pH	  10.6]	  as	  in	  section	  2.2.5.2.	  Homogenates	  
were	  passed	  through	  a	  double-­‐layer	  of	  Miracloth	  (EDM	  Chemicals).	  Extracts	  were	  clarified	  
twice	  by	  centrifugation.	  The	  final	  crude	  extracts	  were	  stored	  at	  -­‐20	  °C.	  
4.2.2.2.	   Protocol	   2.	   Vacuum-­‐infiltrated	   leaves	  were	   flash-­‐frozen	   in	   liquid	   nitrogen	   and	  
ground	  up	  using	  a	  mortar	  and	  pestle.	  Ground	  leaf	  material	  was	  washed	  3	  times	  with	  PBS	  
or	  5-­‐6	  times	  with	  T-­‐PBS	  [0.1%Triton	  X-­‐100	  (Sigma-­‐Aldrich)	  in	  PBS	  buffer]	  by	  homogenizing	  
in	   4	   v/w	   using	   a	   T25	   digital	   ULTRATTURRAX®	   homogenizer	   (IKA)	   and	   subsequently	  
centrifuging	  at	  13,000	  rpm	  (Beckman	  T	  Coulter	  Avanti®	  J25TI	  centrifuge)	  for	  10	  min	  at	  4	  
°C.	  LALF-­‐E7	  was	  extracted	  from	  the	  washed	  and	  pelleted	  plant	  material	  with	  2-­‐5	  v/w	  of	  8	  
M	  urea	  extraction	  buffer	  at	  4	  °C	  with	  shaking	  for	  0-­‐4	  h	  and	  overnight.	  Extracts	  were	  passed	  
through	  a	  double-­‐layer	  of	  Miracloth	  and	  were	  clarified	  twice	  by	  centrifugation	  at	  13,000	  
rpm	  for	  20	  min	  at	  room	  temperature	  (RT).	  The	  final	  crude	  extracts	  were	  stored	  at	  -­‐20	  °C.	  
4.2.2.3.	   Ammonium	   sulphate	   precipitation	   to	   enrich	   crude	   extracts.	   The	   amount	   of	  
ammonium	  sulphate	  (A.S.)	  to	  add	  to	  crude	  extracts	  for	  a	  final	  concentration	  of	  20%	  (w/v)	  
was	   determined	   via	   an	   online	   ammonium	   sulphate	   calculator	   (EnCore	   Biotechnology,	  
2014).	  The	  crude	  extracts	  were	  mixed	  with	  A.S.	  for	  1	  h,	  at	  4	  °C	  with	  shaking.	  Precipitated	  
proteins	  were	  pelleted	  by	  centrifugation	  at	  13,000	  rpm	  for	  20	  min	  at	  4	  °C.	  The	  pellet	  was	  
resuspended	  in	  extraction	  buffer.	  The	  supernatant	  was	  subsequently	  treated	  with	  40%,	  
60%	  and	  80%	  ammonium	  sulphate.	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4.2.3.	  Purification	  of	  LALF-­‐E7	  by	  nickel	  ion	  (Ni2+)	  affinity	  chromatography.	  
LALF-­‐E7	  crude	  extracts	  were	  prepared	  from	  50	  g	  FLW	  using	  protocol	  2.	  Imidazole	  (Merck	  
Millipore)	   and	   NaCl	   were	   added	   to	   a	   final	   concentration	   of	   20	   mM	   and	   500	   mM	  
respectively.	   A	   1	  ml	   or	   5	  ml	   nickel	   affinity	   column	   (HisTrap™	  HP,	   GE	   Healthcare)	  was	  
equilibrated	  with	  5	  column	  volumes	  (CV)	  of	  equilibration	  buffer	  [500	  mM	  NaCl,	  8	  M	  urea,	  
20	  mM	  imidazole	  in	  50	  mM	  Na-­‐PO4	  pH	  8.0].	  The	  crude	  extract	  was	  loaded	  onto	  the	  column	  
using	  a	  150	  ml	  SuperLoop.	  Thereafter	  the	  column	  was	  washed	  with	  10	  CV	  of	  equilibration	  
buffer	  or	  wash	  buffer	  [equilibration	  buffer	  at	  pH	  6.5].	  LALF-­‐E7	  was	  eluted	  over	  20	  CV	  of	  a	  
linear	  gradient	   (from	  0%	  to	  100%)	  of	  elution	  buffer	   [equilibration	  buffer	  with	  500	  mM	  
imidazole]	  and	  an	  additional	  5	  CV	  step	  of	  100%	  elution	  buffer.	  The	  ÄKTA	  Explorer™	  system	  
and	  the	  UNICORN	  4.11	  software	  (GE	  Healthcare)	  were	  used.	  All	  fractions	  were	  collected	  
in	   1	   or	   5	  ml	   aliquots,	   depending	   on	   the	   column	   used,	   and	   stored	   at	   -­‐20	   °C.	   Relevant	  
fractions	  were	  analysed	  by	  western	  blots	  and	  SDS-­‐PAGE	  gels.	  
Relevant	   elution	   fractions	   were	   pooled	   and	   extensively	   dialysed	   against	   130	   v/v	  
renaturing	  buffer	  [10	  mM	  Tris,	  pH	  8.0].	  The	  dialysis	  was	  carried	  over	  4	  h,	  followed	  by	  an	  
overnight	   round	   and	   a	   final	   round	   of	   4	   h.	   Thereafter,	   dialysed	   samples	   were	   filter-­‐
sterilized	  through	  a	  0.2	  µm	  Corning®	  syringe	  filters	  (Sigma-­‐Aldrich)	  and	  stored	  at	  4	  °C.	  
4.2.4.	  Detection	  and	  quantification	  of	  LALF-­‐E7	  
4.2.4.1.	   SDS-­‐PAGE	   and	  western	   blots.	  Refer	   to	   section	   2.2.7.	   Gels	   were	   stained	   with	  
Coomassie	  Brilliant	  Blue	  stain	   (Bio-­‐Rad)	   for	  2	  h	  at	  37	  °C	  and	  destained	  with	  destaining	  
solution	  [30%	  (v/v)	  methanol	  and	  10%	  (v/v)	  glacial	  acetic	  acid	  in	  distilled	  water];	  or	  they	  
were	  stained	  with	  Aqua	  StainTM	  (Vacutec)	  for	  1	  h	  at	  37	  °C	  and	  rinsed	  in	  distilled	  water.	  For	  
protein	  detection	  on	  western	  blots	  the	  primary	  antibodies	  used	  were	  the	  polyclonal	  anti-­‐
HPV-­‐16	  E7	  rabbit	  serum	  (I.	  Hitzeroth,	  Biopharming	  Research	  Unit,	  MCB,	  UCT),	  monoclonal	  
mouse	  anti-­‐HPV-­‐16-­‐E7	  antibodies	  [716-­‐218]	  (Abcam)	  and	  anti-­‐6xHis	  (Sigma-­‐Aldrich).	  The	  
secondary	   antibodies	   used	   were	   the	   goat	   anti-­‐rabbit	   and	   goat	   anti-­‐mouse	   IgG	   whole	  
molecules	  conjugated	  to	  alkaline	  phosphatase	  (Sigma-­‐Aldrich).	  Polyclonal	  and	  anti-­‐rabbit	  
antibodies	  were	  used	  at	  a	  dilution	  of	  1:5,000.	  The	  remaining	  antibodies	  were	  used	  at	  a	  
dilution	  of	  1:2,000.	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4.2.4.2.	   Dot	   blots.	   A	   piece	   of	   nitrocellulose	   membrane	   was	   divided	   into	   squares	   of	  
approximately	  1.5	  cm2	  ,	  3	  µl	  of	  sample	  were	  dotted	  per	  square	  and	  allowed	  to	  air-­‐dry.	  The	  
nitrocellulose	  membrane	  was	  then	  treated	  as	  for	  normal	  western	  blots.	  	  
4.2.4.3.	   Western	   blot	   densitometry.	   The	   plant-­‐produced	   LALF-­‐E7	   was	   quantified	   by	  
western	  blot	  densitometry	  using	  a	   serial	  dilution	  of	  E.	   coli-­‐produced	   LALF-­‐E7	   inclusion	  
bodies	  as	  a	  protein	  standard	  and	  anti-­‐His	  antibodies	  as	  a	  detection	  method.	  The	  Syngene	  
Gene	   Genius	   imaging	   system	   (Artisan	   Technology	   Group)	   and	   GeneTools	   software	  
(Syngene)	  were	  used.	  	  
4.2.5.	  Liquid	  chromatography	  mass	  spectrometry	  (LCMS)	  	  
Selected	   Ni2+	   affinity	   chromatography	   elution	   fractions	   containing	   LALF-­‐E7	   were	  
electrophoresed	   in	   a	   15%	   SDS-­‐PAGE	   gel	   and	   putative	   LALF-­‐E7-­‐containing	   bands	   were	  
sequenced	   by	   LCMS	   at	   the	   Centre	   for	   Proteomic	   and	  Genomic	   Research	   (CPGR;	   Cape	  
Town).	  
4.2.6.	  Tumour	  regression	  experiments	  
4.2.6.1.	  Animals.	  Female	  C57/BL6,	  SPF-­‐1	  and	  SPF-­‐2	  mice	  from	  the	  Research	  Animal	  Facility	  
(Health	   Sciences	   Faculty,	  UCT)	  were	  maintained	  under	  biosafety	   level	   2	   (BSL-­‐2)	   at	   the	  
Animal	  Unit	  (Health	  Sciences	  Faculty,	  UCT).	  Permission	  for	  this	  study	  was	  granted	  by	  the	  
Research	  Animal	  Ethics	  Committee,	  UCT	  (AEC	  013/024).	  	  
4.2.6.2.	  Tumour	  cells.	  The	  C3	  and	  C3-­‐3	  cells	  used	  in	  this	  study	  were	  grown	  and	  maintained	  
in	   RPMI	   media	   supplemented	   with	   10%	   foetal	   calf	   serum,	   1%pen-­‐strep,	   0.1	   mg/ml	  
Kanamycin	  and	  0.8	  mg/ml	  G418	  (Sigma-­‐Aldrich).	  The	  C3-­‐3	  tumour	  cell	  line	  was	  generated	  
by	  R.	  Lamprecht	  (BRU,	  UCT)	  as	  follows:	  C3	  tumour	  cells	  were	  used	  to	  inoculate	  8-­‐9	  weeks	  
old	  female	  C57/BL6	  mice.	  Thereafter,	  two	  tumours	  from	  these	  mice	  were	  excised,	  cut	  into	  
small	   fragments	   and	   trypsinized.	   Released	   cells	   were	   washed	   and	   expanded	   in	   RPMI	  
media.	  To	  test	  the	  tumorigenicity	  of	  these	  cells,	  female	  C57/BL6	  were	  inoculated	  and	  had	  
90%	  tumorigenicity.	  The	  resulting	  cell	  line	  was	  named	  C3-­‐3	  and	  was	  stored	  at	  -­‐80	  °C	  until	  
needed.	  The	  C3-­‐3	  cells	  were	  kindly	  prepared	  and	  scaled	  up	  to	  10	  ml	  or	  2.5	  x	  106	  cells	  for	  
animal	  inoculations	  by	  R.	  Lamprecht	  and	  M.	  Hendrikse	  (BRU).	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4.2.6.3.	   Tumour	   inoculation	  and	  mice	   immunizations.	  Thirty-­‐nine	  8-­‐9	  weeks	  old	  mice	  
were	  inoculated	  with	  5	  x	  105	  C3-­‐3	  cells	  in	  a	  final	  volume	  of	  200	  µl	  subcutaneously	  (s.c.),	  
into	  the	  right	  inguinal	  site,	  after	  intraperitoneal	  (i.p.)	  anaesthesia.	  Tumour	  development	  
was	  monitored	  daily.	  When	  tumours	  were	  palpable	  (approximately	  2-­‐3	  mm	  in	  size),	  10	  
mice	  received	  the	  placebo	  vaccine	  [200	  µl	  of	  10	  mM	  Tris,	  pH	  8.0],	  10	  mice	  received	  the	  
positive	  control	  vaccine	  [4.6	  µg	  E.	  coli-­‐produced	  LALF-­‐E7	  in	  10	  mM	  Tris,	  pH	  8.0	  to	  a	  final	  
volume	  of	  200	  µl],	  and	  19	  mice	  received	  the	  plant-­‐produced	  LALF-­‐E7	  vaccine	  [4.6	  µg	  10	  
mM	  Tris,	  pH	  8.0	  to	  a	  final	  volume	  of	  200	  µl].	  Each	  group	  was	  composed	  of	  equal	  numbers	  
of	  SPF1	  and	  SPF2	  mice.	  The	  immunizations	  were	  administered	  by	  s.c.	  injections	  and	  were	  
repeated	  weekly	  to	  a	  total	  of	  4	  immunizations	  per	  mice.	  	  
The	  plant-­‐produced	  LALF-­‐E7	  vaccine	  was	  prepared	  in	  this	  study.	  All	  steps	  from	  extraction	  
to	   purification	  were	   done	   using	   depyrogenized	   glass	   ware	   and	   endotoxin-­‐free,	   sterile	  
plastic	   ware.	   The	   Tris	   buffer	   and	   the	   E.	   coli-­‐produced	   vaccines	   were	   prepared	   by	  M.	  
Granadillo	   as	   reported	   in	   Granadillo	   et	   al.	   (2011).	   All	   vaccines	   were	   filter-­‐sterilized	  
through	  a	  0.2	  µm	  membrane	  and	  a	  sample	  of	  each	  was	  plated	  on	  a	  LB	  agar	  plate	  without	  
antibiotics.	  Plates	  were	  incubated	  at	  27	  °C	  and	  37	  °C,	  and	  examined	  for	  growth	  after	  24	  
and	  48	  h.	  In	  the	  absence	  of	  bacterial	  growth,	  the	  vaccinations	  were	  considered	  safe	  for	  
animal	  immunizations.	  
4.2.6.5.	  Data	  collection.	  Tumour	  sizes	  were	  monitored	  daily	  after	  inoculation	  and	  twice	  a	  
week	  after	  the	  first	  immunization	  using	  a	  caliper	  when	  possible.	  Tumour	  volumes	  were	  




In	  the	  case	  of	  multiple	  tumours,	  all	  tumours	  were	  included	  to	  calculate	  the	  total	  tumour	  
volume.	  Mice	  were	  euthanized	  if	  one	  of	  the	  tumours	  reached	  20	  mm	  in	  length	  or	  if	  signs	  
of	  discomfort	  were	  shown.	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4.3.	  Results	  
4.3.1.	  Optimization	  of	  LALF-­‐E7	  crude	  extraction	  
Automated	   chromatography	  purification	   systems	   require	   crude	  extracts	   that	  have	   low	  
viscosity	  and	  no	  particulate	  matter.	  The	  initial	  LALF-­‐E7	  crude	  extracts	  obtained	  using	  the	  
extraction	  protocol	  1	  were	  viscous	  and	  could	  not	  be	  passed	  through	  a	  0.45	  µm	  membrane	  
filter.	  In	  order	  to	  obtain	  more	  appropriate	  crude	  extracts	  to	  purify	  LALF-­‐E7	  the	  initial	  crude	  
extract	  was	  treated	  by	  A.S.	  precipitation.	  It	  was	  seen	  by	  western	  blots	  that	  LALF-­‐E7	  was	  
soluble	  at	  20%	  A.S.,	  as	  it	  was	  found	  in	  the	  supernatant	  fraction	  and	  was	  not	  detected	  in	  
the	  pellet	  fraction	  (Figure	  4.1).	  Thereafter	  it	  was	  found	  insoluble	  at	  40%	  A.S.	  LALF-­‐E7	  was	  
also	  more	  concentrated	  after	  these	  precipitation	  steps	  compared	  to	  the	  crude	  extract.	  
From	  this	  it	  was	  concluded	  that	  at	  the	  20%	  A.S.	  step,	  all	  the	  plant	  particulate	  matter	  could	  
be	   removed	   from	   the	   crude	  extract	  while	   concentrating	   LALF-­‐E7,	   and	   that	   it	   could	  be	  
further	   concentrate	   at	   the	  40%	  A.S.	   step.	  However,	   stained	   gels	   showed	   that	   the	  A.S.	  
treatment	  did	  not	  remove	  contaminant	  host	  proteins	  (see	  lane	  40p).	  Additionally,	  after	  
resuspending	  the	  pellet	  obtained	  at	  the	  40%	  A.S.	  precipitation	  step	  in	  8	  M	  urea	  extraction	  
buffer,	  the	  extract	  was	  still	  viscous	  and	  could	  not	  be	  completely	  dissolved.	  	  
	  
	  
Figure	   4.1.	   Ammonium	   sulphate	   precipitation	   of	   LALF-­‐E7.	   LALF-­‐E7	   crude	   extract	   (CE)	   from	   5	   g	   FLW,	  
prepared	  using	  protocol	  1	  was	  subjected	  to	  20-­‐80%	  A.S	  precipitation.	  Insoluble	  (20-­‐60p)	  and	  soluble	  (20-­‐
80s)	   fractions	  were	  analysed	  by	  western	  blot	  using	  anti-­‐E7	  polyclonal	  antibodies	   (left-­‐hand-­‐side)	  and	  by	  
Coomassie-­‐stained	  SDS-­‐PAGE	  gel	  (right-­‐hand-­‐side).	  No	  pellet	  was	  formed	  at	  the	  80%	  A.S.	  precipitation	  step.	  
(-­‐),	  pRIC3.0	  empty	  vector.	  Mw,	  Page	  Ruler™	  molecular	  weight	  marker.	  Band	  sizes	  (kDa)	  are	  indicated	  on	  the	  
left-­‐hand-­‐side.	  The	  arrows	  point	  to	  the	  expected	  size	  of	  LALF-­‐E7	  of	  ≈	  22	  kDa.	  No	  pellet	  was	  formed	  at	  the	  
80%	  A.S.	  precipitation	  step.	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Another	  approach	  for	  the	  extraction	  of	  LALF-­‐E7	  was	  developed	  which	  was	  analogous	  to	  
the	  extraction	  of	  the	  E.	  coli-­‐produced	  counterpart,	  described	  by	  Granadillo	  et	  al.	  (2013).	  
Here	  the	  leaf	  material	  was	  washed	  with	  PBS	  in	  order	  to	  remove	  the	  majority	  of	  the	  plant	  
host	   soluble	   proteins,	   while	   the	   highly	   hydrophobic	   LALF-­‐E7	   stayed	   in	   the	   insoluble	  
fraction.	  Thereafter,	  LALF-­‐E7	  was	  solubilized	  from	  the	  plant	  material	  with	  urea	  extraction	  
buffer.	  Two	  concentrations	  of	  urea	  were	  tested,	  6	  M	  and	  8	  M.	  	  
The	  extraction	  protocol	  worked	  as	  expected	  (Figure	  4.2A),	  no	  LALF-­‐E7	  was	  lost	  during	  the	  
PBS	  washes,	  and	  the	  final	  crude	  extract	  was	  cleaner	  than	  the	  extracts	  obtained	  with	  the	  
previous	  extraction	  protocol	  (compare	  the	  lanes	  6M	  and	  8M	  to	  PE).	  There	  seemed	  to	  be	  
slightly	   more	   LALF-­‐E7	   when	   extracted	   with	   8	   M	   urea	   than	   with	   6	   M,	   which	   was	   as	  
expected.	  Furthermore,	  there	  were	  two	  contaminant	  proteins,	  which	  only	  appeared	  after	  
the	  solubilisation	  of	  LALF-­‐E7.	  One	  of	  approximately	  35	  kDa	  and	  the	  second,	  larger	  than	  55	  
kDa.	   These	   were	   in	   excess	   compared	   to	   LALF-­‐E7	   which	   was	   not	   clearly	   detectable	   in	  
stained	  gels.	  Furthermore,	  the	  addition	  of	  0.1%	  Triton	  X-­‐100	  to	  the	  PBS	  washes	  and	  a	  total	  
of	  5-­‐6	  washes	  done	  in	  later	  crude	  extract	  preparations,	  did	  not	  remove	  these	  contaminant	  
proteins,	  suggesting	  they	  were	  also	  highly	  hydrophobic.	  However,	  the	  addition	  of	  Triton	  
X-­‐100	  seemed	  to	  increase	  the	  extraction	  of	  LALF-­‐E7	  (data	  not	  shown).	  It	  was	  concluded	  
that	  the	  extraction	  protocol	  2	  could	  be	  used	  as	  a	  pre-­‐purification	  step,	  as	  most	  proteins	  
were	  removed	  from	  the	  final	  LALF-­‐E7	  crude	  extract,	  and	  that	  Triton	  X-­‐100	  could	  continue	  
to	  be	  used.	  	  
An	  additional	  problem	  encountered	  during	  the	  extraction	  of	  LALF-­‐E7,	  was	  that	  there	  were	  
relatively	  large	  amounts	  of	  LALF-­‐E7	  remaining	  in	  the	  washed	  and	  pelleted	  leaf	  material	  
after	  the	  solubilisation	  step	  with	  8	  M	  urea	  extraction	  buffer	  (Figure	  4.2B).	  To	  maximize	  
the	  amount	  of	  LALF-­‐E7	  extracted	  from	  the	  leaf	  material,	  4-­‐5	  v/w	  extraction	  buffer	  was	  
used,	  instead	  of	  2-­‐3	  v/w.	  Additionally,	  a	  time	  trial	  was	  done	  in	  which	  the	  leaf	  material	  was	  
incubated	  with	  extraction	  buffer	  for	  0-­‐4	  h	  and	  overnight.	  It	  was	  found	  that	  the	  increase	  in	  
8	  M	  urea	  extraction	  buffer	  volume	  did	  not	  seem	  to	  decrease	  the	  amount	  of	  LALF-­‐E7	  found	  
in	  the	  insoluble	  fraction.	  Increasing	  the	  incubation	  period	  slightly	  increased	  the	  amount	  
of	  LALF-­‐E7	  extracted,	  however	  it	  degraded	  during	  the	  overnight	  step	  (data	  not	  shown).	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Figure	  4.2.	  LALF-­‐E7	  crude	  extraction	  protocol	  2.	  (A)	  Leaf	  material	  expressing	  LALF-­‐E7	  was	  ground	  up	  with	  
liquid	  nitrogen	  and	  washed	  3	  times	  with	  PBS	  (W1-­‐3).	  LALF-­‐E7	  was	  solubilized	  from	  the	  leaf	  material	  with	  
extraction	   buffer	   containing	   6	  M	   or	   8	  M	   urea	   (6M	   and	   8M,	   respectively).	   The	   final	   crude	   extracts	   are	  
compared	  to	  a	  crude	  extract	  sample	  prepared	  using	  the	  previous	  extraction	  protocol	  (PE).	  (+),	  purified	  E.	  
coli-­‐produced	  LALF-­‐E7.	  Mw,	  Page	  Ruler™	  molecular	  weight	  marker.	  Band	  sizes	  are	  indicated	  on	  the	  side	  in	  
kDa.	  Top	  panel,	  Coomassie-­‐stained	  SDS-­‐PAGE	  gel.	  Bottom	  panel,	  anti-­‐E7	  polyclonal	  western	  blot.	  (B)	  Anti-­‐
E7	  polyclonal	  western	  blot	  comparing	  the	  amount	  of	  LALF-­‐E7	  in	  the	  soluble	  and	  insoluble	  fractions	  after	  the	  
solubilisation	  step	  with	  8	  M	  urea	  extraction	  buffer.	  (S),	  8	  M	  urea-­‐solubilized	  LALF-­‐E7.	  (P),	  insoluble	  LALF-­‐E7	  
found	  in	  the	  pelleted	  leaf	  debris.	  Arrows	  point	  at	  the	  expected	  size	  of	  LALF-­‐E7	  of	  ≈	  22	  kDa.	  
	  
The	  plant-­‐produced	  LALF-­‐E7	  could	  also	  be	  characterized	  in	  terms	  of	  its	  stability	  in	  crude	  
extracts	  and	  in	  frozen	  leaf	  material.	  Three	  temperatures	  were	  used	  to	  test	  the	  stability	  of	  
LALF-­‐E7	  in	  crude	  extracts,	  4	  °C,	  -­‐20	  °C	  and	  -­‐80	  °C,	  as	  well	  as	  storage	  for	  1,	  2	  and	  3	  weeks.	  
LALF-­‐E7	  crude	  extracts	  degraded	  at	  4	  °C,	  while	  storing	  the	  crude	  extracts	  at	  -­‐20	  °C	  and	  -­‐
80	  °C	  was	  comparable,	  and	  longer	  storage	  periods	  of	  time	  did	  not	  seem	  to	  lead	  to	  losses	  
in	   LALF-­‐E7	   (Figure	  4.3).	   Likewise,	   it	  was	   seen	   that	   LALF-­‐E7	  was	   stable	   in	   -­‐80	   °C	   frozen	  
leaves	  for	  up	  to	  17	  months	  after	  harvesting.	  This	  leaf	  material	  was	  used	  throughout	  this	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  Figure	  4.3.	  Stability	  of	  LALF-­‐E7	  in	  crude	  extracts.	  LALF-­‐E7	  was	  extracted	  using	  protocol	  1.	  Aliquots	  were	  
stored	  in	  triplicates	  at	  4	  °C,	  -­‐20	  °C	  and	  -­‐80	  °C	  for	  1,	  2	  and	  3	  weeks.	  Arrows	  show	  expected	  LALF-­‐E7	  size	  of	  ≈	  
22	  kDa.	  
	  
4.3.2.	  Purification	  of	  LALF-­‐E7	  by	  Ni2+	  chromatography	  
Initially,	  a	  1	  ml	  HisTrap	  column	  was	  used	  to	  purify	  LALF-­‐E7.	  LALF-­‐E7	  eluted	  within	  elution	  
fractions	  1	  and	  2	  as	  seen	  by	  a	  single	  large	  peak	  in	  the	  chromatogram	  of	  more	  than	  5,000	  
Milli	   absorbance	   units	   (mAU)	   at	   280	   nm	   (A280;	   not	   shown).	   The	   eluted	   LALF-­‐E7	   was	  
concentrated	   and	   partially	   pure.	   A	   contaminant	   protein	   of	   approximately	   17	   kDa	   and	  
possibly	  another	  of	  approximately	  30	  kDa	  could	  be	  seen	  in	  the	  Coomassie-­‐stained	  SDS-­‐
PAGE	  gel	  (Figure	  4.4).	  Additionally,	  a	  precipitation	  was	  found	  in	  crude	  extracts	  before	  the	  
purification	  which	  corresponded	  to	  a	  25	  kDa	  contaminant	  protein	  and	  degraded	  LALF-­‐E7	  
(Figure	  4.4,	  lane	  P).	  	  
	  
	  
Figure	   4.4.	   Purification	   of	   LALF-­‐E7	   using	   a	   1	   ml	   HisTrap	   Ni2+	   chromatography	   column.	   Left	   panel,	  
Coomassie-­‐stained	  SDS-­‐PAGE	  gel.	  Right	  panel,	  anti-­‐E7	  polyclonal	  western	  blot.	   (-­‐),	  pRIC3.0	  empty	  vector	  
crude	  extract	  using	  protocol	  2.	  Mw,	  NEB	  protein	  molecular	  weight	  marker.	  Band	  sizes	  are	  shown	  on	  the	  left	  
hand	  side.	  (+),	  purified	  E.	  coli-­‐LALF-­‐E7.	  CE,	  LALF-­‐E7	  crude	  extract	  from	  50	  g	  FLW,	  prepared	  using	  protocol	  2.	  
P,	  precipitation	  found	  before	  purification.	  FT,	  flow	  through	  during	  crude	  extract	  loading	  onto	  the	  column.	  
E1-­‐E4,	  elution	  fractions	  1-­‐4.	  Arrows	  point	  at	  the	  expected	  size	  of	  LALF-­‐E7	  of	  ≈	  22	  kDa.	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In	  order	  to	  purify	  large	  amounts	  of	  LALF-­‐E7	  to	  be	  used	  in	  animal	  experiments,	  I	  scaled	  up	  
to	  a	  5	  ml	  HisTrap	  column.	  This	  purification	  was	  repeated	  several	  times,	  testing	  different	  
conditions	  such	  as	  crude	  extracts	  prepared	  using	  2-­‐5	  v/w	  ratio	  of	  8	  M	  urea	  extraction	  
buffer,	  eliminating	  the	  wash	  buffer	  step	  during	  purification,	  as	  well	  as	  using	  imidazole	  only	  
at	   the	  elution	  step	  to	  prevent	  the	   loss	  of	  LALF-­‐E7.	  When	  extracting	  LALF-­‐E7	  with	   large	  
volumes	   of	   extraction	   buffer,	   the	   purified	   LALF-­‐E7	   concentration	   was	   very	   low,	   as	  
indicated	   by	   A280	   values	   of	   1,100	   to	   1,300	   mAU	   (not	   shown).	   However,	   when	   the	  
extraction	  volume	  was	  between	  2-­‐3	  v/w,	  more	  concentrated	  LALF-­‐E7	  was	  obtained	  and	  
within	  less	  elution	  fractions,	  resulting	  in	  a	  A280	  value	  of	  more	  than	  4,000	  mAU.	  Eliminating	  
the	  wash	  step	  at	  low	  pH	  and	  eliminating	  the	  addition	  of	  imidazole	  in	  the	  crude	  extracts	  
and	  equilibration	  buffer	  also	  prevented	  the	  loss	  of	  LALF-­‐E7	  (Figure	  4.5A).	  	  
The	  Ni2+	  chromatography	  elution	  fractions	  from	  the	  5	  ml	  HisTrap	  purifications	  containing	  
LALF-­‐E7	  did	  not	  correspond	  to	  the	  elution	  peak,	  instead	  they	  corresponded	  to	  adjacent	  
later	  fractions.	  This	  suggested	  that	  another	  protein	  or	  proteins	  eluted	  with	  LALF-­‐E7.	  The	  
AquaStained	   gel	   of	   these	   fractions	   indicate	   that	   there	   was	   at	   least	   one	   contaminant	  
protein	   in	   these	   fractions	  between	  46	  and	  58	  kDa	   (Figure	  4.5B).	  Furthermore,	  LALF-­‐E7	  
appeared	  as	  a	  double-­‐band	  in	  the	  AquaStained	  gel	  and	  in	  the	  western	  blot.	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Figure	   4.5.	   Purification	   of	   LALF-­‐E7	   using	   a	   5	   ml	   HisTrap	   Ni2+	   chromatography	   column.	   (A),	   ÄKTA	  
chromatogram.	   Blue	   curve,	   A280	   representing	   protein	   levels.	   Light-­‐green	   curve,	   elution	   buffer	   gradient.	  
Arrow	   shows	   the	   elution	   peak	   corresponding	   to	   approximately	   elution	   fractions	   1-­‐7.	   Black	   box,	   elution	  
fractions	  5-­‐7	  corresponding	  to	  LALF-­‐E7.	  (B),	  analysis	  of	  relevant	  fractions	  by	  AquaStained	  SDS-­‐PAGE	  gel	  and	  
anti-­‐E7	   polyclonal	   antibodies	   western	   blot	   (left	   and	   right	   hand	   side,	   respectively).	   Mw,	   NEB	   protein	  
molecular	  weight	  marker.	  Band	  sizes	  are	  shown	  on	  the	  left-­‐hand-­‐side.	  (+),	  E.	  coli-­‐LALF-­‐E7	  inclusion	  bodies.	  
CE,	  LALF-­‐E7	  crude	  extract	  from	  50	  g	  FLW,	  prepared	  using	  protocol	  2.	  FT,	  flow	  through	  during	  crude	  extract	  
loading	  onto	  the	  column.	  E4-­‐E13,	  elution	  fractions	  4-­‐13.	  Arrows	  point	  at	  the	  doublet	  bands	  representing	  
LALF-­‐E7	  ≈	  20	  and	  22	  kDa.	  	  
	  
The	  LALF-­‐E7	  double	  bands	  were	  sequenced	  by	  mass	  spectrometry.	  The	  results	  indicated	  
that	  LALF-­‐E7	  was	  indeed	  present	  in	  these	  samples	  by	  the	  presence	  of	  HPV-­‐16	  E7	  protein	  
hits.	  However,	  there	  seemed	  to	  be	  other	  contaminant	  proteins,	  such	  as	  the	  Histone	  H4	  
and	  H2b	  as	  well	  as	  the	  gremin-­‐like	  protein	  of	  N.	  benthamiana.	  Therefore,	  after	  dialysis,	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the	   quantification	   of	   LALF-­‐E7	  was	   done	   using	  western	   blot	   densitometry,	  with	  E.	   coli-­‐
produced	  LALF-­‐E7	  as	  a	  standard,	  which	  was	  more	  specific	  and	  representative	  of	  the	  true	  
amount	  of	  LALF-­‐E7	  in	  the	  samples	  selected	  (Figure	  4.6).	  The	  partially	  purified	  and	  dialyzed	  
LALF-­‐E7	  appeared	  as	  a	  double	  band	  again,	  and	  so	  did	  the	  purified	  LALF-­‐E7	  provided	  by	  M.	  
Granadillo	   for	  the	  animal	  experiments,	  unlike	  the	  non-­‐purified	  plant-­‐produced	  LALF-­‐E7	  
and	   E.	   coli-­‐produced	   LALF-­‐E7	   inclusion	   bodies.	   It	   was	   also	   seen	   that	   the	   apparent	  
molecular	   weight	   of	   LALF-­‐E7	   was	   lower	   in	   the	   purified	   E.	   coli-­‐produced	   preparation	  
(Figure	  4.6),	  and	  it	  was	  higher	  in	  the	  E.	  coli-­‐produced	  inclusion	  bodies	  compared	  to	  the	  
plant-­‐produced	  LALF-­‐E7	  (compare	  the	  “Plant”	  lane	  to	  the	  inclusion	  body	  protein	  standard	  
and	  “E.	  coli”	  lanes).	  
The	   yield	   of	   the	   plant-­‐produced	   LALF-­‐E7	   was	   calculated	   as	   15	   mg/kg	   FLW	   at	   a	  
concentration	  of	  0.0231	  mg/ml.	  The	  expression	  of	  LALF-­‐E7	  from	  pRIC3.0-­‐cTP	  on	  3	  dpi	  was	  
extrapolated	  to	  be	  on	  average	  49.7	  mg/Kg	  FLW	  in	  crude	  extracts	  prepared	  using	  protocol	  
1.	  Therefore,	  30%	  of	  expressed	  LALF-­‐E7	  was	  recovered	  during	  the	  purification	  process.	  	  
	  
Figure	  4.6.	  Quantification	  of	  partially	  purified	  and	  dialysed	  LALF-­‐E7.	  Relevant	  fractions	  obtained	  during	  
the	  purification	  of	  LALF-­‐E7	  by	  Ni2+	  affinity	  chromatography	  were	  pooled	  and	  dialyzed	  against	  Tris	  buffer.	  
The	  dialyzed	   LALF-­‐E7	  was	   then	  quantified	   by	  western	   blot	   densitometry	   using	  E.	   coli-­‐produced	   LALF-­‐E7	  
inclusion	  bodies	   as	   standard	   (grey	   triangle	  with	   loaded	  amounts	   shown	  above	   in	  µg).	  Mw,	  NEB	  protein	  
molecular	  weight	  marker	  with	  sizes	  shown	  in	  kDa.	  Plant,	  partially	  purified	  and	  dialyzed	  plant-­‐produced	  LALF-­‐
E7.	  E.	  coli,	  purified	  E.	  coil-­‐produced	  LALF-­‐E7.	  Arrows	  point	  at	  the	  LALF-­‐E7	  doublet.	  	  
	  
	  
	  1	  	  	  	  	  	  	  	  0.5	  	  	  	  	  0.27	  	  	  0.14	  	  	  	  	  0.07	  	  	  Mw	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4.3.3.	  Tumour	  regression	  experiments	  
In	  order	  to	  determine	  the	  efficacy	  of	  our	  plant-­‐produced	  LALF-­‐E7	  and	  to	  compare	  it	  to	  the	  
E.	  coli-­‐produced	  counterpart,	  these	  candidate	  vaccines	  were	  tested	  in	  tumour	  regression	  
experiments	  in	  a	  mouse	  model.	  	  
Female	  mice	  were	  inoculated	  with	  tumourigenic	  C3-­‐3	  cells.	  Seven	  days	  post	  inoculation,	  
tumours	  were	  palpable	  in	  all	  mice.	  Mice	  were	  immunized	  on	  day	  7	  post	  inoculation	  and	  
at	  weekly	  intervals	  thereafter	  for	  a	  total	  of	  4	  immunizations	  per	  mouse.	  Mice	  received	  a	  
placebo	  vaccine,	  Tris	  buffer;	  4.6	  µg	  of	  the	  E.	  coli-­‐produced	  LALF-­‐E7	  vaccine	  or	  4.6	  µg	  of	  
the	  plant-­‐produced	  LALF-­‐E7	  vaccine.	  Thereafter,	  tumours	  were	  measured	  twice	  a	  week.	  	  
Most	   mice	   showed	   rapid	   tumour	   growth	   reaching	   more	   than	   500	   mm3	   and	   were	  
euthanized	  if	  a	  tumour	  reached	  20	  mm	  in	  length.	  Most	  mice	  presented	  multiple	  tumours	  
on	   day	   24	   post	   inoculation.	   However,	   mice	   in	   the	   E.	   coli-­‐LALF-­‐E7	   group	   showed	   less	  
multiple	  tumour	  formation	  than	  the	  other	  groups	  (Table	  4.1).	  The	  tumours	  in	  the	  plant-­‐
LALF-­‐E7	  and	  the	  placebo	  group	  grew	  very	  rapidly	  in	  the	  last	  three	  days	  of	  the	  experiment,	  
reaching	  more	  than	  1,000	  mm3.	  In	  the	  E.	  coli-­‐LALF-­‐E7	  group,	  mice	  showed	  a	  mean	  tumour	  
volume	  of	  less	  than	  800	  mm3	  (not	  shown).	  
Tumour	  regression	  was	  observed	  in	  one	  mouse	  in	  the	  E.	  coli-­‐LALF-­‐E7	  group	  and	  two	  mice	  
in	   the	  plant-­‐LALF-­‐E7	   group.	  Of	   these,	   the	  mouse	   in	   the	  E.	   coli-­‐LALF-­‐E7	   group	  and	  one	  
mouse	  of	   the	  plant-­‐LALF-­‐E7	  group	  had	  complete	   tumour	  regression	   from	  4.0	  and	  13.5	  
mm3,	  respectively,	  to	  undetectable	  tumours.	  Furthermore,	  although,	  not	  showing	  tumour	  
regression,	  some	  mice	  showed	  relative	  slow.	  Mice	  were	  considered	  slow	  progressors	  if	  
their	  total	  tumour	  volume,	  accounting	  for	  multiple	  tumours	  as	  well,	  did	  not	  reach	  more	  
than	  599	  mm3	  by	  the	  end	  of	   the	  experiment,	  since	  most	  mice	  presented	  total	   tumour	  
volumes	  above	  this	  value	  on	  the	  day	  they	  were	  euthanized.	  	  
Overall,	   the	  plant-­‐produced	  LALF-­‐E7	  was	  comparable	  to	  the	  E.	  coli-­‐LALF-­‐E7	   in	  terms	  of	  
tumour	   regression	  and	   slow	  progression.	  However,	   it	   seemed	   to	  not	  prevent	  multiple	  
tumour	   formation	   and	   tumours	   that	   did	   not	   progress	   slower,	   seemed	   to	   progress	   to	  
higher	  volumes	  than	  the	  E.	  coli-­‐LALF-­‐E7	  group,	  comparable	  to	  the	  Tris	  control,	  except	  for	  
four	  outliers	  that	  showed	  extreme	  tumour	  growth	  towards	  the	  end	  of	  the	  experiment.	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These	  observations	  did	  not	  seem	  to	  be	  influenced	  by	  the	  SPF	  type	  or	  age	  of	  the	  mice	  used	  
in	  this	  study.	  
	  
Table	  4.1.	  Summary	  of	  the	  tumour	  regression	  experiment	  
Treatment	   Tris	  buffer	   E.	  coli-­‐produced	  LALF-­‐E7	   Plant-­‐produced	  LALF-­‐E7	  
Multiple	  tumour	  
formation	  
8/10	  (80%)	   3/10	  (30%)	   14/19	  (74%)	  
Slow	  progressors	   2/10	  (20%)	   3/10	  (30%)	   5/19	  (26%)	  
Tumour	  regression	   0/10	  (0.0%)	   1/10	  (10%)	   2/19	  (10.5%)	  
Mice	  remaining	  
tumour-­‐free	  
0/10	  (0.0%)	   1/10	  (10%)	   1/19	  (5.0%)	  
	  
The	  survival	  rate	  of	  mice	  vaccinated	  with	  the	  plant-­‐LALF-­‐E7,	  representing	  the	  percentage	  
of	  mice	  not	  euthanized	  at	  each	  time-­‐point,	  was	  higher	  than	  that	  for	  the	  placebo	  mice,	  but	  
lower	  than	  that	  for	  the	  E.	  coli-­‐LALF-­‐E7	  mice	  by	  the	  end	  of	  the	  experiment	  (Figure	  4.7).	  	  
	  
Figure	  4.7.	  Mouse	  survival	  rate.	  Percentage	  of	  mice	  alive	  at	  each	  time	  point	  was	  calculated	  for	  each	  group.	  
Blue	   spheres,	   Tris	   buffer	   group.	   Purple	   triangles,	  E.	   coli-­‐produced	   LALF-­‐E7	   group.	  Green	   squares,	   plant-­‐
produced	  LALF-­‐E7	  group.	  Days	  0-­‐14	  post	  inoculation	  are	  omitted	  for	  illustration	  purposes.	  
	  
On	   the	   other	   hand,	   the	   rate	   of	   tumour	   volumes	   reaching	   500	   mm3	   was	   comparable	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experiment,	  where	  mice	  in	  the	  plant-­‐LALF-­‐E7	  group	  seemed	  to	  have	  fewer	  tumours	  over	  
500	  mm3	  than	  in	  the	  E.	  coli-­‐LALF-­‐E7	  and	  the	  placebo	  groups	  (Figure	  4.8).	  
	  
Figure	  4.8.	  Mice	  showing	  tumour	  volumes	  of	  less	  than	  500	  mm3.	  Percentage	  of	  mice	  with	  a	  total	  tumour	  
volume	  of	  less	  than	  500	  mm3	  at	  each	  time	  point	  was	  calculated	  for	  each	  group.	  Blue	  spheres,	  Tris	  buffer	  
group.	  Purple	  triangles,	  E.	  coli-­‐produced	  LALF-­‐E7	  group.	  Green	  squares,	  plant-­‐produced	  LALF-­‐E7	  group.	  Days	  
0-­‐14	  post	  inoculation	  are	  omitted	  for	  illustration	  purposes.	  
	  
4.4.	  Discussion	  
4.4.1.	  Optimization	  of	  LALF-­‐E7	  crude	  extraction	  
The	  fact	  that	  higher	  accumulation	  of	  LALF-­‐E7	  was	  obtained	  using	  pRIC3.0	  and	  chloroplast	  
targeting	   than	   when	   expression	   vectors	   pEAQ-­‐HT	   and	   pTRAc	   were	   used	   or	   when	   no	  
targeting	   was	   used,	   suggested	   that	   pRIC3.0-­‐cTP-­‐LALF-­‐E7	   could	   possibly	   allow	   the	  
production	  of	  enough	  quantities	  of	   LALF-­‐E7	   for	   its	  purification	  and	   subsequent	  animal	  
testing.	  Scaling-­‐up	  of	  LALF-­‐E7	  expression,	  extraction	  and	  purification	  strategies	  were	  thus	  
explored.	  	  
For	  consistency,	  I	  used	  Agrobacterium	  cultures	  at	  an	  OD600	  of	  1.0	  during	  the	  large-­‐scale	  
production	  of	  LALF-­‐E7.	  However,	  this	  could	  be	  reduced	  to	  0.5	  as	  it	  was	  as	  effective	  as	  an	  
OD600	  of	  1.0	  (see	  Chapter	  2).	  Since	  the	  addition	  of	  a	  silencing	  suppressor	  did	  not	  have	  a	  
major	   impact	  on	  the	  expression	  of	  LALF-­‐E7,	   I	  opted	  to	  express	  LALF-­‐E7	  targeted	  to	  the	  
chloroplasts	   alone.	   Using	   fewer	   bacterial	   strains	   would	   also	   simplify	   the	   scaling-­‐up	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In	  order	  to	  obtain	  appropriate	  crude	  extracts	  to	  purify	  LALF-­‐E7	  through	  the	  automated	  
ÄKTA	  chromatography	  system,	  I	  pre-­‐purified	  LALF-­‐E7	  crude	  extracts	  prepared	  using	  the	  
protocol	  1	  by	  A.S.	  precipitation	  (Englard	  and	  Seifter,	  1990).	  However,	  this	  treatment	  did	  
not	  remove	  host	  proteins	  and	  it	  did	  not	  result	  in	  a	  less	  viscous	  final	  crude	  extract,	  which	  
is	  required	  for	  automated	  affinity	  chromatography	  systems.	  In	  fact,	  it	  appeared	  that	  the	  
A.S.	   treatment	  concentrated	  every	  protein	   in	   the	  crude	  extract,	   and	   therefore	  did	  not	  
have	  the	  desirable	  effect	  that	  was	  expected.	  This	  could	  have	  been	  a	  result	  of	  all	  proteins	  
being	  denatured	  by	  8	  M	  urea	  which	  could	  have	  eliminated	  the	  selective	  precipitation	  of	  
proteins	  according	   to	   their	   intrinsic	  properties,	   resulting	   in	  all	  proteins	  precipitating	  at	  
one	  step.	  Therefore,	  A.S.	  precipitation	  was	  of	  limited	  usefulness.	  	  
I	   subsequently	   focused	   on	   developing	   an	   extraction	   protocol	   that	   would	   result	   in	   a	  
“cleaner”	  crude	  extract	  that	  would	  also	  minimize	  the	  manipulation	  of	  LALF-­‐E7-­‐containing	  
material.	  The	  new	  protocol	  was	  analogous	  to	  the	  crude	  extract	  preparation	  used	  for	  E.	  
coli-­‐produced	   LALF-­‐E7	   (Granadillo	   et	   al.,	   2013).	   Most	   host	   soluble	   proteins	   were	  
successfully	  removed	  by	  washing	  the	  plant	  material	  with	  PBS	  before	  solubilising	  LALF-­‐E7	  
with	  urea.	  This	  protocol	  represented	  a	  more	  efficient	  way	  of	  extracting	  LALF-­‐E7	  from	  plant	  
material	  and	  could	  be	  used	  as	  a	  pre-­‐purification	  step.	  
Two	   urea	   concentrations	   were	   tested,	   6	   M	   which	   was	   the	   concentration	   used	   by	  
Granadillo	  et	  al.	  (2013),	  and	  8	  M	  which	  was	  the	  concentration	  used	  before	  in	  this	  study.	  
No	  significant	  difference	  was	  seen,	  and	  therefore,	  for	  consistency	  8	  M	  urea	  continued	  to	  
be	  used	  throughout	  this	  study.	  	  
It	  was	  seen	  that	  even	  with	  8	  M	  urea	  extraction	  buffer,	  and	  a	  4-­‐hour	  incubation	  period,	  the	  
extraction	  of	   LALF-­‐E7	   from	  plant	  material	  was	  not	  complete.	   Increasing	   the	  volume	  of	  
extraction	  buffer,	  did	  not	  seem	  to	  have	  an	  effect	  on	  the	  extraction	  efficiency	  of	  LALF-­‐E7.	  
This	  suggested	  a	  close	  association	  of	  LALF-­‐E7	  and	  leaf	  material.	  As	  seen	  in	  Chapter	  3,	  the	  
chloroplast-­‐targeted	  LALF-­‐E7	  forms	  protein	  body	  (PB)-­‐like	  structures	  that	  possibly	  remain	  
associated	   to	   the	   chloroplast	   envelope	   membranes.	   To	   circumvent	   this,	   differential	  
ultracentrifugation	  of	  plant	  material	  could	  be	  done	  to	  purify	  the	  plant	  chloroplasts	  before	  
solubilizing	  LALF-­‐E7	   (Elias	  and	  Givan,	  1978;	  Ferro	  et	  al.,	  2002).	  This	  could	  benefit	   from	  
more	   extraction	   buffer	   being	   available	   to	   solubilize	   less	   plant	   material,	   which	   could	  
increase	   the	  extraction	  of	   LALF-­‐E7.	  Alternatively,	  other	   stronger	  denaturing	   conditions	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could	  be	   tested	   to	  determine	   if	  more	  LALF-­‐E7	  can	  be	   recovered	  without	   leading	   to	   its	  
degradation	  or	  break	  down	  as	  seen	  for	  the	  overnight	  incubation	  of	  plant	  material	  with	  8	  
M	  urea	  extraction	  buffer.	  	  
It	  was	  seen	  that	  LALF-­‐E7	  was	  stable	  in	  crude	  extract	  preparations	  only	  for	  a	  short	  period	  
of	  time	  when	  stored	  at	  4	  °C.	  This	  could	  be	  due	  to	  urea-­‐induced	  carbamylation	  that	  can	  
lead	   to	  protein	  degradation	   (Sun	  et	  al.,	   2014).	  On	   the	  other	  hand,	   LALF-­‐E7	  was	  highly	  
stable	  in	  frozen	  plant	  material	  at	  -­‐80	  °C,	  being	  detected	  after	  17	  months	  post	  infiltration	  
and	  harvest.	  This	  suggests	  that	  the	  plant	  material	  acts	  as	  a	  protective	  matrix	  where	  the	  
protein	  can	  be	  kept	  for	  long	  periods	  of	  time.	  This	  can	  also	  be	  due	  to	  the	  PB-­‐like	  structures	  
formed	  by	  LALF-­‐E7	  in	  the	  chloroplasts,	  that	  might	  concentrate	  it	  and	  stabilize	  it	  (Torrent	  
et	  al.,	  2009;	  Hofbauer	  and	  Stoger,	  2013).	  This	  is	  useful,	  as	  plant	  material	  does	  not	  need	  to	  
be	  processed	  immediately	  after	  harvesting	  and	  can	  be	  used	  as	  a	  natural	  long-­‐term	  storage	  
method.	  	  
4.4.2.	  Purification	  of	  LALF-­‐E7	  
Once	   the	  extraction	  of	  LALF-­‐E7	  was	  optimized,	   its	  expression	  was	  scaled-­‐up	   to	   further	  
develop	  a	  purification	  strategy	  based	  on	  Ni2+	  affinity	  chromatography.	  A	  drawback	  of	  the	  
large-­‐scale	   extraction	   of	   LALF-­‐E7	   using	   protocol	   2	   was	   that	   more	   host	   contaminant	  
proteins	  became	  more	  detectable.	  This	  was	  not	  unexpected	  and	  is	  often	  seen	  that	  when	  
scaling	  up	  starting	  material	  for	  extraction,	  more	  proteins	  can	  be	  extracted.	  	  
I	   first	  tested	  a	  HisTrap	  column	  volume	  of	  1	  ml	  as	  a	  pilot	  experiment.	  This	  showed	  that	  
LALF-­‐E7	   could	   be	   concentrated	   as	   seen	   by	   the	   high	   A280	   obtained	   during	   the	  
chromatography	  and	  the	  fact	  that	  LALF-­‐E7	  was	  clearly	  visible	   in	  stained	  gels,	  despite	  a	  
possible	  17	  kDa	  contaminant	  being	  present.	  However,	  LALF-­‐E7	  eluted	  at	  a	  very	  low	  elution	  
buffer	  percentage,	   suggesting	   that	   it	  was	   loosely	  bound	   to	   the	  Ni2+	   resin.	   This	   further	  
suggested	  that	  LALF-­‐E7’s	  His-­‐tag	  might	  not	  have	  been	  fully	  exposed	  to	  the	  resin,	  possibly	  
influenced	  by	  the	  conditions	  used.	  	  
Using	  a	  larger	  column	  volume,	  removing	  the	  imidazole	  present	  in	  the	  equilibration	  buffer	  
and	  eliminating	  the	  wash	  step	  at	  low	  pH	  proved	  to	  enhance	  the	  purification	  conditions.	  
However,	   complete	   removal	   of	   contaminant	  proteins	  was	  not	   achieved.	  Nevertheless,	  
LALF-­‐E7	  seemed	  to	  be	  in	  excess	  to	  contaminant	  proteins	  in	  later	  elution	  fractions.	  	  
	   79	  
The	  fact	  that	  a	  small	  portion	  of	  LALF-­‐E7	  co-­‐eluted	  with	  most	  contaminant	  proteins	  in	  early	  
elution	  fractions,	  while	  it	  was	  more	  strongly	  detected	  in	  later	  elution	  fractions,	  suggested	  
that	   a	   portion	   of	   LALF-­‐E7	   molecules	   is	   associated	   with	   these	   host	   proteins.	   The	  
contaminant	  proteins	  were	  not	  found	  in	  the	  flow-­‐through.	  In	  fact,	  no	  proteins	  seemed	  to	  
be	  detected	  in	  the	  flow-­‐through	  as	  seen	  in	  the	  chromatogram	  and	  stained	  gel	  in	  Figure	  
4.5.	  The	  apparent	  interaction	  of	  LALF-­‐E7	  and	  host	  proteins	  was	  not	  completely	  eliminated	  
by	  the	  denaturing	  conditions	  used	  in	  the	  process,	  nor	  by	  the	  addition	  of	  the	  detergent	  
Triton	   X-­‐100,	   suggesting	   this	   association	   was	   strong.	   This	   could	   account	   for	   the	  
incomplete	  exposure	  of	   the	   LALF-­‐E7’s	  His-­‐tag	   leading	   to	   loose	  binding	  and	   for	   the	   co-­‐
elution	  of	  these	  proteins	  with	  LALF-­‐E7.	  This	  could	  be	  seen	  in	  both	  column	  volumes	  used,	  
but	  was	  more	  prominent	  when	  the	  5	  ml	  HisTrap	  columns	  were	  used,	  probably	  due	  to	  the	  
larger	  volume	  of	  resin	  available	  that	  could	  have	  led	  to	  a	  better	  binding	  of	  LALF-­‐E7	  and	  
LALF-­‐E7-­‐host	  protein	  complexes.	  This	  may	  be	  confirmed	  by	  the	  fact	  that	  LALF-­‐E7	  eluted	  
in	  later	  fractions	  when	  a	  larger	  HisTrap	  column	  was	  used.	  	  
Overall,	  the	  use	  of	  Ni2+	  affinity	  chromatography	  seemed	  to	  have	  only	  concentrated	  LALF-­‐
E7,	  but	  not	  purified	   it.	   It	   appeared	   that	   LALF-­‐E7	  was	  mostly	  purified	  by	   the	  extraction	  
protocol	  2	  which	  removed	  the	  bulk	  of	  the	  host	  contaminant	  proteins.	  	  
It	  was	  noted	  that	  after	  the	  affinity	  chromatography,	  the	  plant-­‐produced	  LALF-­‐E7	  appeared	  
as	  a	  double	  band.	  This	  was	  also	  seen	   for	   the	  E.	  coli-­‐produced	  LALF-­‐E7.	  Similar	  doublet	  
formation	   was	   observed	   by	   Demurtas	   et	   al.	   (2013),	   who	   proposed	   these	   were	  
phosphorylated	   forms	   of	   the	   protein.	   The	   HPV-­‐16	   E7	   protein	   is	   known	   to	   be	  
phosphorylated	  at	  serine	  residues	  (Munger	  and	  Halpern,	  1997).	  
The	  final	  concentration	  of	  LALF-­‐E7	  after	  the	  affinity	  chromatography	  was	  0.0231	  mg/ml,	  
equivalent	  to	  a	  yield	  of	  15	  mg/kg	  FLW	  which	  represented	  a	  recovery	  rate	  of	  30%.	  This	  low	  
recovery	  rate	  can	  be	  attributed	  to	  the	  incomplete	  extraction	  of	  LALF-­‐E7	  from	  leaf	  material	  
and	  the	  manipulation	  of	  crude	  extracts	  during	  affinity	  chromatography.	  Manipulation	  of	  
protein	   extracts	   can	   lead	   to	   protein	   degradation	   and	  protein	   loss.	   There	   is	   a	   negative	  
relationship	  between	  protein	  recovery	  and	  number	  of	  purification	  steps.	  
The	  downstream	  processing	  of	  most	  recombinant	  proteins	  can	  account	  for	  80%	  of	  the	  
production	  cost,	  which	  in	  fact	  currently	  represents	  a	  bottleneck	  in	  the	  development	  of	  
low-­‐cost	  biopharmaceuticals	   (Rybicki,	   2009;	   Fischer	  et	  al.,	   2012;	   Sabalza,	  Christou	  and	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Capell,	   2014).	   Therefore,	   it	   is	   important	   that	   an	   economic	   and	   efficient	   purification	  
method	   is	   applied	   to	   increase	   the	   recovery	   of	   LALF-­‐E7,	   if	   it	   is	   to	   have	   a	   future	   as	   a	  
therapeutic.	  However,	  the	  low	  yield	  of	  LALF-­‐E7	  could	  be	  a	  reflection	  of	  its	  low	  expression	  
levels	  in	  plant	  leaves.	  Even	  though	  the	  best	  conditions	  yet	  achieved	  for	  plant-­‐produced	  
LALF-­‐E7	   were	   used,	   namely,	   a	   replicative	   expression	   vector	   and	   chloroplast	   targeting	  
which	  increased	  the	  expression	  of	  LALF-­‐E7	  by	  26.8-­‐fold,	  LALF-­‐E7	  only	  expressed	  at	  levels	  
up	   to	   0.5%	   total	   soluble	   protein	   (TSP)	   or	   50	  mg/kg.	   This	   yield	   was	   lower	   than	   those	  
reported	  for	  other	  E7-­‐based	  plant-­‐expressed	  proteins.	  For	  example,	  Buyel	  et	  al.	   (2012)	  
report	  the	  expression	  of	  a	  HPV-­‐16	  E7	  fusion	  protein	  of	  233	  mg/kg	  FLW	  in	  N.	  benthamiana.	  	  
Whitehead	  et	  al.,	  (2014)	  report	  expression	  levels	  of	  a	  Zera®-­‐fused	  HPV-­‐16	  E7	  protein	  of	  
150	  mg/kg,	  while	  expression	  levels	  of	  1,100	  mg/kg	  were	  obtained	  when	  the	  E7	  protein	  
sequence	  was	  shuffled.	  This	  suggests	  that	  this	  protein	  might	  be	  detrimental	  to	  the	  plant	  
cells.	  Since	  E7	  can	  interact	  with	  other	  proteins	  besides	  the	  retinoblastoma	  protein	  (Moody	  
and	  Laimins,	  2010;	  Roman	  and	  Munger,	  2013),	  it	  is	  possible	  that	  it	  interferes	  with	  plant	  
cell	   pathways,	   which	   is	   not	   seen	   for	   E7	   expression	   in	   prokaryotic	   expression	   systems	  
(Granadillo	   et	   al.,	   2013).	   The	   effects	   of	   E7	   together	   with	   symptoms	   induced	   by	   the	  
replicative	  vector	  seen	  in	  Chapter	  2	  might	  have	  compromised	  the	  expression	  of	  LALF-­‐E7,	  
compared	   to	   other	   plant-­‐produced	   proteins.	   Furthermore,	   Demurtas	   et	   al.	   (2013)	  
reported	  a	  His-­‐tag	  being	  detrimental	  to	  the	  expression	  of	  transplastomic	  HPV-­‐16	  E7-­‐based	  
protein	   (E7GGG)	   in	   algae	   cells.	   When	   a	   different	   affinity	   tag	   was	   used,	   the	   protein	  
expression	  level	  was	  increased.	  	  
Overall,	   it	   could	   be	  worth	   to	   test	   the	   expression	   of	   LALF-­‐E7	   in	   a	   different	   expression	  
vector,	   such	   as	   pTRA-­‐cTP,	   while	   removing	   the	   His-­‐tag	   and	   developing	   non-­‐
chromatographic	  purification	  strategies.	  For	  example,	  chloroplasts	  could	  be	  purified	  by	  
differential	   ultra-­‐centrifugation	   techniques	   and	   thereafter,	   LALF-­‐E7	   could	  be	   extracted	  
from	   the	   chloroplast	   envelopes	   (Elias	   and	  Givan,	   1978;	   Ferro	  et	  al.,	   2002).	   This	  would	  
provide	  a	  more	  practical	  means	  of	  purifying	  LALF-­‐E7.	  Alternatively,	  targeting	  LALF-­‐E7	  to	  
secretory	  pathways	  fusing	  it	  to	  carrier	  molecules	  and	  could	  increase	  its	  expression	  levels,	  
as	  demonstrated	  by	  Franconi	  et	  al.	   (2006)	   for	  HPV-­‐16	  E7,	  and	  Massa	  et	  al.	   (2007)	  and	  
Buyel	  et	  al.	  (2012)	  for	  E7GGG.	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4.4.3.	  Tumour	  regression	  experiments	  
The	   E.	   coli-­‐produced	   LALF-­‐E7	   was	   previously	   shown	   to	   induce	   tumour-­‐specific	   cell-­‐
mediated	  responses	  and	  tumour	  regression	  in	  mice	  (Granadillo	  et	  al.,	  2011).	  In	  this	  study,	  
I	   tested	   the	   plant-­‐produced	   LALF-­‐E7	   to	   determine	   whether	   it	   would	   have	   the	   same	  
successful	  effects.	  	  
Numerous	   HPV	   E7-­‐based	   plant-­‐produced	   therapeutic	   vaccine	   candidates	   have	   been	  
tested	  in	  tumour	  protection	  as	  well	  as	  tumour	  regression	  experiments	  (Franconi	  et	  al.,	  
2002,	  2006;	  Massa	  et	  al.,	  2007;	  Venuti	  et	  al.,	  2009;	  Demurtas	  et	  al.,	  2013).	  However,	  since	  
it	   is	   important	   that	   the	   therapeutic	   vaccine	  be	  efficient	  at	  eliminating	  already	  existing	  
tumours	  or	  at	  least	  at	  minimizing	  their	  growth	  (Ma	  et	  al.,	  2010;	  Morrow,	  Yan	  and	  Sardesai,	  
2013),	   in	   the	   current	   pilot	   experiment,	   I	   prioritized	   the	  determination	  of	  whether	   the	  
plant-­‐produced	  LALF-­‐E7	  could	  induce	  tumour	  regression	  in	  mice	  animal	  models.	  	  
It	  was	  previously	  observed	  that	  mice	  inoculated	  with	  our	  group’s	  tumour-­‐inducing	  C3	  cell	  
line	  showed	  spontaneous	  tumour	  regression	  even	  in	  placebo	  groups	  (M.	  Granadillo	  and	  
R.	   Lamprecht,	   unpublished	   data).	   Therefore,	   a	   more	   tumorigenic	   cell	   line	   (C3-­‐3)	   was	  
developed	   in	   order	   to	   distinguish	   between	   spontaneous	   and	   vaccine-­‐induced	   tumour	  
regression.	   These	   rapidly	   formed	   tumours	   in	   90%	   of	   inoculated	   mice	   in	   previous	  
experiments	  (R.	  Lamprecht,	  unpublished	  data).	  The	  high	  tumorigenicity	  was	  also	  observed	  
in	  the	  present	  study	  that	  led	  to	  tumour	  development	  in	  all	  mice	  by	  7	  days	  post	  inoculation.	  	  
The	  vaccine	  dosage	  used	  in	  the	  present	  study	  was	  4.6	  µg	  of	  protein	  per	  immunization.	  
This	   was	   lower	   than	   generally	   used	   for	   tumour	   regression	   studies	   based	   on	   HPV	   E7-­‐
derived	  vaccines.	  For	  example,	  Granadillo	  et	  al.	   (2011)	  used	  30-­‐120	  µg	  of	  LALF-­‐E7	  and	  
Wick	  and	  Webb,	  (2011)	  used	  100	  µg	  of	  Pentarix.	  However	  due	  to	  technical	   limitations,	  
this	  represented	  the	  maximum	  possible	  dose,	  given	  that	  the	  maximum	  injection	  volume	  
allowed	  was	  200	  µl	  per	  mouse.	  	  
Other	  groups	  have	  used	  low	  antigen	  doses	  of	  E7-­‐based	  vaccines	  and	  demonstrate	  their	  
anti-­‐tumour	  effects	  as	  well	  as	  the	  induction	  of	  antigen-­‐specific	  humoral	  and	  cell-­‐mediated	  
immune	  responses	  (Franconi	  et	  al.,	  2002,	  2006;	  Massa	  et	  al.,	  2007;	  Venuti	  et	  al.,	  2009;	  
Demurtas	  et	  al.,	  2013).	  However,	  they	  only	  test	  the	  prophylactic	  activity	  of	  the	  vaccine	  
(Demurtas	  et	  al.,	  2013),	  vaccinate	  on	  days	  0	  or	  3	  post	  tumour	  cell	  inoculations	  (Franconi	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et	   al.,	   2002;	  Massa	  et	   al.,	   2007),	   and/or	  measure	   the	   tumour	  progression	   in	   terms	  of	  
tumour-­‐free	  mice	  (Massa	  et	  al.,	  2007;	  Venuti	  et	  al.,	  2009;	  Demurtas	  et	  al.,	  2013).	  In	  the	  
present	   study,	   mice	   were	   only	   immunized	   after	   tumour	   development	   and	   tumour	  
progression	  was	  measured	  in	  terms	  of	  tumour	  volumes.	  Therefore,	  the	  above	  mentioned	  
studies	  are	  of	  limited	  comparison	  to	  the	  current	  study.	  	  
Due	   to	   the	   tumour	   cell	   strength	   and	   low	   vaccine	   dosages,	   it	   was	   seen	   that	   tumour	  
development	  was	  very	  rapid	  and	  did	  not	  seem	  to	  reach	  a	  plateau	  before	  mice	  had	  to	  be	  
euthanized.	  This	  was	  seen	  in	  the	  plant-­‐LALF-­‐E7	  group	  as	  well	  as	  in	  the	  E.	  coli-­‐LALF-­‐E7	  and	  
the	  placebo	  groups,	  suggesting	  it	  was	  not	  due	  to	  an	  adverse	  effect	  of	  the	  antigens.	  	  
Whitehead	  et	   al.	   (2014)	  used	  antigen	  dosages	  of	  5	  µg	  Zera®-­‐16E7SH	   fusion	  protein	   in	  
tumour	  regression	  experiments.	  The	  fact	  that	  they	  could	  observe	  differences	  in	  tumour	  
progression	  of	  mice	   in	   the	  vaccinated	  group	  compared	  to	   the	  placebo	  group,	  suggests	  
that,	  indeed,	  the	  high	  tumorigenicity	  of	  the	  C3-­‐3	  cells	  might	  have	  obscured	  the	  potential	  
of	  the	  plant	  and	  E.	  coli-­‐produced	  LALF-­‐E7	  vaccinations.	  Furthermore,	  the	  Zera®	  peptide	  
acted	  as	  an	  adjuvant	  in	  these	  experiments,	  and	  so	  did	  LALF	  in	  the	  studies	  performed	  by	  
Granadillo	  et	  al.	  (2011).	  Therefore,	  the	  differences	  seen	  here	  compared	  to	  Whitehead	  et	  
al.	  (2014)	  are	  unlikely	  to	  be	  entirely	  due	  to	  the	  Zera®	  peptide.	  	  
In	  the	  present	  study,	  differences	  between	  the	  vaccination	  groups	  could	  be	  better	  seen	  in	  
terms	  of	  survival	  rates	  and	  the	  relative	  ability	  to	  delay	  tumour	  growth.	  It	  could	  be	  seen	  
that	  by	  the	  end	  of	  the	  experiment	  the	  plant-­‐	  and	  E.	  coli-­‐LALF-­‐E7	  groups	  had	  better	  survival	  
rates	  than	  that	  of	  the	  placebo	  group,	  however,	  the	  plant-­‐LALF-­‐E7	  group	  survival	  rate	  was	  
lower	  than	  that	  of	  the	  E.	  coli-­‐LALF-­‐E7.	  It	  was	  also	  noticed	  that	  the	  E.	  coli-­‐LALF-­‐E7	  group	  
showed	  less	  multiple	  tumour	  formation.	  On	  the	  other	  hand,	  the	  plant-­‐produced	  LALF-­‐E7	  
vaccine	  seemed	  to	  limit	  tumour	  growth	  to	  500	  mm3,	  to	  a	  better	  extent	  than	  the	  E.	  coli-­‐
produced	  vaccine.	  The	  differences	  seen	  between	  the	  vaccine	  groups	  were	  very	  small	  and	  
not	  statistically	  relevant.	  However,	  they	  suggested	  that	  the	  two	  vaccines	  are	  somewhat	  
comparable	  and	  did	  have	  an	  effect	  on	  the	   immune	  response	  of	   the	  mice	  tested,	  since	  
these	  groups	  performed	  slightly	  better	  that	  the	  placebo	  group.	  The	  fact	  that	  10%	  of	  mice	  
showed	   tumour	   regression	   in	   the	   vaccine	   groups	   versus	   no	   regression	   in	   the	   placebo	  
group	  could	  further	  confirm	  that	  this	  is	  due	  to	  the	  immunizations.	  However,	  spontaneous	  
regression	  cannot	  be	  ruled	  out.	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The	  E.	  coli-­‐produced	  LALF-­‐E7	  was	  previously	  tested	  against	  TC-­‐1	  and	  C3	  cell-­‐tumours	  by	  
Granadillo	  et	  al.	  (2011)	  and	  by	  our	  group	  (unpublished	  data),	  using	  high	  vaccination	  doses	  
of	  60	  µg.	  LALF-­‐E7	  was	  able	  to	  induce	  strong	  tumour-­‐specific	  cell	  mediated	  responses	  as	  
seen	  by	  ELISPOT	  assays.	  Therefore,	  in	  future	  studies,	  higher	  vaccine	  doses,	  lower	  number	  
of	  C3-­‐3	  cells	  in	  inoculums	  as	  well	  as	  larger	  group	  sizes	  could	  allow	  for	  a	  more	  conclusive	  
characterization	   of	   the	   effects	   of	   plant-­‐produced	   LALF-­‐E7	   in	   tumour	   regression	  
experiments.	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Chapter	  5:	  Conclusions	  
Therapeutic	  vaccines	  are	  greatly	  needed	  for	  human	  papillomavirus	  infections	  due	  to	  the	  
large	  number	  of	  individuals	  that	  are	  already	  infected	  by	  the	  viruses	  who	  will	  not	  benefit	  
from	   the	   prophylactic	   vaccines,	   and	   for	   those	   that	   have	   developed	   HPV-­‐associated	  
malignancies.	  Since	  more	  than	  85%	  of	  HPV-­‐associated	  cervical	  cancer	  cases	  and	  deaths	  
occur	  in	  developing	  countries,	  it	  is	  important	  that	  a	  future	  therapeutic	  vaccine	  is	  not	  only	  
efficient,	  but	  also	  cost-­‐effective	  (Giorgi,	  Franconi	  and	  Rybicki,	  2010).	  	  
The	   current	   study	   explored	   the	   possibility	   of	   producing	   a	   cost-­‐effective	   therapeutic	  
vaccine	  candidate	  for	  HPV-­‐16	  which	  is	  based	  on	  a	  mutated	  viral	  E7	  oncoprotein	  fused	  to	  
a	  cell	  membrane-­‐penetrating	  and	   immunomodulatory	  peptide,	  LALF	   -­‐	  creating	  LALF-­‐E7	  
(Granadillo	  et	  al.,	  2011).	  
The	   aims	   of	   this	   study	   were	   (1),	   to	   optimize	   the	   expression	   of	   LALF-­‐E7	   in	   Nicotiana	  
benthamiana	  leaves;	  (2),	  to	  determine	  the	  subcellular	  localization	  of	  LALF-­‐E7	  in	  plant	  cells;	  
(3),	  to	  develop	  a	  large-­‐scale	  extraction	  and	  purification	  strategy,	  and	  finally	  (4),	  to	  test	  the	  
plant-­‐produced	   LALF-­‐E7	   in	   a	   mouse	   tumour	   model	   to	   determine	   whether	   it	   was	  
comparable	  to	  the	  E.	  coli-­‐produced	  LALF-­‐E7	  in	  terms	  of	  tumour	  regression.	  	  
The	  highest	  expression	  levels	  of	  LALF-­‐E7	  obtained	  were	  achieved	  by	  using	  the	  replicating	  
expression	  vector	  pRIC3.0,	  and	  targeting	  LALF-­‐E7	  to	  the	  plant	  chloroplasts	  via	  the	  rbcS1	  
chloroplast	   transit	   peptide	   (cTP).	   Compared	   to	   cytoplasmic	   localization,	   chloroplast	  
targeting	  increased	  the	  expression	  of	  LALF-­‐E7	  by	  26.8-­‐fold.	  Silencing	  suppressors	  did	  not	  
have	  a	  significant	  impact	  on	  the	  expression	  of	  LALF-­‐E7	  as	  they	  only	  increased	  it	  by	  1.3	  fold.	  
I	  concluded	  that	  the	  effect	  of	  increased	  gene	  copy	  number	  early	  post	  infiltration	  of	  the	  
plant	  leaves	  by	  the	  replicating	  expression	  vector,	  and	  the	  subcellular	  localization	  of	  LALF-­‐
E7	   had	   a	  major	   impact	   on	   its	   accumulation	   levels,	   circumventing	   the	   effects	   of	   gene	  
silencing.	  
I	  proved,	  by	  fluorescent	  confocal	  microscopy,	  that	  LALF-­‐E7	  is	  indeed	  targeted	  to	  the	  plant	  
chloroplasts.	  I	  further	  described	  how	  LALF-­‐E7	  potentially	  forms	  protein	  bodies	  (PBs)	  when	  
targeted	  to	  these	  compartments,	  and	  hypothesized	  a	  mechanism	  for	  this.	  The	  potential	  
of	  the	  LALF	  peptide	  to	  induce	  PB	  formation	  has	  important	  implications.	  It	  could	  possibly	  
be	  fused	  to	  other	  proteins	  to	  increase	  their	  yields,	  since	  PB	  formation	  increases	  stability	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and	  concentration	  of	  target	  proteins	  as	  well	  as	  facilitates	  their	  purification	  (Torrent	  et	  al.,	  
2009;	  Hofbauer	  and	  Stoger,	  2013).	  Furthermore,	  it	  would	  be	  interesting	  to	  determine	  if	  
targeting	   LALF-­‐E7	   to	   the	   endoplasmic	   reticulum	   (ER),	  where	   PBs	   are	   naturally	   derived	  
from,	  would	  increase	  the	  accumulation	  of	  this	  protein.	  Another	  advantage	  of	  targeting	  
LALF-­‐E7	  to	  the	  ER	  would	  be	  that	  the	  PBs	  would	  possibly	  be	  easier	  to	  purify,	  by	  for	  example,	  
differential	  ultracentrifugation,	  as	  done	  by	  Whitehead	  et	  al.	  (2014),	  unlike	  the	  current	  PB-­‐
like	   structures	   seen	   for	   cTP-­‐LALF-­‐E7	   that	  were	   closely	   associated	  with	   the	   chloroplast	  
envelopes.	  	  
It	  was	  seen	  that	  the	  cTP-­‐LALF-­‐E7	  expressed	  to	  »	  50	  mg/kg	  fresh	  leaves	  [0.5%	  total	  soluble	  
proteins	  (TSP)].	  Even	  though	  this	  was	  the	  highest	  accumulation	  level	  obtained	  for	  LALF-­‐
E7	  produced	  in	  plants	  and	  that	  this	  was	  obtained	  using	  the	  best	  conditions	  described	  so	  
far,	  this	  expression	  level	  was	  low	  compared	  to	  that	  of	  other	  plant-­‐produced	  proteins.	  This	  
could	  be	  a	  consequence	  of	  strong	  symptoms	  induced	  by	  the	  replicating	  vector	  used,	  or	  
possible	  cell	  toxicity	  induced	  by	  the	  target	  protein.	  To	  circumvent	  this,	  the	  use	  of	  the	  non-­‐
replicating	  vector,	  pTRAc	  and	  targeting	  to	  the	  chloroplasts,	  ER	  or	  apoplast	  could	  be	  tested.	  
Alternatively,	   the	  HPV-­‐16	   E7	   sequence	  used	  here	   could	   be	   replaced	  with	   the	   shuffled	  
sequence	  used	  by	  Whitehead	  et	  al.	  (2014),	  creating	  LALF-­‐16E7SH	  which	  could	  possibly	  be	  
less	  toxic.	  Since	  viable	  expression	  levels	  for	  plant	  expression	  systems	  are	  considered	  to	  be	  
>	   1%	   TSP	   (Fischer	  et	   al.,	   2004),	   further	   increase	   in	   the	   accumulation	   of	   LALF-­‐E7	   in	  N.	  
benthamiana	  leaves	  is	  probably	  needed.	  	  
Scaling	  up	  the	  production	  of	  LALF-­‐E7	  was	  not	  a	  challenge,	  and	  it	  was	  possible	  to	  develop	  
an	  extraction	  strategy	  that	  removed	  the	  bulk	  of	  host	  contaminant	  proteins,	  acting	  as	  a	  
partial	   purification	   step.	   In	   fact,	   this	   protocol	   was	   more	   successful	   at	   removing	  
contaminant	  proteins	  than	  the	  use	  of	  affinity	  chromatography.	  This	  is	  hypothesized	  to	  be	  
due	  to	  the	  close	  interaction	  of	  LALF-­‐E7	  with	  other	  insoluble	  host	  proteins	  that	  led	  to	  their	  
co-­‐elution	   during	   affinity	   chromatography.	   It	   suggested	   that	   LALF-­‐E7	   was	   closely	  
associated	  to	  these	  proteins	  since	  this	  interaction	  did	  not	  seem	  to	  have	  been	  prevented	  
by	  the	  denaturing	  conditions	  used	  throughout	  the	  extraction	  and	  purification	  process.	  	  
It	  would	   be	   useful	   to	   develop	   an	   alternative	   non-­‐affinity	   chromatography	   purification	  
strategy	   for	   LALF-­‐E7,	   that	   would	   also	   lead	   to	   a	   further	   more	   concentrated	   final	  
preparation.	   For	   example,	   chloroplasts	   could	   be	   purified	   by	   differential	   ultra-­‐
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centrifugation	   techniques	   and	   thereafter,	   LALF-­‐E7	   could	   be	   extracted	   from	   the	  
chloroplast	  envelopes	  (Elias	  and	  Givan,	  1978;	  Ferro	  et	  al.,	  2002).	  This	  could	  facilitate	  the	  
purification	  process	  and	  would	  provide	  a	  means	  of	  enrichment,	  since	  the	  final	  extracts	  
could	  have	  smaller	  volumes	  than	  the	  current	  LALF-­‐E7	  extracts.	  
It	  was	  shown	  by	  Beiss	  et	  al.	  (2015)	  that	  a	  range	  of	  high	  temperature	  treatments	  can	  be	  
applied	   to	  plant	   crude	  extracts	   that	  promote	  host	   contaminant	  protein	   removal.	   Such	  
treatments	   could	  be	   tested	  at	   the	   last	   step	  of	   soluble	  protein	   removal	  during	   LALF-­‐E7	  
crude	  extract	  preparations.	  It	  is	  known	  that	  LALF-­‐E7,	  and	  HPVs’	  E7	  proteins	  in	  general,	  are	  
heat-­‐resistant	  since	  they	  contain	  cysteine	  residues	  that	  form	  disulphide	  bonds	  resistant	  
to	  reducing	  conditions	  and	  boiling	  for	  long	  periods	  of	  time	  (Imai	  et	  al.,	  1991;	  Demurtas	  et	  
al.,	   2013;	   Roman	   and	  Munger,	   2013).	   Therefore,	   high	   temperature	   treatments	   of	   the	  
plant	  material	  containing	  LALF-­‐E7	  could	  be	  used	  to	  remove	  the	  few	  proteins	  that	  remain	  
possibly	  associated	  to	  LALF-­‐E7.	  High	  temperatures	  could	  as	  well	  increase	  the	  extraction	  
efficiency	  of	  LALF-­‐E7	  from	  the	  plant	  material.	  	  	  
Furthermore,	  the	  His-­‐tag	  could	  be	  removed	  from	  the	  LALF-­‐E7	  sequence.	  As	  suggested	  by	  
Demurtas	  et	  al.	  (2013),	  this	  affinity	  tag	  could	  be	  detrimental	  for	  the	  expression	  of	  certain	  
proteins.	   If	   this	   is	   true	   for	   LALF-­‐E7,	   removing	   the	  His-­‐tag	   could	   lead	   to	   higher	   protein	  
accumulation	  levels.	  
Finally,	   I	   tested	   the	   plant-­‐produced	   LALF-­‐E7	   in	   tumour	   regression	   experiments	   using	  
female	  C57/BL6	  mice	  as	  animal	  models	  and	  an	  enhanced	  C3	  cell	   line	   (C3-­‐3)	  as	  a	  HPV-­‐
specific	   tumour	  model.	   It	  was	   not	   possible	   to	   evaluate	   the	   anti-­‐tumour	   effects	   of	   the	  
plant-­‐produced	  and	  the	  E.	  coli-­‐produced	  LALF-­‐E7	  in	  the	  present	  study	  due	  to	  low	  antigen	  
doses	  and	  the	  high	  tumorigenicity	  of	  the	  C3-­‐3	  cell	  line.	  However,	  differences	  in	  survival	  
rate	  and	  percentage	  of	  mice	  having	  very	  large	  tumour	  volumes	  compared	  to	  that	  of	  the	  
placebo	   group	  may	   suggest	   that	   the	   plant-­‐produced	   LALF-­‐E7	   had	   an	   influence	   in	   the	  
immune	   response	   of	   these	   mice.	   This	   needs	   to	   be	   confirmed	   using	   higher	   doses	   of	  
antigen,	   lower	   number	   of	   tumorigenic	   cells	   and	   larger	   vaccination	   groups.	   Another	  
alternative	  could	  be	  the	  use	  of	  a	  homologous	  prime-­‐boost	  vaccination	  strategy,	  as	  done	  
by	  Wick	  and	  Webb	  (2011).	  Nevertheless,	  it	  is	  known	  that	  LALF-­‐E7	  is	  able	  to	  elicit	  tumour-­‐
specific	  immune	  responses	  and	  tumour	  regression	  in	  mice,	  if	  a	  higher	  antigen	  dose	  than	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that	  used	  in	  this	  study	  is	  given	  (Granadillo	  et	  al.,	  2011).	  It	  is	  unlikely	  that	  the	  plant-­‐derived	  
LALF-­‐E7	  is	  unable	  to	  elicit	  similar	  responses.	  	  
A	   possible	   alternative	   to	   the	   vaccine	   design	   implemented	   in	   this	   study	   is	   the	   use	   of	  
pseudovirions	  (PsVs)	  to	  deliver	  the	  therapeutic	  vaccine	  in	  the	  form	  of	  encapsidated	  DNA.	  
Our	   group	   has	   recently	   succeeded	   in	   producing	   plant-­‐made	   HPV-­‐16	   PsVs	   capable	   of	  
encapsidating	  a	  reporter	  gene-­‐encoding	  plasmid	  that	  were	  able	  to	  infect	  mammalian	  cells	  
and	  express	   the	   reporter	  gene	   in	  a	   similar	  way	   to	  a	  natural	   viral	   infection	  mechanism	  
(Lamprecht	  et	  al.,	  2016).	  The	  reporter	  gene	  in	  the	  encapsidated	  plasmid	  could	  therefore	  
be	  replaced	  by	  the	  sequence	  encoding	  for	  LALF-­‐E7	  to	  create	  such	  a	  vaccine.	  This	  could	  
further	  act	  as	  a	  chimeric	  vaccine,	  eliciting	  anti-­‐L1	  and	  anti-­‐L2	  humoral	  as	  well	  as	  anti-­‐E7	  
cell-­‐mediated	  immune	  responses.	  
In	   summary,	   I	   report	  here	   for	   the	   first	   time	   the	  entire	   chain	  of	   research	   involving	   the	  
expression	   of	   LALF-­‐E7	   in	   plants,	   and	   the	   testing	   of	   its	   immunogenicity	   and	   possible	  
therapeutic	  activity	  in	  a	  mouse	  model.	  There	  have	  been	  numerous	  improvements	  to	  its	  
accumulation	  in	  N.	  benthamiana	  leaves,	  but	  there	  is	  further	  possible	  optimizations	  and	  
different	  strategies	  that	  can	  be	  implemented.	  This	  study	  was	  also	  important	  as	  a	  proof	  of	  
concept	   that	   protein	   localization	   plays	   a	   great	   role	   in	   protein	   accumulation	   in	   plant	  
expression	  systems.	  It	  was	  also	  a	  proof	  of	  concept	  that	  our	  group’s	  cTP	  efficiently	  targets	  
proteins	   to	   the	   chloroplasts	   as	   shown	   by	   fluorescent	   microscopy.	   This	   study	   further	  
indicated	  new	  avenues	  for	  the	  possible	  applications	  of	  the	  LALF	  peptide	  as	  a	  potential	  PB-­‐
inducer	  that	  could	  enhance	  the	  expression	  of	  other	  recombinant	  proteins.	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